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Rationale: Transplantation-accelerated arteriosclerosis is one of the major challenges 
for long-term survival of patients with solid organ transplantation. Though 
stem/progenitor cells (SPCs) have been implicated to participate in this process, the 
origin of these SPCs and the underlying mechanisms behind their contribution to 
disease have not been fully defined. 
Objective: The objective of our study was to investigate the role of c-Kit+ SPCs in 
allograft-induced lesion formation, and to explore the underlying mechanisms. 
Methods and Results: c-Kit+ SPCs were detected in allograft-induced neointima 
lesions using immunostaining. By using an inducible lineage tracing mouse model, we 
showed that c-Kit+ SPCs are an important source of neointimal smooth muscle cells 
(SMCs) and endothelial cells (ECs), contributing to neointima formation in an aortic 
allograft transplantation model. We performed allograft transplantation between 
different donor and recipient mice, as well as bone marrow transplantation 
experiments, demonstrating that c-Kit+ SPCs-derived cells originate from non-bone 
marrow tissues of recipient mice, but not donor mice. ACK2, which specifically binds 
and blocks c-Kit function, ameliorates allograft-induced arteriosclerosis. Stem cell 
factor (SCF) and vascular endothelial growth factor (VEGF) levels were significantly 
increased in blood and neointimal lesions after allograft transplantation. C-Kit+ SPCs 
were harvested from grafts to investigate underlying mechanisms in vitro. 
Mechanistically, SCF facilitated cell migration through SCF/c-Kit axis and downstream 
activation of small GTPases, MEK/ERK/MLC and JNK/c-Jun signalling pathways, 
while VEGF induced c-Kit+ SPCs migration via AKT/FAK signalling. 
Conclusions: Our findings provide evidence that recipient non-bone marrow-derived 
c-Kit+ SPCs migrate to allograft lesions, differentiate into SMCs and ECs contributing 
to vascular remodelling in an allograft transplantation model. Mechanisms involving 
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Chapter 1: Introduction 
 
1.1 Blood Vessels 
Blood vessels transport blood from the heart to all the tissues and organs in the body 
(Figure 1.1). Three major types of vessel comprise the whole circulatory system: 
arteries, capillaries and veins. Blood is pumped from heart into the circulation 
sequentially from the arteries into capillaries and ultimately veins. During this process, 
oxygen and nutrients are delivered to tissues throughout the body and deoxygenated 
blood then returned to the lungs for re-oxygenation. 
 
Figure 1.1 Blood vessels. Oxygenated blood is pumped from the left ventricle of the 
heart and circulates throughout the body.  Deoxygenated blood returns to the right 
atrium where it is pumped to the lungs for re-oxygenation. Both artery and veins are 
comprised of tunica intima, tunica media and tunica adventitia layers. Tunica intima 
consists of endothelial cells and basement membrane. Tunica media consists of 
smooth muscle cells and elastic fibres. Tunica adventitia includes several cell types 





According to their diameter, arteries can be divided into the subcategories of large 
arteries and arterioles. All large arteries have a classic three-layered structure 
including tunica adventitia, media and intima. The outermost layer is the tunica 
adventitia, which is comprised of connective tissue (mainly collagen), fibroblasts, 
nerves, resident stem/progenitor cells (SPCs), adipocytes and vasa vasorum. Smooth 
muscle cells (SMCs), elastic fibres and collagens make up the media layer. The inner 
layer is the tunica intima, which is covered by a single layer of endothelial cells (ECs) 
in direct contact with blood flow. Extracellular matrices (ECMs), form the subintimal 
layer and participate in the structural integrity of EC. Large arteries can be further 
subdivided into either elastic or muscular arteries. In elastic arteries such as the aorta 
and the carotid artery, there are SMCs distributed throughout the intima as well as in 
subintimal layers. In the media layer, multiple layers of SMCs are surrounded by 
elastin fibres forming SMC contractile units. This elastin structure is required to provide 
strong flexibility within elastic arteries that must expand due to high blood pressure. 
Elastic arteries are normally located close to the heart. Muscular arteries such as the 
femoral, ulnar and radial arteries, are smaller and generally branch from elastic 
arteries. Rather than mitigate systolic and diastolic pressure fluctuation, they are found 
in areas according to tissues or organs demand.  
When the diameter of an artery is less than 0.3mm, it can be defined as an arteriole. 
Although arterioles also have a three-layer structure, all three layers are thinner than 
in large arteries and constitute of 1 to 2 layers of smooth muscle cells in the media. 
Arterioles branch into capillaries.  
1.1.2 Veins 
Similar to arteries, veins can be separated into the large veins or venules according to 
diameter. Large veins are also made up of three layers of tissue. However, the venous 
media layer contains fewer SMCs compared to same size of artery. Additionally, most 
veins are equipped with valves to prevent backflow. The venae cavae are the two 
largest veins returning deoxygenated blood back into the atrium. The inferior vena 
cava returns blood from the lower body, and the superior vena cava returns blood 
located above the heart. Other large veins such as subclavian vein and jugular vein, 
are generally called large collecting vessels. Venules are small veins with a diameter 
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of less than 1mm. The total number of venules in the body contain approximately 25% 
of the blood in the whole venous system. Distinct to arterioles, venules have a thinner 
structure and are equipped with pores. 
1.1.3 Capillaries 
Capillaries are formed from a sole EC layer and have a diameter of less than 10μm.  
The main function of capillaries is substance exchange from arterioles to parenchymal 
cells within the microcirculation1. According to structure, capillaries can be divided into 
three types including continuous, fenestrated and sinusoid capillaries. Continuous 
capillaries provide an uninterrupted lining layer, in which ECs are connected by 
intercellular junctions, allowing only small molecules to pass through. Both fenestrated 
and sinusoidal capillaries have pores within cells or intercellularly, which allow big 
molecules and even cells to pass through capillary. ECs seated upon basement 
membrane along with pericytes which are also known as mural cells2. Pericytes and 
ECs can be connected by integrin and gap junctions. These structures allow pericytes 
to exchange substances with neighbouring cells. Identifying features of pericytes vary 
in different tissues. For example, pericytes located near venules express the proteins 
desmin and αSMA proteins, whereas those within capillaries solely express desmin 
but not αSMA. Recently, according to surface markers, pericytes have been divided 
into two types which are type I (nestin-NG2+) and type II (nestin+NG2+) pericytes. It 
has been shown that type I pericytes are involved in adipogenesis and fibrosis, 
whereas type II pericytes function in myogenesis, angiogenesis and neurogenesis. It 
has now been widely accepted that pericytes have a role in tissue regeneration.  
1.1.4 Vascular Function and Disease  
The basic function of blood vessels is to transport blood and exchange nutrients into 
target tissues. A blood vessel has no autorhythmicity and therefore cannot 
independently transport the blood. Instead, blood within vessel is primarily propelled 
under pressure derived from the heart. Meanwhile, the vessels can also regulate blood 
pressure via adjusting their diameter by the autonomic nervous system control. 
Through vessel contraction and dilation, system blood pressure can be maintained at 
a stabilized level when increased flow is required into a specific vascular bed. Once 
pumped from the heart, blood firstly flows into the aorta followed by peripheral arteries 
under the pressure difference. Afterwards blood is squeezed into arterioles. Arterioles 
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are widely distributed in all of the organs and constitute the largest source of vascular 
resistance. When the arterioles lumen diameter decreases, or media wall gets thicker, 
blood pressure would increase. At the end, blood continues to flow from arterioles into 
capillaries, during which blood velocity sharply drops. Two transport types are 
responsible for molecule exchange between capillaries and tissues. One is 
transcellular transport within single endothelial cells, in which molecules larger than 
3nm such as albumin and proteins would pass across via vesicles. Another one is 
paracellular transport, in which molecules smaller than 3nm such as water, ions and 
gas could cross the capillary wall through clefts between ECs. In some specific tissues 
such as blood brain barrier however, cells have no paracellular transport because of 
tight junctions and therefore the molecules can only pass by transcellular transport. 
Through venous vascular system, blood is collected back into the heart. 
Vascular diseases are a class of diseases in which vascular function is damaged 
because of various pathological factors. ECs dysfunction occurs early in vascular 
diseases. ECs dysfunction, increases permeability in large vessel, allowing large 
molecules or even inflammatory cells accumulation and potentially resulting in 
haemorrhage (erythrocyte), atheroma (lipid accumulation) or vasculitis (inflammatory 
cells accumulation). During pathogenesis, large vessels can be occluded leading to 
downstream vessel ischemia or even cellular necrosis in patients.  Depending upon 
the location of lesion, vascular disease can be divided into arterial and venous disease. 
Atherosclerosis is an inflammatory disease characterised by endothelial cell 
dysfunction, leukocyte infiltration, lipid oxidation and fatty streak accumulation with 
disturbed laminar flow due to the development of atheromatous plaques. Fibrous 
plaque expansion and protrusion into the lumen of vessels can lead to acute clinical 
syndromes, such as cerebral or myocardial infarction, or develop into thrombosis, 
hemorrhage, ulceration, and calcification. Similarly, arteriosclerosis is defined by 
arterial lesion due to non-lipid mediators. Aortic dissection is another kind of media 
layer disease, in which blood flows in the vessel wall and tears layers apart. 
Hypertension and connective tissues disorders are predisposing causes in aortic 
dissection. Venous insufficiency, because of venous reflux, which is caused by 
diseases such as vein thrombosis and phlebitis, is the most common in venous 
diseases. Venous insufficiency can lead to complications such as varicose veins and 
ulcers. Lower limb deep vein thrombosis is one severe vein disease and can increase 
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risk of pulmonary embolism. When the clot flows into pulmonary arteries via the 
circulation, it can be fatal. As the principal underlying cause of cardiovascular disease, 
the leading cause of death and morbidity worldwide; atherosclerosis and 
arteriosclerosis have enormous clinical relevance. 
1.2 Organ Dysfunction and Transplantation 
Organ dysfunction refers to a condition in which the tissues lose their homeostasis 
capability and eventually function. Organ failure can be induced due to many 
pathological factors such as sepsis, nonsteroidal anti-inflammatory antibiotics, and 
accumulation of biological by-products. Heart failure occurs when the heart is unable 
to pump sufficient blood to meet metabolic demands. Patients who suffer from severe 
heart failure may show symptoms such as dyspnoea, lower limb swelling and coughing 
blood. Alternatively, hepatic failure results from insufficient synthetic or metabolic 
function. This may arise from risk factors such as hepatitis virus, chemical exposure 
or cancer. New York Heart Association (NYHA) divides heart function into four classes 
according to severity of symptoms. NYHA IV is the terminal or end stage of heart 
failure in which situation patients can not undertake physical activity without discomfort. 
In counterpart, glomerular filtration rate (GFR) being below 15 (ml/min/1.73m2) in 
kidney is defined as end-stage renal disease. In patients with chronic liver disease, a 
diagnosis model for end-stage liver disease has recently been implemented. This 
model combines several serum biomarkers including bilirubin, creatinine and 
international normalised ratio (INR) for prothrombin time. Beside drugs, all the patients 
with organ failure disease need urgent and powerful treatment. For example, 
implantation of left ventricular assist devices are necessary for patients who are at 
cardiac end stage, to prevent mortality. For patients with kidney or liver failure, dialysis 
is one widely used treatment. During this process, waste can be filtered out of the body 
to replace dysfunctional kidney/liver. 
Organ transplantation, which refers to an organ being removed from one body to 
another as recipient, is alternative treatment for severe organ failure patients. Several 
organs including heart, lung, liver and kidney have been successfully transplanted and 
organ transplantations are currently widely performed in clinic. In general, organ 
transplantation can be divided into auto-transplantation, allo-transplantation, iso-
transplantation and xenotransplantation. Auto-transplantation refers to a surgery to 
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transplant a regenerated tissue to other injury places from the same person, such as 
skin transplantation and vein graft transplantation for coronary artery bypass surgery 
(CABG). Iso-transplantation means transplanting tissues to genetically identical 
recipients (such as transplantation between identical twins), whereas xenograft 
indicates organ transplantation from one species to another. The most common type 
of organ transplantation in clinic is allo-transplantation, which refers to a surgery 
process transferring organs between genetically non-identical members from the 
same species. In past decades, organ transplantation has gone through rapid 
development and significantly improved survival rate of organ failure patients. In fact, 
it was shown that in the United States, the one-year survival rate after cardiac 
transplantation has been over 90%3. One year survival rate post liver4 and kidney5 
transplantation is within 80-95%. Because of surgical technique advancement and 
introduction of immunosuppression drugs, short term (within six months or 1 year) graft 
failure has dramatically decreased below 10%. Cyclosporine and tacrolimus are 
examples of immunosuppression drugs which target on T cells and inhibit their 
activation. Data has shown that the rate limiting enzyme in T cells activation is a 
serine–threonine phosphatase, called calcineurin. With calcineurin stimulated, 
phosphorylated nuclear factor of activated T-cells (NFAT) is dephosphorylated and 
translocates from cytoplasm into nucleus promoting target gene activation6. Both 
cyclosporine and tacrolimus could inhibit calcineurin function and thereafter arrest T 
cells activation. Sirolimus and everolimus could inhibit T cells proliferation via targeting 
mTOR7. Because the lymphocyte lacks salvage pathways for synthesis of guanosine 
nucleotides, mycophenolate acid could inhibit lymphocyte DNA metabolism, by 
directly blocking de novo guanosine nucleotides synthesis.  
To note, although short term survival rate in organ transplantation patients has 
significantly increased, long term graft failure is still high. For example, 5 years graft 
failure is around 20% and 10 years organ failure can reach to 40% high. Several risk 
factors were reportedly involved in organ failure after transplantation and these factors 
can be generally divided into four categories, including transplant rejection, recipient 
factors, transplant factors and treatment related factors. Although acute rejection 
mediated by T lymphocytes can be partly inhibited via immunosuppression drugs, the 
innate immune system could react towards the graft tissue. Patient’s recovery 
response to graft transplantation varies due to individual differences. Patient’s age and 
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complications with diabetes, dyslipidaemia, hypertension, cancer and viral infection 
could all severely effect and therefore reduce long term survival rate for organ 
transplantation patients. Donor transplant condition also affects organ transplantation 
result. For example, when the graft transplant is dysfunctional due to primary factors 
or during transfer process, organ dysfunction would be anticipated. Meanwhile, factors 
such as donor age, sex and potential infection would all contribute to graft failure. 
Furthermore, improper treatment or side effects after organ transplantation would as 
well lead to severe graft dysfunction. Although immunosuppression drugs could 
decrease rates of acute graft rejection, they would at the same time increase patients 
risk for infection and cancer. Cyclosporine as calcineurin inhibitor, has nephrotoxicity, 
which would result in renal graft dysfunction8. In addition, the timing on dialysis before 
transplantation has also been demonstrated an independent risk factor for kidney 
transplantation failure.    
1.3 Allograft Vasculopathy/Arteriosclerosis  
Although all risk factors above could contribute to graft failure, various studies revealed 
that in large proportion, graft failure does not result from primary organ dysfunction, 
but from ischemia due to narrowed arteries. For example, after cardiac transplantation, 
allograft ischemia could occur earlier in less than 2 h, and nearly all the graft could 
undergo ischemia within 6 h. When ischemia further progresses, 
vasculopathy/arteriosclerosis develops. Cardiac allograft vasculopathy (CAV) is a 
chronic disease in which the graft coronary artery lumen becomes narrow while the 
vessel wall becomes thick and hard (Figure 1.3). CAV could lead to severe graft 
damage, even to heart failure or sudden death. Most recent report showed that 5 and 
10 years post cardiac transplantation, occurrence rate of CAV is around 30 and 50%, 
respectively9. Notably, 5 years survival rate in patients with CAV is merely 75%, lower 
than the patients without vascular disease. In fact, CAV is reported to be leading cause 
for long term transplant organ failure. Similar to other organ transplantation, CAV is 
caused by both immunologic and non-immunologic factors. CAV is characterized by 
diffuse lesions within vessel wall. CAV Lesions can be divided into vasculitis, intimal 
hyperplasia and atheroma plaque10. Initially after transplantation, inflammatory cells 
including lymphocytes and macrophages accumulate at intima layers leading to ECs 
inflammation, which is called vasculitis. Then injured ECs express cytokines or growth 
factors production that can activate proliferation of SMCs or fibroblasts within the 
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intima layer. Meanwhile, these proliferating cells also secrete ECMs such as collagen 
and fibronectin leading to vascular wall fibrosis. In fact, intimal hyperplasia mainly 
includes dysfunctional ECs, proliferating SMCs, clotting development and fibrotic 
ECMs. When inflammation further develops, atheroma plaque occurs which 
characterized by accumulation of degenerative materials such as inflammatory cells, 
SMCs, lipid, calcium and fibrous ECMs. As compensation, SMCs in the media layer 
would stretch out to form aneurysms, which keep lumen diameter in a relatively 
constant level. Over time, atheroma progresses in size and thickness, eventually 
reaching to SMCs remodelling capacity or plaque rupture occurrence. The plaque 
protrudes into the vascular lumen, narrowing the vessel and restricting the blood flow. 
When the plaque ruptures, debris and small clot would spread into small vessels 
resulting in lumen closure and acute major vascular event. To note, all CAV lesions 
would occur simultaneously but not separately. Other factors, rather than entirely 
vasculitis, are involved.  Inflammatory cells also participate in intimal hyperplasia and 
atheroma plaque processes. Furthermore, data has shown that inflammatory cells do 
not solely limit in ECs layer, but could extend to all three layers of the vessel. 
Compared with native atherosclerosis, CAV also has its pathological characters. For 
example, CAV could occur with a concentric but not eccentric stenosis. In addition, the 












Figure 1.3 Cardiac allograft vasculopathy (CAV). Post transplantation surgery, 
inflammatory cells accumulate at intima layers leading to ECs activation. Dysfunctional 
ECs express cytokines and stimulate SMCs or fibroblast proliferation. These ECs 
secrete ECMs leading to vascular wall fibrosis. Vasculitis, intimal hyperplasia and 
atheroma plaque are typical pathological process. SMCs migrate from media layer into 
the intima layer as a response to lumen narrowing. Over time, atheroma progresses 
in size and thickness, forming the lesion. The lesion protrudes into the vascular lumen, 
narrowing the vessel and restricting the blood flow. When the plaque ruptures, clot 
occludes the lumen. Typical cardiac allograft vasculopathy (CAV) lesion is concentric 
but not eccentric stenosis. CAV, Cardiac allograft vasculopathy; ECs, endothelial cells; 
SMCs, smooth muscle cells; ECMs, extracellular matrices. (Figure Source: Colvin-
Adams M, Harcourt N, Duprez D. Endothelial dysfunction and cardiac allograft 






1.3.1 Immune Response 
Similar to other organ transplantation, both cellular and humoral immune response are 
involved in CAV. Cellular immune response is a result of activated T lymphocytes 
which exert direct cytotoxicity or release cytokines in response to exogenous antigens. 
Humoral immune response refers to immunity mediated through antibodies and/or 
complement system. Furthermore, the innate immune system is also known to be 
involved in CAV pathology. 
1.3.1.1 Cellular Immune Response  
Immune response  to non-self-antigens are recognized by recipient immune system12.  
From the transplant tissue staining, it was shown that T cells are present at higher 
levels and infiltrate within the neointima13. Three mechanisms are responsible for T 
cell response. Firstly, when the donor tissue is allo-transplanted to recipient, recipient 
T cells recognise intact donor molecules complex with peptide on donor antigen 
presenting cells (APCs) , leading to extremely strong and acute rejection which is 
called direct recognition12. Secondly, indirect recognition also play an important role in 
allo-graft rejection12. Distinct from direct recognition, in indirect recognition, donor 
antigen, is digested, internalised and presented by recipient APCs. Afterwards 
recipient APCs are recognized by T lymphocytes. Third, semi-direct pathway is also 
shown involved in T cells activation, although the mechanism is unclear14. In semi-
direct recognition, by intracellular exchange between donor cells and recipient APCs, 
donor MHC is presented by host APCs inducing T cells response. Afterwards, 
activated T cells resulted from pathways above, would then secrete inflammatory 
cytokines such as IL-2 and IFN-γ15.  Effector cells such as macrophages, T cells and 
B lymphocytes are activated by these cytokines. When these inflammatory cells are 
recruited to ECs and towards the whole vessel wall layers, vasculitis is induced.  
1.3.1.2 Humoral Immune Response  
Humoral immune response also contributes in CAV formation. Under inflammatory 
molecules regulation, B lymphocytes and monocytes are activated in response to HLA 
molecules. Activated B lymphocytes secrete specific antibodies which bind to donor 
antigens. These antibodies are recognized by phagocyte or complement system, both 
of which exert damage to the allograft tissues. Clinical studies have confirmed that 
HLA-specific antibodies expression16 and complement activity17 are increased within 
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the neointima, which correlated with poor result of transplantation. After 
transplantation, B cell receptor binds with the antigen activating intracellular 
endocytosis and presenting the antigen on the surface of a MHC II molecule. T helper 
(TH) cells activate B cells to differentiate into plasma B cells or memory B cells. Plasma 
B cells are responsible for antibody production, whereas memory B cells are inactive 
and trigger rapid production of antibodies when exposed to a previously recognised 
epitode. Antibodies belong to the glycoproteins immunoglobulin superfamily. All 
antibodies are Y shaped proteins, which consist of two heavy chains and two light 
chains giving antigen binding domains. The domains on the chain determine function 
of antibodies. Fragment crystallisable (Fc) region in heavy chain is constant and 
defines the isotype of antibodies, which include IgA, IgD, IgE, IgG and IgM. When 
binding with respective specific Fc receptor (FcR) on antigen, these antibodies exert 
distinct effects.  All isotype of antibodies have their specific complex structure. For 
example, IgD/E/G are monomer, whereas IgA is a dimer and IgM is one pentamer. 
Fragment antigen-binding (Fab) is the region consisting of part of heavy chain and the 
whole light chain. Variable domain in heavy chain (VH) and light chain (VL) are located 
in the Fab region, and variety in this domain is because of the hypervariable region 
(HVR) or complementarity determining region (CDR). Three genes are located on 
HVR/CDR and variety of variable domain relies on V (D) J recombination. With specific 
differences in domain structure, antibodies recognize targeted antigen. Subsequently, 
antibodies can be recognized by monocytes. Under cytokines stimulation, monocytes 
transform into macrophages, and phagocytose targeted cells. Alternatively, 
complement system is activated and recruited. Complement system is part of the 
immune system, involved in innate and adaptive immune process. Complement 
system is composed of several plasma proteins, which are produced from the liver. 
Once triggered, they would recruit phagocytes or form cell killing membrane attack 
complex. Three signalling pathways including classic complement pathway, 
alternative complement pathway and lectin pathway consist of the complement system. 
1.3.1.3 Innate Immune Response  
The Innate immune system is an evolutionarily preserved defence system, which 
recognises and eliminates exogenous antigen. Damage associated molecular 
patterns (PAMPs), refers to exogenous antigen. When PAMPs on microbes bind with 
pattern recognition receptors (PRRs) on host innate inflammatory cells, inflammation 
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is triggered. Classic PRRs include mannose receptors, scavenger receptors and Toll 
like receptors. For example, toll-like receptors induce mononuclear cell activation 
which occurs in organ transplantation18. Inflammatory cells such as 
monocyte/macrophage, mast cells, phagocyte, granulocytes, dendritic cells and 
natural killer (NK) cells are involved in the innate immune system. When 
immunoreaction persists within the graft tissue, fibrosis follows under the influence of 
cytokines and as a consequence thickens the neointima19. IFN-γ and TGF-β can 
activate macrophages to infiltrate into the neointima, and propagate lesion size by 
tissue remodelling and matrix deposition20.  
1.3.1.4 Donor Derived Immune Response 
 In addition to recipient immunoreaction, donor grafts also provide immune cells 
contributing to CAV process. After transplantation, donor immune cells migrate into 
recipient lymph nodes and present antigens. In fact, by transplanting transgenic heart 
to wild type (WT) animals, donor dendritic cells can be detected within 3h, which 
probably initiate recipient T cells activation21.  Meanwhile, donor lymphocytes activity 
was also be detected after transplantation. It was shown that after transplantation, 
donor CD4+ T cells were activated as a response to MHC class II on recipient B cells22. 
When CD4+ T cells from donor graft were depleted, autoimmune antibodies decreased. 
Furthermore, ligands expressed on donor graft are also related to lesion formation. 
Programmed death-ligand 1(PDL1) is a ligand, which transmits an inhibitory signal 
reducing T cells proliferation. Data was shown that PDL1 expression on donor grafts 
inhibited allograft rejection by modulating T cells activation23. However, selectin 
molecules from donor cells can accelerate neointima formation via binding and 
recruiting leucocytes24.  
1.3.2 Allograft Transplantation Mouse Model 
Rodent models in allotransplantation provide deep understanding of underlying 
mechanisms and potential therapeutic approaches25. Heterogenic heart 
transplantation mouse model was established since 197326. This surgery involved the 
transplantation of heart graft to a recipient mouse. This important model provides 
researchers the opportunities to further study alloreactivity, although in the expense of 
a challenging microsurgery technique. When the graft is transplanted into 
immunocompetent recipients, acute rejection occurs because of MHC molecules 
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mismatch. MHC molecules can be divided into class I and class II groups, which are 
recognized by CD8 and CD4 T cells, respectively. CD4 and CD8 reactions vary in 
different organ grafts. Histocompatibility is decided by specific MHC in each strain. 
MHC haplotype in C57BL/6J and BALB/c mice are H2b and H2d, respectively. This is 
the basis why these two strains are commonly used in allo-transplantation mouse 
models. For example, it was shown that when transplanting a C57BL/6J (H2b) kidney 
to a BALB/c (H2d) mouse or vice versa, allo-graft rejection occurs at a post-
transplantation level27. Within the MHC mutant animals, allo-immune reaction would 
also develop.  B6.H-2bm12 is a spontaneous mutation within the β-chain on class II MHC 
molecules28. When a heart from a B6.H-2bm12 mouse was transplanted to a C57BL/6J 
(H2b) mouse, CAV developed demonstrating the involvement of CD4 T cells. Besides 
of cellular immunity, humoral immune rejection activities are also prevalent in allo-
transplantation. It was shown that, when transplanting serum antibodies to RAG1-/- 
mice, acute rejection can be induced29. Recombination-activating genes (RAGs) 
encode enzymes which are important in the rearrangement and recombination of 
antibodies and T cell receptors via manipulating V (D) J recombination.  T cell receptor 
(TCR) recognizes MHC molecules. Similar to antibodies, diversity of TCR relies on V 
(D) J recombination. Therefore, in RAG1-/- mice, both mature T cells and B cells 
mediated antibodies cannot be produced30. In previous study, data showed that 
although adaptive system is damaged in RAG1-/- mice, CAV could still occurs because 
of NK cells involvement31. Using the same RAG1-/- mice, and transferring donor 
alloantibodies, C4d was found deposited in graft artery. Because C4d is a protein 
which is involved in classic complement system pathway, this result indicated that 
complement system also contributed to allo-immuno reaction after transplantation. 
To simplify the disease model and directly visualize vascular processing pathology, a 
vascular allograft accelerated arteriosclerosis mouse model was developed. Currently, 
three different types of surgery are mainly used to recapitulate this animal model. The 
first artery allograft transplantation was established in 1994, in which donor vessel 
grafts from B.10A (2R) (H-2h2) were transplanted to carotid arteries of recipient 
C57BL/6J (H-2b) mice via side-to-end suture32. Another artery allograft transplantation 
was performed by transplanting 1cm donor thoracic aorta to recipient infrarenal aorta 
by end-to-end anastomosis33. In 2000, our previous laboratory group work developed 
a simple and effective vascular graft allo-transplantation mouse model34. With the 
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assistance of a cuff similar to vein graft transplantation surgery35, a segment of artery 
graft from C57BL/6J (H-2b) mice was transplanted to BALB/c (H-2d) by end-to-end 
connection34. With these artery allo-graft transplantation mouse models, the functions 
of these molecules in this disease can be further understood. For example, 
intracellular adhesion molecular (ICAM) is one glycoprotein, which is located on the 
surface of ECs and inflammatory cells. ICAM plays a important role in developing 
vasculitis by recruiting leucocyte infiltrating into vessel wall. When donor graft derives 
from ICAM-/- mice is allotransplanted, arteriosclerosis lesion can be analysed with the 
mice expressing ICAM. IFN-γ is another cytokine regulating T cells proliferation and 
macrophage accumulation in the neointima. When IFN-γ gene was knocked out, 
recipient mice would not develop severe lesion after allograft transplantation36. In 
addition, it was shown that IFN-γ could also upregulate MHC and adhesion molecules 
on circulating cells as well as vessel wall. This may provide us with an insight in the 
role of IFN-γ in this immune incompatible mouse model37. 
Mouse models do not successfully recapitulate clinically relevant transplantation 
pathology. Anatomical and utilisation of surgery procedures are different in both 
settings.  Transplantation surgeries in mice do not involve immunosuppressive drugs 
to prevent acute graft rejection and this is one major difference compared with current 
clinical transplantation.  Differences between animal models and the clinic must be 
safely addressed cautiously and in strict compliance with laws and regulations.   
1.3.3  ECs Dysfunction  
ECs dysfunction is a hallmark of vascular disease. ECs are the first target of the 
immune system after organ transplantation. EC rejection by inflammatory cells results 
in ECs dysfunction, which is characterised by increased permeability and inflammatory 
cell accumulation. After antigen molecules on ECs are recognized by immune cells, 
they are directly attacked either by cytotoxic or by inflammatory cell secreted cytokines, 
such as IL-2, IFN-γ and TNF-α. Adhesion molecules expression such as VCAM and 
ICAM, is increased within ECs leading to recruitment of inflammatory leucocytes. 
Recruited inflammatory cells further exacerbate EC dysfunction by increasing vascular 
permeability. These immune cells may secrete cytokines such as PDGF and TGF-β, 
both of which stimulate SMCs proliferation and ECMs accumulation in the intima layers. 
As a consequence of ECs dysfunction, clotting molecules, platelet, lipid and ECMs 
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accumulation within the intima layer may develop and potentially encourage intimal 
hyperplasia. When this process develops, apoptosis of ECs may be observed.  
1.3.4 Endothelial Stem/Progenitor Cells (ESPCs)  
When ECs within the donor graft become dysfunctional or are eliminated in response 
to immune activation, host cells may integrate into the ECs layer either for repair or 
further impairment. Although its function is still under debate, re-endothelialisation in 
CAV lesion by recipient cells has been confirmed in a number of studies. Endothelial 
stem/progenitor cells (ESPCs) are able to proliferate and differentiate into ECs. 
However, there is no clear consensus on the precise definition of these cells. To 
prevent any confusion in this thesis, ESPCs from bone marrow source mentioned 
below are referred as endothelial progenitor cells (EPCs) whereas endothelial 
progenitors (EPs) mean the resident ESPCs distributed at the several locations (for 
example, vessel wall, spleen, liver, heart and lung).  
1.3.4.1 Endothelial Cells (ECs) Differentiation 
ECs are identified by their specific markers such as CD31, tie-2, vWF, VE-cadherin, 
VEGFR, and endothelial nitric oxide synthase (e-NOS).  Up-regulation of ECs gene 
expression relies on promoter activation. The ETS domain is one gene containing 3 
α-helices and 4 β-sheets interacting with a core sequence of 5′-GGA(A/T)-3′ being 
identified in nearly all ECs related gene promoters38. ETS family proteins are important 
transcription factors binding with the ETS domain. Classic ETS family proteins are 
identified based on similar conserved domains and the most important is the pointed 
domain which functions by binding with the ETS domain third α-helices 38. To date, 19 
ETS family proteins have been identified within human ECs. Amongst all of them, 
ETS1/2 are the most important transcription factors and relatively well-established in 
ECs differentiation. ETS1 is composed of 440/441 amino acids within the pointed 
domain from the N-terminal towards to acidic transactivation domain.  The ETS binding 
domain is flanked by two auto-inhibitory domains. ETS proteins were reported to 
consist of several isoforms when undergoing alternative splicing. On gene level, ETS1 
and ETS2 loci are located in the same chromosome with FLI1 and ERG, respectively, 
in head to head orientation39. ETS1/2 are expressed in ECs for endothelial tube 
formation. Under angiogenesis stimuli such as hypoxia and inflammation exist, their 
expression are increased.  ERG and Fli1 as another two ETS family proteins are 
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responsible for vascular integrity. However, the elimination of these two transcript 
factors does not necessarily result in ECs death indicating their roles can be 
compensated by other ETS family proteins. ETS family transcript factors such as ETV6, 
ELK3, and ETV2 are also involved in vascular integrity via ECs differentiation. Several 
mechanisms have been identified in the regulation of ETS family transcript factors 
Post-genetic modification such as phosphorylation, acetylation, ubiquitination and 
sumoylation are responsible for ECs gene expression. Alternatively, by binding with 
other transcript stimulators such as FoxC2 and klf2, ECs gene expression can be 
regulated. Although, a large profile of transcript factors have been associated with ETS 
family proteins, the precise effect is unclear.  Homo-dimerization or polymerization 
may control the activity of ETS family proteins. Other transcript factors such as SCL, 
GATA, Fox and klf transcription factors have been shown to be related to ECs gene 
expression.  
1.3.4.2 ESPCs Identification 
Since the first time that the CD34 and VEGFR2 double positive cells showed potential 
to proliferate and differentiate into the mature EC-shaped cells expressing ECs 
markers such as CD31, E-selectin and eNOS, several methods have been suggested 
to identify putative ESPCs40. It was proposed that uptake of acetylated-low density 
lipoprotein (ac-LDL), binding with ulex europaeus agglutinin-1 (UEA-1) and 
differentiation potential to cells expressing ECs markers are specific characters of 
ESPCs40. However later on, large amount of studies suggest that this method alone is 
far from sufficient to define ESPCs, since the potential described above is shared 
amongst other cell types. Therefore, ESPCs were later identified by another in vitro 
method termed colony-forming assay. After one-week culture on fibronectin-coated 
dishes, adhering central rounded cells surrounded by thin flat cells can be observed. 
After selecting with specific ECs markers, targeted cells are nominated as the colony 
forming unit-Hill (CFU-Hill) ESPCs41. However it was again refuted by the fact that 
hematopoietic monocyte and/or immune cells could mimic CFU-Hill ESPCs42, 43. With 
the addition of failure to form new blood vessel and the slow rate of proliferation in vivo, 
these captured CFU-Hill cells were suggested to resemble hematopoietic lineage cells. 
Another population termed endothelial colony-forming cells (ECFCs) were 
recommended within an alternative EC/PCs colony forming assay44, 45. Under this 
method, the peripheral cells were cultured on collagen I coated plate with suitable 
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culture medium. After not more than 3 weeks, adhering cells expressing ECs markers 
were suggested to mimic ECFCs. In fact, ECFCs in this method were shown forming 
heterogeneous populations with hierarchy proliferating potential in vitro. More 
importantly, ECFCs were able to generate novel capillary like ECs in both in vitro and 
in vivo. This indicates that ECFCs are a sub-population of real ESPCs. To date, 
proposed ESPCs in most studies are identified by various stem/progenitor markers 
such as CD34, c-kit, and CD133 with/without some ECs markers such as CD105, 
CD106, CD144, VEGFR 1/2 and TIE2, although none of marker patterns have been 
shown exclusively in ESPCs.  
1.3.4.3 Circulating Endothelial Progenitor Cells (EPCs) 
Bone marrow was the first proposed to harbour ESPCs or EPCs. It has been 
demonstrated that in bone marrow niche, EPCs homeostasis is under regulation of 
several cytokines (such as VEGF, Ang-1, SDF-1 and SCF). These cytokines are 
known to be secreted by surrounding cells such as pericytes and ECs. Once these 
secreted cytokines bind to their corresponding receptors (for example, VEGFR, TIE-
2, CXCR4, c-kit and Notch) respectively, EPCs begin to migrate, proliferate or 
differentiate following its related signalling pathway. In disease states such as hypoxia, 
induced hypoxia-inducible factor-1 (HIF-1) increases expression of VEGF along with 
Ang-1 within the bone marrow microenvironment46. When stromal cells sense the 
change of VEGF concentration, eNOS are phosphorylated via the VEGFR/Akt-
dependent signalling pathway47. With the mechanism of S-nitrosylation, MMP9 is 
activated48. Then increased level of MMP9 rapidly alters quiescent bone marrow niche 
by cleaving membrane bounded SCF on stromal cells into soluble form. Soluble SCF 
could mobilize c-kit+ EPCs from the bone marrow and into the circulation49. SDF 
belongs to the chemokines family. Under hypoxia, SDF along with its corresponding 
receptor CXCR4 is upregulated within stromal cells50. AMD3100 is a mobilizing agent 
which acts as an antagonist of CXCR4. Reversible blocking of SDF/CXCR4 binding in 
the bone marrow by AMD3100 mobilized EPCs51. In addition, family of integrins is also 
involved in EPCs mobilization. Data was shown that α4-integrin is an important 
molecule to mediate EPCs adhesion. Disruption between α4-integrin and fibronectin 
results in EPCs mobilization and thereafter increases ischemic neovascularization52.  
1.3.4.4 Resident Endothelial Progenitors (EPs) 
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Recent studies showed that the circulating or bone marrow derived EPCs cannot 
explain all the new vessel formation in the vessel wall53. In fact, apart from bone 
marrow cells, non-bone marrow cell sources (such as vessel wall, muscle, adipose 
tissue, dermis, intestine and liver) of EPs are recently reported to distribute in local 
tissues. Among all of these vascular tissues, vessel wall is one rational organ to 
harbour EPs. According to definition, resident EPs are cluster of local cells with 
potential to proliferate and differentiate into ECs. In fact, several population of EPs 
have been identified within vessel wall. For example, EPs were isolated from both 
human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells 
(HAECs)53. When cultured in vitro, these EPs showed potential to generate multiple 
ECs colonies including ECFC with both high and low proliferating potential, similar to 
umbilical cord blood derived ESPCs. Side population of c-kit+  cells within endothelial 
layer were also demonstrated to be able to generate functional vessel54. Elimination 
of c-kit impaired function within these EPs such as proliferating and vasculogenesis 
potential, which cannot be rescued by wild type bone marrow transplantation. 
Peripheral vascular endothelium is also reported to harbour one side population of 
EPs, characterized by Hoechst dye efflux ability in CD31+CD45− EC fraction55. 
Although these EPs showed similar surface marker to conventional ECs, the gene 
hierarchy within them is completely diverse. It was suggested that this population of 
EPs is quiescent but possesses self-expanding and colonies forming potential in vitro. 
When these cells were transplanted to ischemia mice, they showed potential to form 
de novo vessel. In addition to endothelium, a distinct niche namely the vasculogenesis 
zone locates between the media and adventitia layer was also reported. It was 
reported in this region, one population of EPs exist, with a high expression of CD34 
along with VEGFR2 and TIE2 but not CD31 and CD4556. These EPs have the potential 
to generate de novo functional vessel verified by sprouting and capillary-formation 
assays. In fact, all three mural layers within coronary arteries were reported to harbour 
proliferating c-kit+VEGFR2+EPs which connect with other supporting cells57. Once 
these EPs are cultured and injected in a stenosis induced immunosuppressed dogs, 
they generate vasculogenesis in all large, medium and small vessels forming complete 
human coronary arteries. But still, caution is never non-necessary similar to However, 
it needs to be taken into account for EPCs identification from bone marrow, since niche 
mentioned are not excluded from other pro-angiogenic cells (for example, HS/PCs, 
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fibroblast, mesenchymal stem cells (MSCs) and pericytes), all of which also have a 
self-renew feature. Along with other factors including growth factors, laminal flow, 
hypoxia and oxidized stress, EPs are proposed to be stimulated by secreted paracrine 
factors from pro-angiogenic vascular cells to adjust from a quiescent state and transfer 
into a proliferation state along with migration to injury site, similar to bone marrow 
derived EPCs.   
Figure 1.3.4.4 Vascular wall resident Stem/Progenitor cells (SPCs). SPCs are 
distributed across all of three vessel walls. EPs mainly locate in the intima and 
vasculogenesis zone. In media layer, MSCs are detected along with side population 
of progenitor cells. Adventitia harbour most abundant populations of SPCs, including 
adventitia SPCs, EPs, HSCs, MSCs and perivascular SPCs. All of these populations 
of SPCs can be recruited under vascular signals. SPCs, stem/progenitor cells; EPs, 
endothelial progenitor cells; MSCs, mesenchymal stem cells; HSCs, hematopoietic 
stem cells; AMPCs, adventitial macrophage progenitor cells. (Figure Source: Psaltis 






The lung and heart were also reported to harbour resident EPs. It was found that the 
lung tissue possesses a pool of c-kit+ cells located in bronchioles as well as alveolar 
wall niche59. Expression of NANOG, OCT3/4, SOX2, and Kruppel-like factor 4 (Klf4) 
indicate multipotent potential within these adult c-kit+ human lung stem cells.  In fact, 
it was shown that these cells are self-renewing, clonogenic, and multipotent involved 
in lung homeostasis59. However, debate exists concerning the role of c-kit+ cells during 
lung homeostasis or in the other words, the terminal fate of this population of cells. It 
was initially reported c-kit+ cells could repopulate SMCs and/or epithelial cells59. This 
was however later disproved by one study, to show that these c-kit+ pulmonary 
progenitor population cells were actually EPs acquiring endothelial lineage but not 
SMCs or epithelial cell lineage60. This was verified by another lineage tracing study. 
This study showed that in c-kitkit/CreER; ROSA26-RFP, RFP (because of c-kit promotor 
induced Cre recombination activation) was only expressed in lung vascular endothelial 
but not epithelial cells61.  Within the heart chamber, c-kit+ SPCs with potential to 
differentiate into terminal non-hematopoietic cells, were thought derived from bone 
marrow and involved in de novo cardiomyocyte formation62. However, subsequent 
studies denied this phenomenon and found that bone marrow source of c-kit+Lin-
   HSCs showed no ability to differentiate into cardiomyocyte63 . Delivery of bone 
marrow derived c-kit+ cells did not increase the left ventricle function64. Although c-
kit+ cells do contribute to de novo cardiomyocytes, the percentage is only 
approximately 0.03 in both growing and adult mouse heart. Considering cellular fusion, 
the percentage could fall to below approximately 0.00865. Afterwards these c-kit+ cells 
were shown to guide mainly ESPCs towards an endothelial fate when using a lineage 
tracing method65. However, it is worthy to point out that whether these c-kit+ cells 
acquiring ECs fate are indeed EPs or pre-existing ECs still need further investigation 
to determine.  
1.3.4.5 Source of ESPCs in Allograft Vasculopathy 
It is vital to identify the source of ESPCs in AV. It was speculated that after ECs 
damage, donor derived cells would be activated, and this could contribute to ECs 
regeneration. However, this was challenged by other studies claiming that lost ECs 
can be replaced by recipient source of cells. In one study from our lab it was shown 
that after vascular allograft transplantation, all ECs in donor graft were absent due to 
apoptosis or necrosis within 4 weeks66. Meanwhile, recipient source of circulating 
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ESPCs would be activated to regenerate damaged endothelium and generate 
microvessel neo-vasculogenesis. The intermediate situation is also reported, in which 
both donor and recipient source of cells contribute to mixture of ESPCs and involve in 
ECs regeneration67. An explanation of this disparate phenomenon is because of 
different model or treatment used. For example, although similar in some aspects, the 
whole immune system is not the same between the mouse and human. Therefore, 
after allo-transplantation, severity of immune reaction can be distinct between animal 
models and human tissue, which could partly explain the different results generated 
from various groups. In other words, severity of donor graft injury could possibly decide 
whether they still preserve enough potential to involve in ECs regeneration. Afterwards, 
it is also important to clarify the source of recipient ESPCs. It was shown that 
approximately 30% of regenerated ECs derive from bone marrow in mouse66, whereas 
in rat only few bone marrow cells contribute to ECs regeneration68. These disparity 
results may be due to differences within species and technique used. Another 
important issue to address is whether ESPCs from other sources such as vessel wall, 
adipose tissue or spleen are involved in AV and if so, the precise mechanisms involved 
need to be clarified. 
1.3.4.6 ESPCs Regeneration in Allograft Vasculopathy 
After allo-immune reaction induced ECs dysfunction, damaged ECs and inflammatory 
cells release chemokines in a autocrine and paracrine fashion within the graft vessel 
wall. Chemokine attraction, mobilises and homes ESPCs to graft vessel. After aortic 
transplantation in mice, SDF-1 is upregulated within the graft recruiting CXCR4+ stem 
cells towards the neointima69. Meanwhile, when interacting with adhesion molecules 
expressed on graft endothelium, ESPCs could adhere to the vessel. ECs dysfunction 
would also lead to ECMs exposure and subsequently platelet adhesion, both of which 
facilitate ESPCs adhesion. During ESPCs migrating and homing process, ESPCs to 
ECs commitment can develop occur simultaneously. Although evidence of ESPCs to 
ECs differentiation is lacking in CAV, studies on this process are many in other animal 
models. So far, literature describes ECMs, SDF, VEGF and sheer stress as main 
contributors of EC commitment from ESPCs. ESPCs to ECs commitment is under the 
governance of transcription factors, partly played by histone deacetylases (HDACs). 
HDACs mediated histone deacetylation is a process in which acetyl is removed from 
the N-terminal lysine residues on acetylated histones, altering chromosome structure 
37 
 
and enabling the access of transcript factors to DNA and initiating differentiation of 
SPCs. HDACs involvement in ESPCs differentiation to ECs can stem from the 
inhibition of HDACs and the downregulation of  ECs markers and in turn can be 
rescued by Hox-A9 overexpression70. HDAC-3 was specifically reported to induce sca-
1+ embryonic stem cells to differentiate into ECs and accelerate re-endothelialisation 
of injured arteries. Other HDACs such as HDAC-1, 2,4,7,8 were also suggested for 
ECs differentiation. However, the precise mechanisms are unestablished as 
deacetylation and the result of enhanced EC markers could be the result of other 
HDACs including HDAC3 and possibly not from a master enzyme regulator71. Another 
important regulator among ECs differentiation are microRNAs. Various microRNAs 
including microRNA – 10, 16, 18a/b, 31, 99b, 107, 126, 148b, 150, 155, 214, 221, 349, 
484, 513, 574-3p, let7 are highly expressed within ESPCs72. During ESPCs 
differentiation process, certain microRNAs are upregulated and subsequently 
targeting specific genes to enhance ECs commitment. For example, microRNA-21 
was shown to be involved in ECs differentiation73. Besides of promoting ESPCs 
differentiation, microRNAs also conversely inhibit this process. It was shown that 
microRNA-107 inhibit EPCs differentiation by decreasing HIF-1β expression74.  
1.3.5 SMCs Phenotype Change in Allograft Vasculopathy 
Smooth muscle cells (SMCs) provide the main structure in media layer of vessel wall. 
Several markers including ɑ-smooth muscle actin (ɑ-SMA), smooth muscle myosin 
heavy chain (SMMHC), calponin and SM-22 are currently used to identify SMCs. 
Traditionally SMCs are divided into two sub-types: quiescent/contractile and 
proliferative. Normally mature SMCs are restricted in the media layer regulating the 
physical vessel tone via constriction. However, in an injured environment with the 
presence of inflammatory mediators and allo-transplantation, SMCs undergo 
proliferation and ECM secretion within the intima. During persist stimuli, media 
quiescent SMCs undergo phenotype alteration losing their contractile property and 
acquiring dedifferentiating SMCs characters. These dedifferentiated SMCs usually 
contribute to AV plaque formation and narrow the vascular lumen. Data showed that 
AV can be alleviated when SMCs proliferation inhibitor such as sirolimus is used75. 
When AV further develops, apoptosis of SMCs can be observed and propagate lesion 
instability. Plague can disintegrate from the wall and block passage of blood flow 
leading to an acute cardiovascular syndrome. It was thought that SMCs only form 
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during embryo stage and SMCs development ceases during postnatal stage76. 
However, it was later found that smooth muscle stem/progenitor cells (SMPCs) are 
one important source of SMCs in adult77.  
1.3.5.1 SMCs Differentiation 
During embryonic stage, SMCs are derived from the neural crest, proepicardium, 
mesothelium, secondary heart field, somites, mesoangioblast, pericytes and SPCs. 
The question of how such various origin integrate into one communal cell type is still 
unknown. But at least in recent decades, one transcript factor serum response factor 
(SRF) along with its coactivator myocardin families have been an integral part of SMCs 
regulation. The enhancer element proximal to oncogene c-fos promoter78 and 
sarcomeric-restricted genes79 (such as skeletal α-actin, α- myosin heavy chain, 
cardiac and skeletal myosin light chain 2, and cardiac troponin T), serum-response 
element (SRE) was identified as one CCArGG box or CArG box element responsible 
for target gene regulation. Structure of CArG box located within 2-3kb distant to 
promoters in various SMCs restricted genes80. Later, gene encoding SRE binding 
protein was cloned, identified and named as serum SRF81. According to its structure, 
SRF belongs to transcript factor within MADS box family. This consist of one N-
terminal structure binding with DNA and/or protein along with one C-terminal 
phosphorylation sites that recruit SRF-associated factors. SMCs differentiation under 
SRF has been addressed by several mechanisms including increasing SRF 
expression, modulating affinity between SRF and SRE, SRF alternative splicing, 
chromatin-associated accessibility of SRF to CArG box and multiple complex 
assembly. Myocardin family mainly including myocardin82 and myocardin related 
transcription factor-A/B (MRTF-A/B)83 was found to be important cofactors of SRF but 
not directly binding to target DNA. Structural analysis of the myocardin family revealed 
that the N-terminal begins with RPEL motifs which is related to G-actin binding.  This 
binding domain functions by interacting with smad1 and SRF. The SAP domain is 
related to chromosome function and the coiled-coil motif stabilises leucine zipper of 
protein on binding with SRF. C-terminal region ends with the transcription activation 
domains (TADs) and is known to activate MRTF-A/B. Myocardin exerts its effect on 
several SMCs genes including ɑ-SMA, SMMHC, calponin, SM-22, and SM myosin 
light chain kinase (MLCK) by binding with SRF to regulate cell differentiation. Binding 
with smad3, myocardin initiates interaction between smad3/ smad-binding elements 
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(SBE) and this effectively increases SMCs gene expression84.  Activation of myocardin 
can also be upregulated via binding between transcript factors coactivators such as 
SRC3 and GATA4. Conversely, several mechanisms are related to myocardin 
activation inhibition. For example, interaction with repressors such as Foxo4, SOX9, 
HRT-2 and uPAR caused inhibition of myocardin. On the other hand, ability of 
myocardin binding to SRF can be inhibited by competing proteins such as Runx2, TDG, 
HERP1and GATA factors. MRTF A/B can be retained outside the nucleus by binding 
with actin monomers and this prevent MRTF A/B from translocating into the nucleus 
exerting functions85. In addition, binding between SRF/myocardin complex and DNA 
could be inhibited by several transcript factors including Msx transcription factors 
(Msx1 and Msx2), Yap1, and the Klf4.  In fact, transcript factors such as SRF, NKX2.5, 
Smad3, Mef2, Foxo and TEAD are all related to SRF/myocardin complex binding. Last, 
post-translocation modification such as phosphorylation, acetylation/de acetylation 
and/or ubiquitination is also related to myocardin expression.   
1.3.6 Smooth Muscle Progenitor Cells (SMPCs)   
Recently, data has shown that smooth muscle progenitor cells (SMPCs) are preserved 
until postnatal stage in both physiologic and pathologic processes. The source of 
SMPCs is highly debated. Bone marrow derived HSCs were thought as one source of 
SMPCs from circulation involved in SMCs differentiation86. Several population of 
SMPCs are identified in all three layers within vessel wall. One population of SMPCs 
with the markers such as sca-1, c-kit, CD34 along with VEGFR2, was firstly found 
harbouring within adventitia of vascular wall87.  This was confirmed by later study that 
sca-1+CD34+ SMPCs expressed on adventitia are under regulation of a sonic 
hedgehog (Shh) signalling88. Recently, another population of CD146+ SMPCs were 
identified within the adventitia from embryonic to postnatal stage89. Lineage tracing 
study revealed that transcript factor Gli1+ SMPCs could proliferate and differentiate 
into SMCs, contributing to neointima formation after vascular injury90. Apart from 
adventitia, media layer was also demonstrated to harbour SMPCs. It was reported that 
one side population of SMPCs with sca-1+c-kit -/lowCD34 -/lowlin- profile are among 
mature SMCs. Once cultured with TGFβ or PDGF, they differentiate into SMCs91. Then 
nearly at the same time, another study draw one bold and shocking conclusion that it 
was not mature SMCs but SMMHC- multipotent vascular stem cells give rise to SMCs 
during vascular disease92. While later this conclusion was proven not convincing 
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enough because of the issues such as unspecific lineage model, lacking of z-stack 
microscope use as well as incorrect media isolation protocol93, this study provide one 
potential substitute candidate for SMCs differentiation. When existing SMCs is 
severely injured, SMPCs could repopulate de novo SMCs. Later it was shown that a 
population of sox10+ multipotent vascular stem cells possess SMCs differentiation 
potential94. Even further, more recent study showed that subpopulation of SMMHC + 
cells are capable of dedifferentiating into SMPCs with induction of stem/progenitor 
transcript factor klf495. This enhances the potential of SMPCs to migrate and 
differentiate into several type of cells including ECs, SMCs and hematopoietic lineage 
cells. The endothelium is also able to induce SMCs transdifferentiating via mechanism 
of endothelial to mesenchymal transition (endMT) although the rate is only 0.01% to 
0.03%96. 
1.3.6.1 SMPCs in Allograft Vasculopathy 
From traditional point of view that SMCs from intima or media layer undergoing 
phenotype change during AV lesion formation it is easy to draw the conclusion that 
SMCs are all from donor source. However, various studies showed that it is not the 
case. Similar to ESPCs origin in AV, origin of SMCs varies in different studies. A study 
showed that SMCs in CAV is donor origin97. However, in mouse aorta allograft 
transplantation model the result showed that SMCs are of recipient origin98. Also 
chimeric population source of cells including both donor and recipient origin is 
reported67. Therefore, percentage of donor and recipient origin possibly also depends 
on lesion development stage (Figure 1.3.6.1). Furthermore, source of recipient SMPCs 
in AV is also debated. It was demonstrated that after cardiac transplantation, more 
than 80% of host SMPCs derive from bone marrow86. However, our group draw an 
opposite conclusion that bone marrow source of SMPCs were not involved in vascular 
allograft lesion formation. A possible reason to explain this discrepancy is whether 
high-resolution microscope was used in the study. Low resolution microscope could 








Figure 1.3.6.1 Proposed role of SPCs in allograft vasculopathy. A. ESPCs replace 
injured ECs after intima injury. B. SPCs from various sources along with/without 
phenotype changed SMCs are recruited under cytokines such as SDF-1 and VEGF. 
Under TGF-β and PDGF stimulation, SPCs differentiate into SMCs contributing to 
neointima formation. C. During lesion formation process, macrophage or HSCs are 
also recruited and serve as inflammatory cells formation. D. Pericytes and EndMT are 
also involved in atherosclerosis progress. E. Vasa vasorum and vessel remodelling 
are enriched in graft vessel. SPCs, stem/progenitor cells; AV, allograft vasculopothy; 
ESPCs, endothelial stem/progenitor cells; SDF-1, stromal derived factor-1; VEGF, 
vascular endothelial growth factor; TGF-β, transforming growth factor-β; PDGF, 
platelet derived growth factor; HSCs, hematopoietic stem cells; EndMT, endothelial to 
mesenchymal transformation. (Figure Source: Psaltis PJ, Simari RD. Vascular wall 









1.3.6.2 SMPCs Maintenance and Modulation in Allograft Vasculopathy  
In vivo, SMPCs reside in the vascular niche, which refers to the microenvironment for 
stem cells to maintain their homeostasis. Once vascular injury is induced such as allo-
immune attack in graft, these cells are mobilized under the stimulation of circulating 
cytokines. Afterwards, relying on cytokines and ECMs, SMPCs home to injured graft. 
In response to persistent stimulation from cytokines, ECMs and sheer stress, they 
acquire terminal cells fate. Within adventitial layer, phenotypic maintenance of SMPCs 
are under control of sonic hedgehog (SHH) signalling pathway. This is demonstrated 
by the fact that decreased number of adventitial SMPCs within aortic root was 
achieved, because of SHH knockout88. This study also showed that the mechanism in 
SHH signalling silencing SMCs differentiation is through decrease expression of 
SRF/myocardin, and overexpression of their related repressors including klf4, msx1 
and foxo4. Similar to mature SMCs, SMPCs were shown cable of migrating when local 
injury occurs. It was shown that in response to vascular injury, chemokines such as 
CCL1/2/5 are highly expressed within SMCs culture medium. When CCL1/2 activates 
CXCR2 on the surface of cells, SMPCs are recruited through via Rac1/p38 signalling99. 
Alternatively, data was shown that SMPCs would migrate in response to SDF100 and 
leptin101 via mechanism of increasing cell chemotaxis and/or cell cytoskeleton 
regulation. During and/or after SMPCs homing to injured tissue, SMPCs to SMCs 
differentiation begins. Several signalling pathways regulate SMCs differentiation. 
Firstly, a mechanism called actin treadmilling is a classic cellular process. During this 
process, F-actin polymerization derived from G-actin results in unbound of MRTF-A/B 
with G-actin. Then unbounded MRTF-A/B transfer from the cytoplasm to the nucleus 
to bind with SRF to induce SMCs gene expression102. Epigenetic modification is 
another pivotal mechanism regulating SMCs differentiation. For example, it was 
reported that spliced HDAC-7 could enhance SRF/myocardin complex binding with 
targeted SMCs promoter genes103 , whereas at the same time HAT-p300 could 
increase myocardin expression, both for SMCs differentiation. Extracellular matrix can 
also promote SMPCs differentiation. It was reported that under the collagen IV 
induction, sca-1+ SMPCs underwent SMCs differentiation which can be abrogated by 
integrin α1, β1, and αv inhibitors104. MicroRNAs are also shown as potential players for 
specific genes to induce SMPC differentiation. For example, micro RNA -10 could 
function by inhibiting HDAC4, which induces SMCs gene expression105, while micro 
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RNA -1 targets on klf4 and promotes SMCs differentiation106. It was also shown that 
micro RNA -143/145 cluster could function at SRF and its coactivators107, 108. SMPCs 
to SMCs differentiation could be further enhanced by several growth factors such as 
TGF-β and PDGF. TGF-β is a multifunctional cytokine regulating cellular physiology 
and specifically induces SMCs differentiation by modulating all related transcript 
factors and/or their coactivators including smad2/3, klf4/5, SRF and myocardin. PDGF 
as another important cell differentiation regulator is also shown involved in SMCs gene 
upregulating via promoting SRF/myocardin complex. This process is via the 
Ras/Raf/MEK/ERK pathway109.  
1.4 Animal Model 
After genome sequencing, it was found that mouse and human share extensive 
similarity between each other. Mouse model is therefore widely used in biomedical 
research for deep understanding human disease and specific gene function. There 
are several other advantages to use mouse as animal model. Mice have a high 
reproduction capacity and this in turn saves money and time. The physiological and 
pathological mechanisms is generally similar to humans. For example, by using 
C57BL/6 or BALB/c strain mice, animal models can be easily established because of 
their stable and detectable gene expression. Luckily, mouse gene is comparably easy 
to manipulate which enables the examination of the functions of specific genes 
feasible. Fluorescently-tagged genes in transgenic mice is one good example. In this 
mouse model, fluorescent reporter gene such as GFP or RFP can be added into the 
mouse genome loci facilitating the tracing of target genes. Alternatively, 
overexpression and knock of target gene such as leptin knock out (db/db) mice is also 
commonly used in various diabetes related studies. Human pathogenesis can even 
be directly observed in immunodeficiency mouse model. CB17 SCID (severe 
combined immunodeficiency) is one strain mouse with spontaneous SCID mutation, 
which results in lymphocyte deficiency. Although sharing similarity with other strains 
of mice in terms of appearance, they can receive human tumour cells enabling direct 
observation of tumour progression. In addition, mouse models also provide researcher 





1.4.1 Wild Type Mouse Strain  
Inbred strains, which is defined as the mice with similar genetic background are widely 
used in medical research. Advantage in inbred stain mouse mainly includes known 
background, which facilitates medical studies. C57BL/6 mice, one type of wild type 
black mouse, is the first mouse strain whereby their full genome sequence is known. 
Besides utilised for physiological and pathological animal model, C57BL/6 mice are 
also used in transgenic mouse models. The sub-strains of C57BL/6J (from Jackson 
Lab) and C57BL/6N (from National Institute of Health) mice are not entirely identical 
at genetic level110. For example, one nonsynonymous mutation occurs on cytoplasmic 
FMRP interacting protein 2 (CYFIP2) within C57BL/6N, resulting in altered response 
to cocaine and methamphetamine, whereas C57BL/6J did not111. This indicates that 
when choosing mouse strain, it is important to avoid false interpretation because of 
incorrect animal model. BALB/c is an albino, inbred strain mouse. The reason to cause 
albinism is a common mutation in tyrosinase gene, which is responsible for melanin 
pigment production 112. Similar to C57BL/6 mice, BALB/c strain is easily bred and has 
minimal weight variations. Because of similar immunology features, BALB/c is 
commonly used in cancer and immunology animal models. 
1.4.2 Transgenic Mouse Model 
Gene expression altering to influence protein function, is the basis of some human 
genetic diseases. This indicates that any sequence variation, such as deletion or 
recombination on specific nucleotide loci or chromosome, would result in predictable 
cellular response. Although it is impossible to modulate gene in human beings, animal 
models provides a solution to this problem. In fact, in vitro cultured cells have provided 
mechanism clues in underlying human disease. However, these models are unable to 
accurately mimic human physiological or pathological state. Human disease models 
are also difficult to replicate purely by in vitro work. Therefore, establishment of mouse 
model provides researchers opportunities to validate their hypothesis in vivo. With 
modulation on target genes, function of candidate genes as well their mechanism can 
be detected. Gene manipulation has advanced rapidly since the discovery of DNA. 
For example, studies in bacterial genome have developed genetic recombination and 
engineering technique. With this important knowledge, method in manipulating gene 
in mouse model was finally established, facilitating greater understanding in human 
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disease. Early mouse genetics were largely based on spontaneous mutations such 
as SCID mice113. After these mutant mice were inbred with wild type animal, number 
of mutant animal can be preserved and expanded. However, low frequency in 
spontaneous mutation is one apparent drawback in this mouse model. Techniques 
in chemical and/or physical mutation was later introduced114. However, difficulty in 
target gene manipulation leads to the emergence of direct target recombination 
technique. Main recombination techniques include mutation gene insertion and gene 
trap approaches. Insert mutation or random integration mutants can be realized by 
DNA insertion/ integration in the mouse genome115 by using transposons116. Gene 
trap represents one recombination technique, in which inserted target genes along 
with report genes such as fluorescent proteins or β-galactosidase are recombined 
into the host genomic sequence. In this case, report genes are regarded as the 
molecular tag for further analysis. This means that only when report genes are 
detectable at transcriptional level, gene manipulation such as insertion or integration 
can be considered successful. The most widely used reporter mouse mice are 
ROSA26- RFP mice117. Rosa26-RFP or Rosa26-CAG-loxP-stop-loxP-tdTomato-
WPRE transgenic mice were constructed by gene trap technique. In this animal model, 
Rosa 26 is a locus which is located at chromosome 6 and widely used transgenic mice 
construct. Stop codon is flanked by loxP sites. Other cell components such as CAG 
promoter (to enhance tdTomato gene expression) and woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) (to stabilize mRNA) were also added 
into this animal model. For example, the animals used in our study were c-kitkit/CreER; 
ROSA26-RFP mice. These mice were generated by crossing c-kitkit/CreER with Rosa26-
RFP or Rosa26-CAG-loxP-stop-loxP-tdTomato-WPRE transgenic mice. In c-kitkit/CreER 
knock in mice, CreER is under regulation of c-kit promoter. In c-kitkit/CreER; ROSA26-
RFP mouse model, Cre recombinase was maintained by ER in cytoplasm. Once the 
animals were injected with tamoxifen, Cre is guided by ER components to translocate 
into the nucleus and recombines the loxp flanked stop codon sequence. C-kit+ cells 
are labelled with tdTomato/RFP signal, which is permanent regardless of cellular 
differentiation state. Currently, gene manipulating can be steadily carried out 
because of development in modern gene techniques. This provide researchers with 




Novel gene manipulation can be utilised for other purposes. Transgenic mice were 
not created until year 1981 and since then several groups have developed strategies 
to insert exogenous DNA sequences into mouse genome118. Specifically, defined 
gene sequence was transferred to pronuclei of fertilized eggs via microinjection. 
Then the fertilized eggs were transferred into pseudopregnant female animals. With 
transgenic mice, several human physiological and disease models were more 
effectively replicated. Transgenic mice assist scientists to observe target gene 
expression in vivo. By inserting report genes, target gene expression during disease 
progression can be visualized. Inducing cytoside gene expression, specific cells can 
be deleted, and the role of these cells can be analysed. Diphtheria toxin A gene is 
one well studied example in which when it is activated under a specific promoter, target 
cells under control of this promoter can be executed119. Thirdly, transgenic animal 
model further facilitates conditional target gene expression. Classic genetic tools are 
inducing tetracycline/doxycycline-inducible mice, creER/loxp system, IPTG/LAC 
operator-repressor animal model and CRISPR-cas9 technique. However, there are 
various limitations that need to be established. For example, off-target induced 
mistakes severely hindered success rate in transgenic animal model. Strains of mice 
with stable expression of specific phenotype were produced. Transgenic gene size 
is a factor to limit traditional vector insertion. However, use of Bacterial Artificial 
Chromosomes (BAC) and Yeast Artificial Chromosomes (YAC) vector systems allow 
for large chromosomal segment homologous recombination120. In other words, more 
complicated large genomic can be transferred into transgenic animal and the role of 
specific SNPs can be analysed.  
1.4.2.1 Knock Out Mouse Model 
Knock out strategy is one transgenic based animal model. In this model selected 
gene is specifically deleted from the genome. Tradition knockout begins with 
designing vectors carrying gene of interest homologue to target gene, along with 
positive selection neomycin resistance (NEOR) gene and negative selection herpes 
simplex virus thymidine kinase (HSV-TK) gene. Then via homologue recombination, 
exogenous mutation gene replaces endogenous gene reaching gene knockout. After 
microinjection genomic altered germ cell into a recipient female enables the 
development of knockout animal and by crossing with WT mice, phenotype 
alterations can be expanded and preserved. From this animal model, loci function 
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during physiological and pathological state can be detected. For example, p53 
knockout (p53-/-) mice provide clues regarding how the loss of tumour suppressor 
p53 gene activates tumors progression121. Animal source of antibodies for 
therapeutic purposes were hindered because of immunogenic mismatch. However, 
by using heavy- and κ light-chain genes disrupted transgenic mice, large scale of 
human polyclonal antibodies were achieved from hybridoma cell lines 122. In addition, 
knockout transgenic animal models provide invaluable unknown information. For 
example, it was found that some disease related genes could induce embryo lethality.  
1.4.2.2 Gene Recombination Mouse Model 
Global gene knockout could indeed mimic disease development at certain degree. 
However, global knockout could also severely complicate disease aetiology analysis. 
In other words, global knockout of target gene leads to the inability to detect the exact 
role of knockout genes in specific cells for pathogenesis. Therefore, conditional 
knockout animal model such as Cre/loxp and FLP-FRT systems were developed 
(Figure 1.4.2.2). Cre/loxp system consists of two vital components which are Cre 
recombinase and loxP sites. Cre recombinase is encoded by a cre gene derived from 
bacteriophage P1. This enzyme mediates recombination of target sequence located 
between loxP sites123. In transgenic mice models, activity of Cre recombinase is 
under control of specific promoters. loxP sites are a pair of the sequences which 
flank one inserted gene. By breeding with each other, Cre/loxP transgenic mice are 
produced. Depending on orientation of loxP in one DNA strand, excision and 
inversion would occur. Specifically, when the pair of loxP are in same direction, 
flanked gene would be cut by Cre recombinase. However, when loxP are in opposite 
direction, flanked sequence is inverted during recombination. In addition, loxP can 
also be located at different DNA strand promoting translocation of gene segment. 
FLP-FRT recombination system, similar to Cre/loxP, is also consist of FLP 
recombinase and FRT sites. FLP recombinase, with its meaning to invert DNA, was 
found in the yeast124. Same as Cre/loxP, FLP exerts recombination once recognizing 
FRT. To note, initial FLP recombinase only works at 30°C, and therefore cannot 
function within mammalian cells. By using these systems, gene knockout models 
under the regulation of specific promoters can be performed. Recombination of 
genes can now be controlled at a specific time point. Cre recombinase fused with 
human estrogen receptor (ER) is one good example (Figure 1.4.2.2). ERs belong to 
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the steroid hormone superfamily of nuclear receptors functioning in binding with 
estrogen125.  ER is composed with five distinct domains. N-terminal begins with A/B 
domains which play a role in binding with co-regulator to regulate target gene 
expression. Subsequently, C domain encodes DNA binding domain responsible for 
binding between ERs and target genes. Following D domain which is a hinge region 
for cell signalling, E/F domains occupy C-terminal containing ligand-binding domain 
(LBD) binding with a specific ligand. In absence of a ligand, ERs are preserved in and 
activated form in the cytoplasm, by binding to heat shock protein 90 (Hsp90) ,one 
chaperone to prevent inactivated ERs from degrading126. After binding with ligand such 
as estrogen 17β-oestradiol, ERs separate from Hsp90 and translocate into nucleus127. 
Therefore, ER and Cre fused CreER could translocate between cytosol and nucleus 
following ER pattern, with which Cre could access to the loxP sites in genes to function 
in recombination. Tamoxifen, or its active metabolite 4-hydroxy-tamoxifen (4-OHT) is 
one widely used activation drug. Tamoxifen is one estrogen antagonist by binding with 
the ER. When ER binds with tamoxifen, it will not exert normal function such as 
promoting cell growth, although it will still translocate from the cytosol into the 
nucleus128. The presence of endogenous estrogen 17β-oestradiol activation is one 
huge block in CreER mice application.  Therefore, several mutants with modified ER 
was performed to overcome this obstacle among CreERTAM (mouse mutant ER) and 
CreERT (human mutant ER). However, both of these procedures was seen to be 
ineffective due to low efficiency and high doses of tamoxifen resulted in cell death. 
This was not solved until the development of models including CreERT2 mice129 and 
MerCreMer mice130. In both animal models, fusion proteins were responsive to 















Figure 1.4.2.2 Strategy of gene recombination mouse model.  A. Vectors, which 
contain genomic sequence are transferred to pronuclei of fertilized eggs via 
microinjection. Then the fertilized eggs are transferred into pseudopregnant female 
animals.  B. Schematic representation of Cre-loxP system. Cre recombinase is 
expressed under s131pecific promoter. Cre could recombine loxP to remove 
the stop cassette. Once stop codon is cut, the reporter gene is expressed in specific 
cells. C. CreERT2, is kept inactive in the cytoplasm by heat shock proteins Hsp90. 
Once binding of tamoxifen, CreERT2 is released from the chaperone and translocates 
into to nucleus. Cre would then recombine at loxP sites. (Figure Source: A, Doyle A, 
McGarry MP, Lee NA, Lee JJ. The construction of transgenic and gene 
knockout/knockin mouse models of human disease. Transgenic research. 




1.4.2.3 Combined Recombination Mouse Model 
In a gene knock in technique, a piece of mutant sequence replaces target host 
sequence in target sites. Although traditional transgenic mouse models provide 
various treasurable results, its drawbacks have been also noted during application. 
For instance, transgenic promoter sequence could result in the change in target gene 
leading to pathological alteration. In opposite, with knock in technology, mutant gene 
could be inserted with known sequence without incurring problems such as location 
variety and isoform recombination, which frequently occurred in traditional random 
integrated transgenic mouse model. Meanwhile, by combing knock in strategy with 
conditional knock out silence genes sequence, conditional gain of gene function can 
be achieved. In fact, this combined transgenic mice model has been wildly used in 
research. For example, since knock in mouse model could enable expression of 
specific gene under compartment promoter, target gene excision in specific cells can 
be achieved. Similarly, CreER recombinase could make sequential control in target 
gene expression feasible. Further, by crossing with Cre/CreER knock in mice with 
Rosa26-reporter mice, cell fate can be traced. 
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New site-specific recombinases such as Dre-rox recombination system133 was more 
recently established.  Dre was also found from P1-like phage, performing similar 
function to Cre recombinase. Distinct to Cre enzyme which recognize loxP 
recombination sites, Dre would perform recombination when in present of rox. Dre-
rox recombination system has been provento perform recombination in both E.coli 
and animal models133. Furthermore, conditional control, similar to CreER, was 
developed by binding Dre with progesterone fusion protein. Combined system was 
utilised by combing two or more recombination systems. This model is designed to 
test occurrence sequence in specific physiological event. This is particularly 
important in my SPCs study area. For example, result from stem cells study with 
single recombination system is always interfered by existing terminal cells. It was 
under debate whether cardiomyocytes labelled in kit-CreER animal are from existing 
cardiomyocytes or stem cells65. By combing Cre-loxP and Dre-loxP systerms, it was 
shown that only few non-cardiomyocytes generate de novo cardiomyocytes134. 
Although the conclusion in this study is still controversial because of the toxicity issue 
of two system in one cells, this combined system provides one potential method in 
solving problems within stem/progenitor cells.  Also, the split protein system showed 
potential in intersectional application. It was shown that Cre can be split into two 
parts which are the Cre-N and the Cre-C. They could spontaneously form back into 
full length functional Cre once reconstitution via α- complementation135. One 
potential application is to put two fragments under regulation of two different 
promoters, once these two promoters are activated at the same time, Cre could 
perform its function.    
1.4.2.4 Recent Development in Transgenic Mouse Models 
Furthermore, there are other techniques being currently used in gene engineering 
technique. RNA interference (RNAi) is one method, to silence target gene expression 
by inducing double stranded RNA formation. Through designing RNAi sequence 
under regulation of a promoter, RNAi could silence target genes in selected cells. 
Moreover, when combing recombination system in the embryo, spatiotemporal gene 
knock out or knock down can be established. However, to note, knockdown by RNAi 
is incomplete and with the problem uncertainty of off target effects. Therefore, cluster 
of techniques based on engineered nucleases system composed of DNA/RNA 
recognition component and cleavage protein were developed. These systems could 
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specifically cut DNA double strands to produce DNA double-strand breaks (DSBs), 
which would then stimulate DNA repair mechanisms, including non-homologous end 
joining (NHEJ) and homology-directed repair (HDR). Zinc-finger nucleases (ZFNs) 
consist of zinc-finger protein which is used to recognize target DNA, and nuclease 
which functions in cutting DNA strand136. Similarly, another example is transcription 
activator-like effector nuclease (TALEN), which is composed of a transcription 
activator-like effector protein and nuclease137. 30 amino acids with conserved ββα 
configuration compose the zinc-finger protein136, whereas transcription activator-like 
effector protein is composed of a series of 33–35 amino acid repeat domains137. Then 
following specific sequence, target sequence can be recognized and modified 
including knockout, insertion or mutation. Recently, CRISPR/CAS which denotes 
clustered regulatory interspaced short palindromic repeats system, was introduced to 
manipulate genomes within both non-mammal138 and mammal139 cells. In fact, 
CRISPR/CAS In fact, CRISPR/CAS was discovered from the immune response in 
bacteria to provide protection against invading foreign DNA in viruses by utilising RNA 
guided cleavage138. Short CRISPR RNA (crRNA) derived from spacer and CRISPR 
DNA would anneal for trans-activating crRNAs (tracrRNAs) to form guide RNA (gRNA). 
Then following gRNA, CAS protein can cut spacer or invading DNA gene from host 
genome. With all of these transgenic tools, more animal models mimicking human 
disease can be built. Potentially in the future, human genetic diseases can 
hypothetically be cured by the development of advanced genetic editing tools. 
1.4.3 Lineage Tracing  
Lineage tracing studies are a way of dynamically observing change in one population 
of targeting cells, and/or their progenies. This technique provides vital information in 
understanding location, function and differentiation state in selected cells. Currently it 
has become one common in vivo technique in observing how cells behave within the 
tissue and correlate with neighbour cells. Similar to other early techniques, lineage 
tracing has also gone through several stages (Figure1.4.3).  
1.4.3.1 Direct Observation 
Direct observation of certain cells, enables researchers to visualise that they derived 
from pre-existing cells. Moreover, one embryo cell could give rise to various functional 
distinct cells and form in different tissues. When the cells are exposed to various 
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factors such as X-ray and drugs, direct observation facilitate physiological alteration 
observation on mitosis, migration and apoptosis within cells. Although direct 
observation is non-invasive and provides researchers opportunities to observe in real 
time on both cellular migration and proliferation. However, when cells are located in 
intact tissues or organs, direct observation is not achievable. Besides, when cellular 
features are similar to other cell types in terms of morphology, it is difficult to recognise 
the intended cell type. Therefore, cells being labelled with dyes were developed which 
is not toxic. Dyes used to label target cells include carbocyanine, fluorescein-
conjugated dextran and horseradish peroxidase (HRP)132. Dye labelling was then 
replaced by report genes. This is because reporter genes do not spread to neighbour 
cells. 
Figure 1.4.3 Lineage tracing.  A. Direct Observation. B. Chimeric lung tissues with 
GFP+ and GFP- cells. C. Cre recombination labelled tdTomato and YFP tissues. D. 
Congetti transgenic mouse with designed multiple colour reporter strategy. GFP, 
green fluorescence protein; YFP, yellow fluorescence protein. (Figure Source: 




1.4.3.2 Reporter Genes  
Reporter gene can be strictly divided into two categories: bioluminescent and 
fluorescent reporter genes. Although both reporter genes are detectable and facilitate 
tracing the fate on target cells, they have distinct mechanism to generate light. 
Bioluminescence can be generated from reporters by chemical reaction. This 
technique is enlightened from the firefly, which can generate light itself and can be 
seen in darkness. In a luciferin reaction, in the absence of oxygen and enzyme, 
substrate luciferin expressed no luminescence. However, once catalysed in presence 
of luciferase and oxygen, luciferin would be transferred into oxyluciferin and release 
the light140. Another widely used example is β-galactosidase which could hydrolyse 
colourless substrate 5-bromo-4-chloro-3-indolyl galactoside (X-Gal), and release 
indolyl molecule which would be subsequently oxidized into an indoxyl, an indigo blue 
substrate141. In a fluorescent setting, a different UV wavelength is emitted compared 
to the absorbed UV wavelength. This is due to loss of energy once exposed to the 
given substance. Therefore, specific substances can be detected at a specific UV 
spectrum. Also, multiple fluorescent labelled substances can be detected in the same 
setting. In fact, currently several fluorescence proteins including green (GFP), red 
(RED), yellow (YFP) and cyan (CFP) are widely used in various studies. Confocal 
microscopes are extensively used to detect fluorescence signal. Simply, a laser beam 
with specific wavelength being filtered from beam splitter, focuses on specimen and 
excites fluorescence.  Mirror galvanometer is an electromechanical instrument which 
senses an electric current by deflecting a light beam with a mirror.  To gain the three 
dimension data, focus could change successively achieved at a focal depth. Emitted 
fluorescence goes through a pinhole lens to reach detector or photomultiplier tube 
(PMT), where fluorescence intensity is collected. After the photon light signal is 
transferred into photoelectrons and further amplified, PMT signal is decoded into a 
digital signal and analysed by the computer.  
Advantage in bioluminescence reporter is its relatively low background because it can 
be detected with no light and therefore no external factors would interfere. 
Bioluminescence subtracts do not exist within the mammal cells and so the detected 
bioluminescence signal would not result from endogenous background. However, 
fluorescent reporters always have high background, since some cells or tissues could 
express fluorescence, referred as autofluorescence. For example, heme shows high 
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red autofluorescence. Another advantage in bioluminescence reporter is that 
bioluminescence signal can be used for quantification. Bioluminescence reporter 
expression could be detected at a high range of signal. Meanwhile, bioluminescence 
reporter could metabolise resembling the pattern of targeted protein. Therefore, 
bioluminescence reporter could spatiotemporally reflect the change in target proteins. 
However, fluorescence proteins are always very stable. They would accumulate but 
not detect the change in labelled proteins. Therefore, fluorescence proteins are not 
appropriate tools for quantification in target gene expression. Furthermore, when 
detecting fluorescence proteins, laser light used, is always with high energy. This could 
result in photo bleaching and even directly cellular toxicity leading to false negative 
results. On the other hand, fluorescence proteins also show their virtue in some other 
aspects. First, fluorescence proteins are bright once activated and can be further 
amplified by its counterpart antibodies, whereas in opposite, bioluminescence reporter 
is always very dim in terms of light leading to relatively low sensitivity. Then by using 
confocal microscope, accurate site can be detected. Further, the image with 2D or 3D 
could facilitate judging cell distribution in spatiality. Moreover, because of various 
fluorescence proteins mentioned above, more than one antigen can be detected in 
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1.4.3.3 Chimeric Mouse Models 
Chimeric mouse model helps to detect the role of specific cells. When transplanting 
cells which are tagged with reporter genes, to wild type recipient, the function of 
transplanted cells can be tested. When bone marrow is transplanted to sub-lethally 
irradiated mice, distribution and function of labelled cells determine the role of bone 
marrow cells in mice physiology or pathology. Although this approach is invasive and 
needs surgery, transplantation could distinguish different role of specific cells between 
host and recipient animals. When transplanting human SPCs into immune 
compromised mice, disease pathology can be observed143. Moreover, it was shown 
that combing unlabelled and labelled embryos together produces mosaic chimeric 
animals, which can be used to trace cells fate and their relationship with neighbouring 
cells. For example, by using mosaics animal models, notch signalling is proven vital in 
adhering ECs stalk cells with each other144. Second application of mosaics chimeric 
animal is detecting cells component and its related dynamic change in the target tissue. 
For instance, by using multicolour mosaics mouse models, leukemic cells have been 
shown to consist of clonal architectures and dynamic change with disease processes. 
In addition, by comparing differences between mutant and wild type cells at a specific 
site, gene function related to disease can be detected. 
1.4.3.4 Transgenic lineage tracing 
Appearance of genetic approaches has pushed lineage tracing study one step further. 
For example, in Rosa26 β-geo145 mice, all of the cells would express reporter gene 
which can be detected exogenously and this is quite useful in chimeric studies. With 
this animal model, labelled cells can be tracked using the techniques such as flow-
cytometry and microscopy. Further, when combing recombination techniques 
(described above) with transgenic reporter gene modified mouse models, quite various 
disease mouse models were built. The Rosa26-CAG-loxP-stop-loxP-tdTomato-WPRE 
transgenic mouse is a widely used animal model. In fact, this mouse model has many 
synonym abbreviations including Rosa26-CAG-LSL-tdTomato, Rosa-LSL-tdTomato, 
Rosa26-Tomato and Rosa26-RFP. In this thesis, Rosa-RFP mice were crossed with 
Cre/CreER transgenic/knock-in mice. Stop codon which is flanked by loxP sites would 
be cut (with or without tamoxifen induction in terms of purpose in studies) within target 
cells which showed recombinase. Subsequently, the fate of selected cells can be 
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traced. Recently, a multicolour report gene construct strategy was also induced. For 
example, mosaic analysis with double markers (MADM) mouse model145 splits GFP 
or RFP gene in two DNA strands and separated by loxP and Cre recombination would 
result in gene reconstitution of fully functional reporter genes. Membrane-targeted 
tdTomato/membrane-targeted EGFP (mT/mG) double-fluorescent reporter mouse146 
was artfully designed with the Rosa26-CAG-loxP- tdTomato -loxP- GFP structure that  
the cells without recombination would express tdTomato signal, whereas after 
recombination, cells are tagged by GFP. Multicolour reporter mice are able to generate 
multiple reporter colours, can provide us with evidence that most tissues consist of 
multiple clones and are potentially not derived from a single cell. For example, 
brainbow mouse was developed by combing more than two florescence reporters. 
With this mouse model, at most 10 combo colours can be generated147. Similarly, the 
confetti mouse uses four different reporter genes to show clonal hierarchy148. However, 
to note, the principle of multicolour reporter mice is based on Cre recombinase random 
recombination. Therefore, conclusions from every study using this animal need to be 
cautiously judged, since the rule of this random recombination related to cellular 
physiology is still unclear. 
1.5 Cell Migration 
Migration is one basic cell physiology, related to SPCs recruitment in AV. The 
development of fluorescence microscopes enables us to visualise, how motile 
structure forms and locates underlying motor protein assembly. This motile structure 
is crucial in regulating cellular posture and position, in response to every extracellular 
biophysical force. These adjustments are mainly controlled through cytoskeleton 












Figure 1.5 Motile cytoskeleton components.  In response to surrounding signals, 
F-actin forms protrusion including filopodia and lamellipodia in front of cells. MTOC 
and Golgi apparatus in the meantime orient to the leading edge for cell migration. 
Adhesion complex forms at the cell membrane to regulate F-actin movement. Myosin 
activity provides traction tension for cell migration. F-actin, filament actin; MTOC, 
microtubule-organizing centre.  (Figure Source: Mayor R, Etienne-Manneville S. 
Nature reviews. Molecular cell biology. 2016;17:97-109 149.) 
 
1.5.1 Filament Assembly  
The cytoskeleton network mainly consist of three biopolymer component types 
including actin, microtubule and intermediate filaments, based on rigidity150. Actin 
filament is one form of polymer built by dimer pairs of globular actin monomers. One 
actin filament consists of two distinct ends, which are point (fast growing) and barbed 
(slow growing) end. Two ends are made of distinct concentrations of actin monomers. 
The barbed end is six times higher than the point end. Homeostasis is regulated by 
the concentration of free actin monomers that the actin filament is exposed to. In other 






setting critical concentration. When the concentration of free actin monomers is higher 
than the critical concentration, actin filaments polymerize. By contrast, actin filament 
goes through depolymerisation when concentration is lower. Within the cell, when the 
concentration of free actin monomers is between critical concentrations at two end, 
asymmetric changes occur. In this situation, point end would grow whereas barbed 
end would shrink. This means that when actin filaments translocate from the places 
with low free actin monomers concentration to higher concentration places, the length 
stays roughly the same. This phenomenon is called treadmilling151. Microtubules are 
rod-like, hollowed polymers with high rigidity. Microtubules are made of protofilaments 
which are assembled from tubulin protein. Similar to actin filaments, motility of 
microtubule is also regulated by treadmilling. Intermediate filaments such as vimetin, 
sesmin, keratin and lamin are flexible proteins. Instead of generating polarized force, 
they are stable and do not treadmill. All of these components comprise the cell 
cytoskeleton. When the cells sense surrounding signals such as chemokines, actin 
would polymerize and translocate, functioning as an engine to produce cell protrusion. 
Actin filaments assembly are the basis for cells to move forward which are carried out 
by several accessory proteins.  
Actin filaments assembly begins with actin nucleation. A nucleus would firstly form and 
rapidly promote F-actin development. Nucleation is one rate limiting step in 
polymerization, because intermediate actin dimer is not stable. Currently, three 
mechanisms are responsible for nucleation. The first mechanism is to form a branch 
from an existing actin filament. When recognizing nucleation promoting factors such 
as WASP/WAVE family proteins, Arp2/3 complex forms to generate a branched 
structure from an existing filament. The structure of Arp2/3 complex is similar to actin. 
In the inactive state, it is not bounded with ATP. Once binding with ATP molecules, 
the Arp2/3 complex is activated for conformation change152. Then WASP/WAVE 
proteins recruit Arp2/3 complex and actin monomers to initiate branch formation from 
existing actin filaments. A second mechanism is via formins, which could bind actin 
FH2 domains to form stable dimers and initiate actin nucleation. The last nucleator- 
spire has four actin monomer-binding WASP-homology 2 (WH2) domains. Therefore, 
a spire could stably bind with four actin monomers to form a short single nascent 
filament and finally incorporate into a mature filament. After nucleation, F-actin 
continues to grow, which refers to actin elongation. After forming dimer actions by FH2 
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domains, formins keep attaching at the filament end. Then adjacent domain FH1 
further recruits profilin actin monomers for rapid elongation. Enabled/vasodilator-
stimulated phosphoprotein (Ena/VASP) is another protein to promote filament 
elongation. Similar to formins, Ena/VASP could bind profilin actin to form tetramers153. 
However, filament growing is not unlimited because of capping proteins. Capping 
proteins could interact with filament end to terminate filament elongation. To note, both 
formins and VASP could inhibit activity of capping proteins. Therefore, the filament 
elongation rate can be regulated. Cofllin is another regulator for actin dynamics154. It 
was shown that cofllin could uncap barbed ends of old filaments and then release free 
actin monomers155. Released free actin monomers bound with ATP are recycled to 
replenish actin concentration at the leading edge. After these free actins bind to the 
new end of filament, direction of F-actin can be determined. When these proteins 
cooperate and are properly regulated, control of rate in actin elongation can be 
acquired.  
1.5.2 Protrusion Formation  
F-actin would then connect distal point of adhesion to sense the signal. On the other 
hand, F-actin could also generate force to facilitate cell migration. F- actin in cell 
protrusion can be divided into filopodia and lamellipodia156. Filopodia locates at cell tip 
and would protrude out of cell body by treadmilling when sensing chemical or 
mechanical stimuli. Because there is VASP attaching at the tip, filpodia could keep 
elongating without being capped or branched. Another kind of F-actin is lamellipodia, 
which binds to branches of existing filaments. Distinct from filpodia, it was found that 
protrusion of lamellipodia relies on elastic Brownian ratchet mechanism157. When the 
slow barbed end of a filament binds to cell membrane, thermal energy would bend the 
filament to store elastic energy. Bending the filament also permits more actin 
monomers to connect. When elastic energy is released during filament unbending, the 
cell membrane would be pushed forward by driving force prompting cellular protrusion. 
With this character, lamellipodia would grow in setting direction when receiving the 
environment signal. 
Formation of protrusions in both filopodia and lamellipodia, are under regulation of 
Rho family small guanosine triphosphate binding proteins (GTPases) mainly including 
Rac, Cdc42 and Rho. GTPases are molecular switches and regulated by 
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conformational states158. When they are bound to GTP catalysed by guanine 
nucleotide exchange factors (GEFs), they are activated to promoting downstream 
signalling. Conversely, when they are bound to GDP by GTPase activating proteins 
(GAPs), they are inactivated. Once activated, Cdc42 could bind to WASP protein and 
Rac relieves WAVE from its inhibition of proteins. Then a conserved region called VCA 
domain in both WASP and WAVE is exposed and binds to Arp2/3 complex. In this way, 
filaments can be elongated and protrude. Meanwhile, WAVE/WASP could also 
regulate Rac/Cdc42 in a feedback loop to precisely control the filament length. Besides 
forming protrusions, Cdc42 could also orient the microtubule-organizing centre 
(MTOC) and Golgi apparatus to the leading edge158. Then MTOC polarity occurs in 
which microtubules form protrusions and deliver vesicles from Golgi to the leading 
edge providing necessary proteins. In addition, Cdc42 could activate downstream 
kinase PAK1, which could further upregulate Cdc42 activity through a positive 
feedback loop. Although GTPases themselves could induce cell protrusion and 
polarity, signal amplifying is still needed when chemoattractant derived from gradient 
difference is low between front and rear of the cell. PIP3 is one crucial molecule which 
functions in transmitting and magnifying the signal. Generation of PIP3 is stimulated by 
PI3K and inhibited by phosphatase PTEN. It was shown that, in migrating cells, PI3K 
accumulates at the leading edge whereas PTEN is restricted at the rear of the cells159. 
Further, PI3K could positively activate and control localization of Cdc42 and Rac.  
1.5.3 Adhesion Complex 
Although filaments could form and protrude, actin polymerization would also occur in 
body and rear of the cells160. Meanwhile, within the cells, newly formed actin bundles 
could at the same time flow back leading to generation of retrograde flow, which 
produce the force, in opposite to direction of cell migration. Besides actin bundles, 
myosin could also contribute to retrograde flow formation161. Therefore, cellular 
translocation rate is one combined result, determined by both forward traction force 
and retrograde flow force. Then how this balance was regulated was later explained 
by a clutch theory160. This theory claimed that, when actin interacts with clutch or 
adhesion complex assembled by integrin and adhesion proteins such as vinculin and 
talin, traction force can be effectively transmitted to cytoskeleton actin facilitating cell 
migration. Conversely, failure in binding between actin and adhesion molecules results 
in weaker forward traction force and thereafter backward movement in cells. Also, 
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focal adhesions could also stabilize stress fibres in the leading edge and prevent 
filaments from deadhesion.  
1.5.3.1 Integrins 
Integrins are one important family of receptor to support cell migration. Each integrin, 
as a transmembrane receptor, consists of two heterodimeric molecules which are α 
and β chains. The long N-terminal of integrin binds with extracellular matrix. C-terminal 
tail within cytoplasmic domains functions in binding with intracellular components. 
Activation of the extracellular part could lead to conformation change in both α and β 
chains. Then altered interactions between these two chains provides the intracellular 
binding site for signalling molecules such as small GTPases and phosphorylated 
tyrosine kinases and this facilitates signal relay from extracellular space to cytoplasm. 
Meanwhile, intracellular signals can also be transmitted out of cells through integrins, 
by which affinity and activity can be regulated162. When the cells migrate, exogenous 
signals would be firstly sensed by filopodia, and then growing number of integrin 
interacts with the extracellular matrix. As the integrin grows into a cluster, nascent 
adhesion forms when myosin II is absent163. At this moment, although nascent 
adhesion is still unstable and cannot sustain cytoskeleton force from F-actin, high force 
derived from myosin II and F-action could promote integrin accumulation.  
1.5.3.2 Adhesion Molecules 
When integrin cluster continues to develop, several group of proteins such as talin, 
vinculin, paxillin, and α-actinin, are recruited to form mature focal adhesion164. In 
addition to forming cell adhesion, these proteins could also transmit signal and 
facilitate cell migration. Talin is the first identified protein, which directly binds with 
integrin. Talin is composed of an N-terminal head and a C-terminal rod domain. In 
native physiology, talin keeps an autoinhibition state by head to rod binding. However, 
once activated by kinases such as PKCα, RIAM, PIP2, talin adopts an extended 
conformation, which facilitates its binding with integrin.  Then whole rod domain would 
stretch and expose more sties, for binding with vinculin or actin. At these moment, talin 
could function in forming focal adhesion and as one mechanosensor, which transmit 
the signal into the cytoplasm for cells to regulate traction force, especially when in 
response to actin retrograde flow. Meanwhile, actomyosin contraction could further 
promote talin conformation change to expose more binding sites. Another vital binding 
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protein is vinculin, which is consist of N-terminal globular head and C-terminal rod tail. 
Similar to talin, vinculin would also maintain autoinhibited form when in native. Once 
activated, they would be recruited by talin and also stretch to expose binding sites for 
other proteins. Head domain of vinculin is responsible for binding with talin, whereas 
the rod domain could bind with Arp2/3, paxillin, VASP and catenins165. Because of its 
role in transmitting the cell force, loss of vinculin would result in adhesion dysfunction.  
It was shown that binding of talin and vinculin promote more actin fibre bundling to 
generate force and in a positive loop, increased contractility force could recruit more 
binding proteins166.   
1.5.4 Myosin II Contractility 
The myosin light chain (MLC) phosphorylation could increase myosin II contractility 
and therefore promote tension transmission. By producing tension when ATP is 
present, Myosin molecules could promote actin filament sliding.  Meanwhile, myosin 
could also involve in adhesion tension transmitting via binding with actin filament. 
Myosin molecules contain two heavy chain and two light chain. From appearance, a 
myosin heavy chain can be divided into head, neck and rod tail regions. The head 
globular domains contain binding regions and could bind with both actin filament and 
ATP. Following is the neck domain which serves as a lever arm, to transfer and amplify 
the chemical energy derived from ATP hydrolysis into kinetic energy. The rod tail 
regions form in dimerization structure and could bind with another myosin molecular 
resulting in an anti-parallel bipolar structure when activated. The MLC divided into 
essential light chain and regulatory light chain, binds at the neck region of the heavy 
chain to regulate myosin function. It was shown that inactivated myosin maintains an 
assembly-incompetent form though head and tail auto-interaction. However, when 
regulatory light chain is phosphorylated, head and tail interaction is unfold and then 
assembly-competent state forms167. Thereafter myosin could bind with filament or 
another myosin molecular. Several kinases have been reported involved in MLC 
phosphorylation such as MLC kinase (MLCK) and Rho-associated (ROCK). For 
example, after stimulation from Ca2+–calmodulin, MLCK is activated to unfold myosin 
auto-interaction. RohA could bind with ROCK and expose its kinase domain to 
phosphorylate MLC. In opposite, MLC phosphatase are responsible for MLC 
dephosphorisation. MLC phosphatase is made of three subunits which are catalytic 
region protein phosphatase (PP1), myosin binding subunit (MYPT1) and a third 
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subunit. When MYPT1 bound to working MLC, PP1 is activated to remove the 
phosphate group from MLC and revert myosin into inactivate state. Activated ROCK 
could phosphorylate MYPT1 at two inhibitory sites and dysfunctions MLC 
phosphatase168. In addition, by phosphorylating different site in both MLC and MHC, 
PKC is also reported to induce myosin activity. Myosin is not directly involved in 
protrusion network, but functions in protrusion regulation. When myosin II is knockout, 
although lamellipodia could remain intact, protrusion production rate cannot be 
regulated169. Myosin regulates protrusion rate by transmitting contractile force to actin, 
and act along with adhesion molecules as clutch to push membrane forward at the 
leading edge. In addition, level of active myosin is dispensable for assembly of nascent 
adhesion. By promoting integrin cluster exposing cryptic sites of binding proteins and 
posture conformation, myosin regulates F-actin binding with adhesion complex. 
Meanwhile, through disperse adhesion molecules, leading edge could stretch from 
central to peripheral edge under myosin tension force.  
1.5.5 Focal Adhesion Disassembly 
When focal adhesion forms at the leading edge, it is still not stable. F-actin 
disassembly occurs at the same time to reorganize protrusion structure. This F-actin 
reorganization was reported result of intracellular signal, transmitted from adhesion 
complex170. Then with assistance of retraction force exerted by myosin motor, cell 
detachment occurs. Deadhesion would also occur in rear part of cells and facilitate 
cells translocation. However, it is worth to point out that, distinct to adhesion complex 
in the leading edge, rear part of the cells have larger and more mature adhesion 
structure. Therefore, proteins or cellular kinases are needed to translocate within cells 
via microtubules to promote adhesion disassembly171. Focal adhesion kinase (FAK) is 
a cytoplasmic tyrosine kinase playing an important role in signalling cascade. FAK is 
composed of three pivotal parts which are N-terminus FERM, central kinase domain 
and C-terminus focal adhesion targeting (FAT) domain. When FAK is inactive, FERM 
auto-binds with kinase domain to inhibit its catalytic capability. Upon activated, FERM 
domain is phosphorylated, and promote recruitment of SH2 contained adaptor proteins 
such as Src172. Then more sites in FAK structures are further phosphorylated to induce 
binding and activation of other kinases. It was shown that  in FAK deficiency cells,  
cells could still adhere but fail to migrate, which indicates that FAK is mainly 
responsible for adhesion turn over173. After cell turn over, FAK downstream signalling 
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would further activate Rac and ERK favouring filament elongation. In fact, it was shown 
that adhesion in cell rear is always strong like an anchor. Therefore, high tension 
provided by myosin II is needed for cell detachment. In addition, several FAK 
downstream singling pathways have been reported to contribute to cell migration. For 
example, FAK/Src complex is responsible for p130cas recruitment and 
phosphorylation. Then recruited Cas/Crk complex promote Rac activation through 
protein DOCK180174. Another signalling to promote cell migration is stimulated when 
FAK binds with PI3K and Grb7. When PI3K and Grb7 are both activated by FAK, they 
cooperate in promoting cells migration175. N-WASP can also be activated directly by 
FAK, to facilitate Arp2/3 complex formation for actin polymerization. Meanwhile, FAK 
could also induce Rac/Cdc42 activation by binding with paxillin176. Paxillin is another 
important component of focal adhesion and relay the signal from extracellular into the 
cells. Paxillin contains five repetitive leucine-rich LD motifs at the N-terminus and four 
cystein-histidine-enriched LIM domains at the C-terminus. LD domains provide 
docking sites for focal adhesion related proteins such as FAK, Src, talin and vinculin. 
When N-terminus site is phosphorylated, paxillin is activated and recruited to focal 
adhesion site. When interacting with FAK/Src complex, paxillin can be activated to 
induce ERK/MLCK signalling, which promote adhesion turn over and cell migration177. 
Afterwards, myosin and stress fibre promote rear part to translocate. This process 
would help to pull the cell forward. To note, all migrating process is rapid and also in 
dynamic change, which means when the first round of migration finishes, the next 
round would begin or has already begun. During the same time, organelles are also 
dragged by F-actin and myosin to move along the cell membrane and assist cellular 
integrity.  
1.5.6 Extracellular Matrix 
ECMs provide a structural platform for the vascular wall and interact with vascular cells 
to regulate diverse cellular biological process (Figure1.5.6). Meanwhile, cells could 
produce de novo ECMs for vessel wall development and remodelling. Pathological 
cytokines could do harm to ECMs homeostasis leading to vascular wall stiffness. 
ECMs can be divided into two forms which are interstitial and pericellular ECMs. 
Pericellular ECMs contact cells to prevent cells from ripping apart, whereas interstitial 
ECMs bind with each other to create a complex network. In a vessel wall, ECMs 
provide support for the basement membrane. Internal elastic laminae locate at the 
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outmost of intima layer comprise of elastin. Internal elastic laminae and basement 
membrane can be connected by connective tissues. ECMs are also rich in collagen 
and elastin fibres within media layer, to enable separation and lubrication to SMCs. 
The outmost layer is the adventitia tunica, in which layer of the ECMs is comprised of 
external elastic laminae and interstitial ECMs. Main forms of ECMs in the vascular wall 
include collagens, elastin, fibronectin (FN), laminins, proteoglycans (PGs), and 
glycosaminoglycans (GAGs) which are highly acidic and hydrated molecules. 
Surrounding cells are responsible for ECMs production within different layers. For 
example, collagen and elastin are derived from SMCs and in adventitial layer ECMs 
are produced by fibroblast178. The vascular cells interact with ECMs through integrin 
and support cells to proliferate, survive and/or differentiate. Several types of ECMs 
could exert distinct effect on target cells. For example, basal laminae proteins such as 
collagen-IV and laminin could enhance SMCs contractile gene expression, whereas 
interstitial matrix proteins could improve SMCs proliferating rate. ECMs damage would 
contributes to cellular biology changes and promote vascular wall remodelling or 
disease. Meanwhile, small molecules can be released from ECMs as matrikines which 
also provide signals for surrounding cells. 
 
Figure 1.5.6 Extracellular Matrices (ECMs). ECMs within the vascular wall contain 






as glycosaminoglycans. According to distribution, they are divided interstitial and 
pericellular ECMs. SMCs and fibroblast are mainly responsible for ECMs production 
within the vessel wall. Besides maintaining vessel structure, ECMs contact with 
neighbouring cells and regulate vessel wall homeostasis. ECMs, extracellular matrices; 
SMCs, smooth muscle cells. (Figure Source: http://slideplayer.com/slide/9806334/.) 
 
1.5.6.1 Collagen 
Collagen is known as a tropocollagen triple helices, as referred as microfibril179. Each 
chain of collagen consists of repeating glycine-prolin-lysine (Gly-X-Y) motifs serving 
for triplet formation. Collagen formation begins from a Non-collagen (NC1) domains 
and the triplex structure can align in a C- to N-terminal direction. During this process, 
under assistance of vitamin C, a hydroxyl base is added to prolin and lysine by prolyl 
hydroxylase and lysyl hydroxylase, respectively. Then glycosylation occurs by adding 
either glucose or galatose to hydroxylysine, and thereafter collagen chains twist into 
triplets. When peptide at each terminal end is cut, tropocollagen forms. Through aldol 
condensation reaction, hydroxylysine and hydroprolysyl are oxidized forming cross 
link between two tropocollagen molecules to form microfibrils. Afterwards they pack 
into fibrillary collagen. For example, collagen I and III belong to the fibrillary collagen 
form and this provides vessel wall tensile strength. They can be stabilized by other 
macromolecules such as decorin and biglycan180. However, some collagens have 
interruptions by non-collagen structures within their triple helical structures favouring 
them to interact with other molecules. For example, by tail to tail interaction, NC1 
domain in collagen IV could initiate dimer triple and helical structures formation. 
Similarly, tetramer and multiple complex comprise of the collagen network. At last, 
collagen molecules could also bind with other kind of ECMs forming multiplexin.  
Collagen could directly interact with cells by integrin. With integrin signalling, cells fate 
is regulated. For example, interaction between collagen and α1β1 integrin stimulates 
SMCs proliferation through MAPK pathway181, whereas α2β1 mediate SMCs 
migration182. Meanwhile, distinct form of collagen could also show different impact on 
cells. When SMCs are cultured in collagen IV, SMCs would express more contractile 
phenotype because of SRF binding, whereas in collagen I environment, SMCs could 
transform into an inflammatory form183. When collagen IV NC1 domain molecules such 
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as arresten was put into ECs culture medium, angiogenesis was inhibited184. Similarly, 
neostatin derived from collagen-XVIII could also inhibit neovascularization185. 
Afterwards, in response to distinct collagen, SMCs or fibroblast would secrete different 
ECMs. When collagen is excessively produced, vessel fibrosis and stiffness would 
occur with more collagen binding by hydroxylysine or hydroprolysyl oxidization. 
1.5.6.2 Elastin 
Elastin is an elastic protein allowing the tissue to recover its origin shape after 
stretching or contracting. By linking to a small soluble precursor tropoelastin, the 
complex elastin would form. Tropoelastin is firstly synthesised and transported from 
the cytoplasm to the extracellular space. This process is facilitated by the elastin-
binding protein (EBP), which prevents tropoelastin from degradation. Once 
tropoelastin is delivered outside of the cells, EBP would recycle back into the 
cytoplasm186. Each tropoelastin consist of hydrophobic and hydrophilic domains. The 
hydrophilic domains contain Lys-Ala (KA) and Lys-Pro (KP) motifs that are involved in 
crosslinking during the formation of mature elastin. Assembly process is mediated on 
microfibrils, which serve as a scaffold. Elastin is produced in both media and adventitia 
layers and is mainly located at the space between the internal and external elastin 
laminae. Elastin fibre consists of fibrillin microfibrils and elastin core, allowing the 
elastic recoil. Elastic recoil is important for the vasculature to maintain its structure 
when they bear dynamic blood flow. Fibrillin microfibrils could provide Elastin with 
scaffold facilitating elastin deposition and assembly. Elastin fibres cover SMCs in a 
concentric fenestrated elastic laminae, which serves as a basic unit of the artery wall187.   
Elastin binds with SMCs via the elastin receptor, which consist of EBP, neuraminidase 
and a protective protein188. When binding with this receptor, elastin suppresses 
migration and proliferating in SMCs. Meanwhile, contractile character in SMCs can be 
maintained. Elastin can assist and preserve myofilament stability through activating 
Rho GTPase. Data showed that when culturing SMCs on elastin, SMCs would 
preserve quiescent state with contractile filament189. However, elastin form could also 
affect SMCs state. For example, when elastin is cleaved and release its fragment EDP, 
this released segment binds with SMCs receptor inducing SMCs migration.  Elastin 
also exerts its effect on inflammatory cells. In opposite to other ECMs such as lamina 
or collagen, Elastin reduce leukocyte adhesion in the neointima. Elastin gene mutant 
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results in uncontrolled SMCs proliferation and intima hyperplasia190. Data was shown 
that mice with elastin gene knockout would die because of vascular occlusion191.  
1.5.6.3 Fibronectin 
Fibronectin is a glycoprotein dimer. C-terminal of each chain is bonded by disulfide 
bond. There are mainly of two types in fibronectin, which are soluble plasma 
fibronectin and insoluble fibronectin composing ECMs. Each fibronectin consists of I, 
II, III three motifs. Different to motif I and II which function in intra-chain bond and 
matrix assembly, motif III mainly functions by binding with cells by interacting with 
integrin. This interaction is because of RGD sequence (Arg–Gly–Asp) within III motif. 
Fibronectin is crucial in cell physiology. For example, when vascular injury is induced 
and bleeding occurs, plasma soluble fibronectin can be activated to form the clot 
protecting the tissue. Then ECs or ESPCs are recruited to injury sites for angiogenesis 
or vasculogenesis. Meanwhile SMCs, fibroblast and leucocyte also accumulate at 
wound site to secret proteases digesting soluble fibronectin. Afterwards, insoluble 
fibronectin along with other ECMs such as collagen is secreted to resemble origin 
structure of the tissue. During this process, SMCs are promoted into phenotypic 
change from contractile type and into a proliferate state. These characters also 
mediate fibronectin involving neointima formation. It was shown that by alternative 
splicing fibronectin motif, leucocyte and SMCs accumulation are decreased. 
Vitronectin also has a similar function in vessel wall remodelling192. 
1.5.6.4 Laminins 
Laminins are large proteins to serve a component of basement membrane. Laminins 
are composed of heterotrimeric proteins including α, β, γ chains. With cross like 
structure, three short arms are used for binding with other laminins, and the long arm 
is for binding with cells. To form a matrices network, laminins interact with other ECMs 
by fibronectin, vitronectin and perlecan. Laminins locate at the basement membrane 
in the vessel wall. Laminins surround and bind cells with distinct isoform. It was shown 
that within the endothelium, α4 and α5 are highly expressed. Whereas in SMCs 
basement membrane, α1 and β2 expression are increased193. They exert several 
functions in vessel wall. For example, Laminins can inhibit leucocyte invasion. 
Laminins isoform expression were thought to be derived from the pericytes to regulate 
leucocyte transmission. Meanwhile, because laminin could directly anchor with ECs 
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by integrin, it was thought that laminins could also convey mechanical signalling from 
the lumen. In addition, SMCs phenotype can also be maintained by laminins in the 
basement membrane. Other ECMs such as PGs and GAGs could function in LDL 
binding, which is associated with atherosclerosis formation. All of these ECMs could 
all cooperate together to regulate homeostasis within the vessel wall. 
1.5.6.5 Metalloproteinase 
ECMs homeostasis is regulated by proteases or metalloproteinases. 
Metalloproteinases include matrix metalloproteinases (MMPs), a disintegrin and 
metalloproteinases (ADAMs), and ADAMs with a thrombospondin motif 
(ADAMTS)194. Their proteases activity relies on their catalytic site, which consist of 
a conserved motif HEXXHXXGXXH and a zinc ion. Metalloproteinase can be divided 
into soluble and membrane anchored form. Among all of these enzymes, MMPs are 
the main enzymes to degrade all ECMs195. By modulating connective tissues or 
adhesion molecules, migration and/or proliferation can be regulated. Tissue 
inhibitors of MMPs (TIMPs) could inhibit MMPs activity, to prevent excessive ECMs 
degradation. MMPs and TIMPs commonly maintain ECMs balance, which is crucial 
for vessel wall remodelling. N-terminal of MMPs is a signal peptide domain, which is 
crucial for MMP activity. When the signal peptide domain is bound to the catalytic 
domain, MMPs are inactive. However, once signal peptide domain is cleaved from 
the catalytic domain, MMPs are activated. Most MMPs also have a haemopexin-like 
domain to respond to a known ligand. Some Membrane-type MMPs (MTMMPs) 
anchor on the cell surface by a cytoplasmic tail or by direct binding by 
glycosylphosphatidylinositol (GPI). Currently, 23 MMPs have been identified in 
human beings196. According to recognized molecules structure and subtracts, 
MMPs can be divided into collagenases, gelatinases, stromelysins, matrilysins, 
MTMMPs and other MMPs. Once produced, MMPs would be secreted into the 
plasma when binding with heparin sulfate glycosaminoglycan known as a pro-MMPs 
form. Alternatively, MTMMPs would reside on the cell surface. Several factors could 
activate pro-MMPs including alteration in heat, PH and chemical agents. Protease 
could also activate pro-MMPs. For example, in non-active form, pro-MMP2 bind with 
TIMP2 and MT1-MMP as a complex. N terminal inhibitory domain of TIMP could 
inhibit function MT1-MMP. However, when TIMP is removed from this complex, 
MMP2 can be activated by signal peptide domain cleavage. Alternatively, signal 
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peptide domain can be cleaved by another MT1-MMP197. In some cases, distinct 
MMPs would cooperate for ECMs degradation. For example, collagenase MMP1 
and MMP8 could recognize and unfold their triple helix in collagen fibril. This signal 
chain is subsequently degraded by gelatinases198.  
1.5.7 Cell Migration within Vessel Wall 
Vessel wall is composed by several cells types including leucocyte, ECs and SMCs 
as shown above. Cell migration is pivotal for vascular homeostasis and vessel 
remodelling. To move to targeted sites, cells would either float from the circulation to 
the tissue such as leucocyte or crawl locally on ECMs surface such as ECs and SMCs, 





Figure 1.5.7 Cell migration in vascular wall: A. Leucocyte migration contains 
continues stages including rolling, capture, adhesion strength and transmigration. 
During these stages, molecules such as selectin, integrin, adhesion molecules and 
chemokines facilitate leucocyte capture on ECs surface. Via paracellular or 
transcellular route, leucocyte transmigrate into basement membrane. B. ECs and 
SMCs begin to crawl in response to signal within the vessel wall. All the stages 
include sensing, extension, attachment, contraction, rear release and recycling. 
Vascular cells crawling is one continues process. ECs, endothelial cells; SMCs, 
smooth muscle cells. (Figure Source: A, Ley K, Laudanna C, Cybulsky MI, Nourshargh 
S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. 
Nature reviews. Immunology. 2007;7:678-689199; B, Lamalice L, Le Boeuf F, Huot J. 






1.5.7.1 Leucocyte Migration 
Leucocyte migration is one continues process which involves several stages including 
rolling, capture, adhesion and transmigrating for vessel wall remodelling. Circulating 
cell recruitment begin to roll by selectins molecules such as L-selectin, P-selectin and 
E-selectin201. When binding and interacting with selectins expressed on 
inflammatory ECs, leucocytes adhere to ECs layers. By leucocyte interaction, more 
inflammatory cells are recruited to the endothelium. With the blood flow, leucocytes 
roll on the ECs surface and form a stronger interaction by binding to selectins. 
Selectin engagement triggers activation of downstream pathways such as PI3K and 
MAPK signalling. Meanwhile cell rolling can also be mediated by integrin. It was 
shown that several integrin types such as α4β1-integrin (VLA4), αLβ2-integrin (LFA1) 
and αMβ2-integrin (Mac, CD11b) could maintain cell rolling, when interacting with 
immobilized vascular cell-adhesion molecule 1 (VCAM1) expressed on ECs199. In 
response to ECs inflammation, ECs would be rapidly mobilized to express both 
ICAM-1 and VCAM-1. Meanwhile, chemokines are also produced by ECs and 
presented on ECs luminal surface. Alternatively, leucocytes could also generate 
chemokines, which is endocytosed by ECs or binds with glycosaminoglycans on 
ECs layer. The most classic G protein-couples receptors (GPCRs) on leucocyte 
could bind these chemokines inducing signalling cascades change and provide 
signals, referred as inside-out signalling202. Several factors are responsible for 
integrin activation. For example, in monocyte, GPCRs downstream molecular, 
phospholipase C (PLC) is activated for VLA4 activation once stimulated by 
chemokines. Meanwhile, via small GTPase activation such as RAP1 and RhoA, 
activity of LFA1 can be regulated. In fact, signal transmitting can be achieved 
through adhesion molecules such as talin and vinculin. With inside-out singling, 
integrin is driven from bent low-affinity conformation to extended high-affinity state 
and binds with inflammatory molecules. Afterwards leucocyte stops rolling and is 
captured on ECs surface. Also, activated integrin could transmit signalling by out-
inside singling to tight this interaction. For example, tyrosine kinase Src could be 
rapidly recruited to integrin. The resulted cytoskeleton arrangement occurs and 
collaborate with activated integrin to form cell adhesion. The effect in leucocyte 
capture varies depending on integrin types.  
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Once captured by inflammatory ECs, leucocytes continue to crawl transmitting ECs 
connection. While transmigration, monocyte firstly crawl into intercellular space 
between ECs to sense the weak site by MAC/ICAM complex203. Binding of ICAM 
and MAC induces MAPK signalling activation, to increase ECs contraction via 
regulating myosin motor. Therefore, intercellular space can be open for leucocyte 
transmigration. Guided by both chemokines and sheer flow, monocyte transmigrate 
through interaction with ECs. During this process, cell migration is also facilitated 
by intercellular interaction between leucocyte and ECs. In fact, it has been 
demonstrated that this interaction is favoured by a docking structure, in which 
binding molecules accumulate and serve as a binding site. Similar to migration 
pattern on extracellular matrix, monocyte could move through paracellular route. For 
example, junction molecules such as PECAM1 and ICAM could bind as a ligand for 
leucocyte receptors and mobilize the cells. These molecules would cluster and form 
a concentration gradient to guide cells to migrate204. In opposite, VE-cadherin which 
cannot mobilize leucocyte would keep away from the docking structure205. With 
reduced ECs intracellular adhesion, more space is opened for monocyte migration 
and meanwhile by adjusting adhesion molecules in a favoured site, monocyte could 
move inwards. In addition to paracellular route, monocyte could also migrate 
through transcellular pathway206. This process minorly occurs but could be rapid. 
Monocyte transcellular migration is achieved by vesiculo vacuolar organelles 
(VVOs). VVOs is a specific ECs organelle that is formed by cabelolea and 
cytoskeleton, contributing to endothelial permeability. With this structure, VVOs 
could transport fluid and macromolecules from the lumen to the cytoplasm. In this 
case, once integrin expressed on leucocyte surface is recognized by ECs adhesion 
molecules, cabelolea translocate from cytoplasm to cell membrane and thereafter 
construct intracellular channels facilitating leucocyte migration. Transcellular 
transmigration is prone to occurring in weak ECs layer in response to ECs 
dysfunction.  
After transmigration through ECs monolayers, leucocyte continue to migrate into the 
basement membrane. As discussed above, ECs basement consist of ECMs 
including collagen and elastin, connected by proteoglycan perlecan. During process 
of penetrating basement membrane, leucocyte would firstly seek the weak point 
because of asymmetric distribution of ECMs. The weak sites in basement 
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membrane locate at the sites, where ECMs are less deposited or the gap between 
pericytes and ECMs. Meanwhile, these sites are also permissive for cytokines. To 
note, ECMs such as glycosaminoglycans (GAGs) could also bind to cytokines for 
leucocyte proliferation or chemotaxis. Furthermore, ECMs could also activate integrin 
signal on leucocytes when migrating.  
1.5.7.2 ECs Migration 
ECs migration is involved in angiogenesis, a process in which blood vessel arise from 
pre-existing vessel. During AV, vascular occlusion results in hypoxic environment. 
Quiescent ECs are then activated by proangiogenic factors to shape the new lumen, 
with new connections to supply surrounding cells demands for oxygen and nutrients. 
Proangiogenic stimuli are mainly chemokines, ECMs and sheer stress. After ECs 
injury, cytokines such as vascular endothelial growth factor (VEGF) and angiopoietin 
are released. VEGF is a signal molecule, which binds to its corresponding receptor 
vascular endothelial growth factor receptor (VEGFR). VEGFR belongs to tyrosine 
kinase receptor and is widely expressed on ECs. VEGFR is consist of an extracellular 
domain, a transmembrane region and intracellular domain. Until currently, in total four 
VEGF subtype (A/B/C/D) and three VEGFR (1/2/3) are found in VEGF/VEGFR 
signalling. When extracellular domain of VEGFR is activated by VEGF, VEGFR 
undergoes dimerization and relays signals into the cytoplasm. Intracellular tyrosine 
kinase is then activated for transphosphorylation on specific tyrosine kinase, which 
could recruit SH2 containing adaptors to convey downstream signalling. Then 
activated Rac and Cdc42 produced ECs protrusion, which is amplified by PI3K 
signalling. Several studies also showed that intercellular interaction inhibit ECs 
migration. Data was shown that VEGF is efficient in dissociating adhesion between 
ECs to facilitate ECs migration207. Angiopoietin is another cytokine released during 
ECs dysfunction. Four forms angiopoietin are now identified which are angiopoietin 
(1/2/3/4). Receptors of angiopoietin are Tie-1 and Tie-2. Similar to VEGF/VEGFR 
signalling, Tie1/2 activation also mediates phosphorylation on specific tyrosine kinase. 
This stimulates downstream migration signalling. In addition to migration, angiopoietin 
also stabilizes nascent vessel. It was shown that angiopoietin could stimulate ECs to 
release cytokines such as TGF-β and PDGF. SMCs or pericytes are recruited under 
these cytokines to contribute to ECs stability via secreting ECMs. 
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ECMs are another stimulus inducing ECs migration. ECMs type determines pattern of 
ECs migration. During normal state, ECs attach to ECMs and preserve endothelium 
integrity. However, once ECMs are eradicated, ECs migration is initiated because of 
altered ECMs. For example, collagen I and fibronectin could support ECs migration208. 
Meanwhile, ECMs could function as cytokines scaffold to reserve cytokines. These 
cytokines could positively or negatively regulate ECs migration. Therefore, when 
ECMs are degraded during vascular remodelling, reserved cytokines can be released 
in the vascular microenvironment to control angiogenesis. Furthermore, interaction 
between ECs and ECMs also plays an important role in ECs migration. Through 
integrin as well as intracellular adhesion molecules, cytoskeleton connects ECs to 
ECMs. Adhesion and de-adhesion processed can be therefore regulated because of 
different type and gradient of ECMs.  Integrin expression on ECs can also be regulated 
by cytokines. For example, αvβ3, αvβ5 and α5β1 on ECs are upregulated by VEGF for 
angiogenesis209. Shortly after integrin engagement, FAK undergoes conformational 
change and controls deadhesion signal. Sheer stress could also induce ECs migration. 
In physiological state, the endothelium is protected by glycocalyx expressed on ECs. 
However, after allo-graft transplantation, ECs are directly exposed to sheer stress. 
Once stimulated by sheer stress, ECs would polarize by cytoskeleton remodelling. 
Signals from sheer stress is sensed by integrin to activate Rho family GTPases to 
generate protrusion. Meanwhile, RhoA is also activated to provide contraction required 
for rear detachment and migration. 
1.5.7.3 SMCs Migration 
Similar to ECs, SMCs migration after vascular injury is also regulated by several 
factors including cytokines, ECMs and sheer stress. In AV, SMCs are induced to 
migrate towards the lesion site. Platelet-derived growth factor (PDGF) is one cytokine 
to induce SMCs migration. PDGF is a dimeric glycoprotein composed of two subunit 
such as PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD. Its 
corresponding receptor is PDGFR, which is a tyrosine kinase receptor and includes 
two isoforms PDGFR-α/β. PDGFR is composed of extracellular immunoglobulin like 
domain and intracellular tyrosine kinase domain. Once binding with PDGF ligand, 
PDGFR dimerises to activate downstream signalling. However, the effect on SMCs 
migration depends on PDFG isoform. For example, PDGF-BB induces SMCs 
mobilization, whereas PDFG-AA inhibits SMCs migration. Meanwhile, besides of 
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direct simulation, PDGF-BB could also induce SMCs to secret cytokines such as FGF-
2 in an autocrine fashion for migration210. Fibroblast growth factor (FGF) is another 
cluster of signalling proteins and data showed that FGF-2 facilitates SMCs motility211. 
Receptor of FGF is FGFR, which is also a tyrosine kinase receptor to pass signal into 
cytoplasm.  
In uninjured vessel, SMCs are trapped in elastin in the media layer. Elastin favours 
SMCs contractile state with little capability to proliferate and migrate. During these 
state, ECMs and SMCs are relatively stable to adhere with each other. However, 
during allograft induced arteriosclerosis, component of ECMs are altered to induce 
SMCs to migrate. ECs dysfunction provides inflammatory cells opportunities in 
continuing to break through the basement layer. In this process, inflammatory cells 
secrete metalloproteinase to degrade ECMs, mainly elastin in graft media layer. 
Meanwhile, to restore the injured tissue, soluble fibronectin accumulates in lesion. 
Then fibronectin, stimulates intimal myocyte, fibroblast or inflammatory cells to secret 
fibrotic ECMs such as collagen I and collagen IV. On the other hand, soluble 
fibronectin is replaced by insoluble fibronectin. Subsequently, along with other fibrotic 
ECMs, fibronectin stimulates phenotypic change of SMCs from a contractile state to a 
proliferating type. Mobility of SMCs is meanwhile upregulated. Several fibrotic ECMs 
induce SMCs migration including fibronectin, collagen I, collagen IV, and lamina212. 
Once integrin adheres with ECMs, signal would be transmitted into SMCs cytoplasm 
triggering cells to migrate via cytoskeleton arrangement. 
Haemodynamic factors would also affect SMCs phenotype change and migration. 
During normal state, SMCs layer is covered by ECs layer. SMCs sense sheer stress 
via ECs signalling. By ECs secreted cytokines, SMCs homeostasis is regulated under 
normal shear stress. However, after ECs dysfunction or death, SMCs are directly 
exposed to shear stress. The balance between percentage of contractile and 
proliferation SMCs form is interrupted. Meanwhile, because of intima hyperplasia, 
normal shear stress is transformed into oscillatory shear stress. It was shown that 
oscillatory shear stress promotes SMCs phenotype transformation into synthetic form. 
Under this state, mobility of SMCs is increased. Then guided by chemokines attraction, 
SMCs migrate to intima layer involved neointima formation. With the neointima further 
proceeding, ESPCs are recruited to the endothelium layer for ECs regeneration. Along 
with residual ECs, newly formed ECs would cover SMCs on lesion surface again.  
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Because of the intruded lesion, AV plaque is naturally divided into two parts according 
to blood flow direction. In upstream regions, blood flow is high shear stress and directly 
strike the vessel wall. In this case, high shear stress induces ECs to secrete nitric 
oxide (NO) which decreases SMCs migration but increases SMCs apoptosis213. 
Therefore, in lesions upstream, SMCs are prone to form a necrotic core and rupture. 
In downstream of the lesion, low shear stress or oscillatory shear stress induce PDGF 
and TGF secretion from ECs. Then under the influence of these cytokines, proliferation 
and migration capability of SMCs are upregulated to support intima thickening214. 
1.6 Hypothesis and Aims 
1.6.1 Rationale 
After vascular allo-transplantation, both recipient and donor derived inflammatory cells 
accumulate in the vascular graft, leading to allograft vasculopathy / arteriosclerosis 
neointima formation. However, the source of other accumulating vascular cells, 
including ECs and SMCs, is still uncertain. Recently, several SPC populations have 
been identified from various tissues, however the role of these cells in allograft 
vasculopathy / arteriosclerosis are still not clear.  
1.6.2 Hypothesis 
We hypothesized that SPCs from both donor and recipient source tissues are involved 
in vascular allograft accelerated arteriosclerosis lesion formation and that the recipient 
source of these SPCs could be various tissues including vascular wall and bone 
marrow.  
1.6.3 Aims 
1.6.3.1 Aim 1: To investigate SPCs population in the vessel wall and bone 
marrow; 
Immunostaining of C57/6J animal tissue was used to identify SPCs in both the vessel 
wall and bone marrow.  




C-kit kit/CreER; Rosa26-RFP knock in mice were established to trace the fate of SPCs 
under physiological conditions. 
1.6.3.3 Aim 3: To detect the fate of SPCs in allo-graft induced arteriosclerosis; 
Vascular allo-transplantation surgery was performed between Balb/c mouse and c-kit 
kit/CreER; Rosa26-RFP transgenic animal, to study SPCs fate from donor and recipient 
mice, respectively. Furthermore, by creating chimeric mice, the role of bone marrow 
or non-bone marrow derived SPCs in allograft accelerated arteriosclerosis could be 
identified. 
1.6.3.4 Aim 4: To study the underlying mechanism of SPCs migration. 
SPCs migration is known to depend on cytokines. Therefore, mobility pattern of SPCs 


















Chapter 2: Methods 
 
2.1     Mice and Artery Allograft Procedure 
All animal breeding and surgeries were performed according to required standards in 
the biological service unit (BSU) at the James Black Centre of King’s College London 
and all procedures were approved by UK Home Office License (PPL70/8944). Chow 
diet with 12-hour light and 12-hour dark environment at 25 °C was applied to all mice. 
C-kit kit/CreER knock-in mice (generated from a C57BL/6 background) were a kind gift 
from the Zhou laboratory, Shanghai Academy of Science, China61. Rosa26-RFP 
reporter mice were purchased from the Jackson Laboratory, USA. C57BL/6J and 
Balb/c mice were purchased from Harlan, Blackthorn, Bicester, UK. C-kit kit/CreER; 
Rosa26-RFP mice were generated by crossing c-kit kit/CreER and Rosa26-RFP reporter 
mice, and tracing the fate of c-kit+ cells as reported previously61. Briefly, the number 
of c-kit kit/CreER animals was firstly expanded by crossing C-kit kit/CreER with C57BL/6 wild 
type (WT) mice. Then c-kit kit/CreER mice were crossed with Rosa26-RFP reporter mice. 
Therefore in theory, the chance to obtain the mice with c-kit kit/CreER ; Rosa26-RFP 
genotype from this strategy was 25%. Genotyping was performed via conventional 
PCR to ensure expression of the target alleles: c-kit-creER (mutant allele: forward: 5’-
GCCTTCTATCGCCTTCTTGACG-3’; reverse: 5’-CAGTCGGCACAAAAGCATCAC-
3’). ROSA-RFP (mutant allele: forward: 5’- AAGGGAGCTGCAGTGGAGTA-3’; 
reverse: 5’- CCGAAAATCTGTGGGAAGTC-3’. WT allele: forward: 5’- 
GGCATTAAAGCAGCGTATCC-3’; reverse: 5’-CTGTTCCTGTACGGCATGG-3’).C-kit 
kit/CreER; Rosa26-RFP mice expressing RFP (red fluorescent protein/Tdtomato) signal 
under the control of the c-kit promoter occurred once tamoxifen induction. 5 pulse 
intraperitoneal injections of Tamoxifen (Sigma, T5648) dissolved in corn oil (20 mg/ml) 
on 5 consecutive days ensured Cre recombinase efficiency (0.1–0.15 mg tamoxifen 
per gram of mouse body weight).  
Aorta transplantation was performed between Balb/c mice and C-kit kit/CreER; Rosa26-
RFP, chimeric mice and wildtype C57BL/6J mice aged 8-12 weeks. Randomised 
selection of male and female mice was applied in experiments. The allograft 
transplantation procedure was performed as described previously66, 98 (Figure 
2.1). Briefly, branching artery of donor aorta segments were carefully enclosed by 
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electrocoagulation to prevent bleeding. Segments were immersed into heparin to 
prevent coagulation. After the recipient mice were anaesthetised with phenobarbital, 
a single 20mm incision in the middle of the neck to expose the right common carotid 
artery. Both distal and proximal ends of the right common carotid artery then were then 
immobilised by two clips. A cut at the middle of the artery between the two clips was 
applied and each end was placed within a 1mm cuff. Donor graft was joined to recipient 
artery by covering over of the cuff. After tight ligation of aortic segment with cuff at 
each end without bleeding, clipper at each end was released carefully followed by 
suture of the muscle and skin. Proper observation was exerted on post-surgery mice. 
For antibody delivery, after aortic segments were implanted to carotid artery, 100 μg 
ACK2 or control IgG in 30% pluronic F-127 gel (Sigma, P2443) was delivered to the 
adventitial side of the transplanted aortic grafts. 
 
 
Figure 2.1 Artery allograft procedure. The right common carotid artery was ligated 
and dissected between the middle ties.  The vessel segment passed through a cuff at 
each end. The vessel end and cuff were then fixed with microhemostat clamps. Vessel 
segment was turned inside out to cover the cuff. The aortic segment (1 cm) was 
harvested and grafted between the 2 ends of the carotid artery by sleeving the ends 
of the vessel over the artery cuff and suturing them together. The vascular clamps 
were removed; pulsations were seen in the grafted vessel. (Figure Source: Dietrich H, 





Hu Y, Zou Y, Dirnhofer S, Kleindienst R, Wick G, Xu Q. Mouse model of transplant 
arteriosclerosis: Role of intercellular adhesion molecule-1. Arteriosclerosis, 
thrombosis, and vascular biology. 2000;20:343-35234.) 
2.2     Immunofluorescence and Immunohistochemical staining. 
For immunofluorescent staining of mouse tissues, tissues were first collected, washed 
with PBS and fixed in 4% paraformaldehyde (PFA, Santa Cruz, sc-281692) at 4 °C for 
2-3 h. Tissues were then dehydrated in 30% sucrose solution (BDH, 102747E) 
overnight at 4 °C, embedded in OCT and frozen at -80°C. Tissues were cut to a 10-
µm thickness using a CryoStar Cryostat (Thermo Scientific). Frozen sections were 
firstly fixed in 4% PFA for 10 min, followed by permeabilisation and blocking in 5% 
donkey serum supplemented with 0.1% Triton X-100 for 1 h at room temperature.  
Tissues, cells or sections were then stained with primary antibodies in 5% donkey 
serum overnight at 4 °C, incubated with Alexa Fluor-conjugated secondary antibodies 
(Invitrogen, 1:500) for 1 h at room temperature, followed by DAPI (Molecular Probe, 
D1306) staining for 8 min. The control group were solely incubated in PBS with 5% 
donkey serum over night at 4 °C and then sequentially put secondary antibodies and 
DAPI. All slides were mounted with anti-fade mounting medium (Dako, s3023). Images 
were acquired using a Leica (TCS SP5) confocal microscopy by myself but not blinded. 
Primary antibodies used in this study are shown in Table 2.2. 
For immunohistochemical staining of mouse tissues, tissues were firstly fixed in 4% 
PFA, dehydrated, and embedded in a paraffin block. Serial sections were cut to a 5-
μm thickness and stained with haematoxylin and eosin following a standard protocol.  
Table 2.2 Primary antibodies used for Immunofluorescence 
Antibody Dilution used Provider Code 
c-Kit  1:50 R&D  AF1356 
c-Kit  1:50 Santa Cruz sc-5535 
CD34  1:100 BD Pharmingen 553731 
CD34  1:100 Santa Cruz sc-7045 
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Sca-1  1:200 Abcam ab51317 
RFP  1:500 Rockland 600-401-379 
α-SMA  1:100 Sigma A5228 
SM22  1:100 Abcam ab14106 
Calponin  1:100 Abcam ab46794 
SCF  1:100 Santa Cruz sc13126 
CD31 1:100 BD Pharmingen 553370 
VE-Cadherin 1:100 Santa Cruz sc-6458 
vWF 1:200 Santa Cruz sc-8068 
e-NOS 1:200 BD Pharmingen 610297 
VEGF 1:200 Santa Cruz sc-53462 
 
2.3     Aorta Preparation for Endothelial En-face Imaging 
Three-month old wild type (C57BL/6J) or C-kit kit/CreER; Rosa26-RFP mice were 
sacrificed by cervical dislocation. PBS was injected into the left ventricle of the heart 
to wash blood from the aortas, followed by a PFA injection to fix the endothelial cells.  
The hearts along with the aortas from the aortic root to bifurcation of the abdominal 
aorta into the common iliac arteries were then isolated intact.  Aortas were carefully 
dissected from the hearts and all heart muscle along with extravascular connective 
tissue around the aortas was gently removed. Aortas were then put into a solution of 
PBS with 5% donkey serum (Dako, Agilent Technologies, Denmark) and 0.2% Triton 
X-100 (Sigma-Aldrich, USA) at room temperature for permeabilisation of the cell 
membrane and blocking.  After 4 h, the tissues were washed with PBS 3×5 min. The 
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tissues were then cut into pieces and divided into the control and the treatment groups. 
The control group were solely stained with VE-cadherin, whereas treatment tissues 
were stained with VE-cadherin and targeting antigens. 
The treatment group vessels were incubated with antibody against VE-cadherin, CD34, 
c-kit and RFP (Table 2.2) at a concentration of 1:100 in PBS with 2% donkey serum 
over night at 4 °C. Meanwhile the control group vessels were incubated with antibody 
against VE-cadherin at a concentration of 1:100 in PBS with 2% donkey serum. The 
following day, the tissues were washed with PBS 3x5 min and treated with the 
appropriate secondary antibodies, diluted in PBS at a concentration of 1:500. After 1 
h incubation at room temperature, tissues were washed 3×5min with PBS and the 
nucleus was then stained with 4', 6-diamidino-2-phenylindole (DAPI) solution (Sigma-
Aldrich, United Kingdom) for 5 min at room temperature. The aortas were washed 3x5 
min with PBS and were then ready for mounting. The aortas were first cut into cross-
sectional rings of similar size before they were opened directly onto slides (Thermo 
Scientific, Germany). The rings were opened with the endothelium facing upwards. A 
drop of fluorescent anti-fade mounting medium (Vector laboratories, United Kingdom) 
was added before lowering the glass cover slip (Hirschmann-Laborgeräte, Germany) 
and the slides were stored at 4°C overnight. Tissues were imaged using the Leica SP5 
confocal microscopy by myself but not blinded. Images were analysed using ImageJ. 
Table 2.3 Primary antibodies used for intima en-face tissue preparations 













RFP 1:500 Rockland 600-401-379 
 
2.4     Aortic Adventitia Preparation for En-face Imaging 
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Wild type (WT) mice were sacrificed by cervical dislocation. Hearts, along with the 
aortas from the aortic root to the bifurcation of the abdominal aorta into the common 
iliac arteries, were isolated intact. The aortas were carefully dissected from the hearts 
and all heart muscle along with extravascular connective tissue around the aortas was 
gently removed. Once whole aortas had been digested in 0.4 mg/ml collagenase at 
37 °C for 6 min, the adventitia was gently separated from the media of each aorta by 
peeling the layer up and over the vessel. Adventitia was then put into a solution made 
of PBS with 0.2% Triton X-100 at room temperature for permeabilisation of the cell 
membrane for 15min after which the tissue was blocked in 5% donkey serum. The 
treatment group adventitial tissues were incubated with a rat monoclonal antibody 
raised against sca-1, CD34 and c-kit with the concentration of 1:100 in PBS with 2% 
donkey serum, whereas the control group adventitia was solely incubated in PBS with 
2% donkey serum over night at 4°C.  After the tissues in both treatment and control 
groups had been washed with PBS 3x5 min, they were treated with the secondary 
antibodies diluted in PBS at a concentration of 1:500. The processes of DAPI staining 
process, slide preparation and image process are as the ones in the endothelial En-
face method 2.3. 
Table 2.4 Primary antibodies used for intima en-face tissue preparations 
Antibody Dilution used Provider Code 









RFP 1:500 Rockland 600-401-379 
 
2.5     Cell Isolation 
Graft cell harvest was performed by cutting the whole vessel into 1 mm small pieces 
followed by collagenase digestion at 38 °C for 30 min. During this process, frequent 
stirring of pieces of artery ensured full digestion of the tissue. Bone marrow cells were 
acquired via flushing of PBS through mouse femur and tibia. Spleen tissue was 
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pulverised. All isolated cells were passed through a 40 μm cell strainer (Falcon, 
352340) to remove excess tissue and/or large clots. Bone marrow and spleen cells 
were incubated with a red blood cell lysis buffer (eBioscience, 00-4333) for 20 min to 
remove peripheral red blood cells. All prepared samples were kept on ice for flow 
cytometry analysis. 
2.6     Flow Cytometry Analysis 
Harvested cell pellets were labelled with antibodies at 1:50 dilution for 30 min on ice. 
After centrifugation and discarding of excess supernatant, the cell pellets were re-
suspended in PBS and then were ready for analysis. Stained cells were collected on 
BD LSR Fortessa II flow cytometry (Becton Dickinson) and data was analysed in 
Flowjo Software. The antibodies applied in this project are shown in table 2.6. 
Table 2.6 Antibodies used for flow cytometry analysis 
Antibody Dilution used Provider Code 
anti-CD34-Alexa 
Fluor647  
1:100 BD bioscience 560233 
anti-CD117(c-kit)-
PE  
1:100 Biolegend 105807 
anti-Ly-6A/E(Sca-
1)-PE/Cy7  




1:100 BD bioscience 562801 
anti-CD31(Pecam-
1)-PE/Cy7  
1:100 Biolegend 102523 
anti-CD45- Alexa 
Fluor647  
1:100 Biolegend 103124 
anti-CD146-FITC 1:100 eBioscience 11-1469-41 
anti-
CD201(EPCR)-PE 










1:100 eBioscience 120407 
anti-CD44-PE/Cy7 1:100 eBioscience 103029 
anti-Ki-67-FITC 1:100 eBioscience 11-5698-82 
 
2.7     Bone Marrow Reconstitution 
The procedures used in the creation of chimeric mice were performed as previously 
described98. Briefly, harvest of donor bone marrow cells by flushing mouse femurs and 
tibias with PBS was followed by removal of excess tissue and/or large clots via passing 
cells through a 40 μm cell strainer in a similar procedure described above. Harvested 
cells were stored in serum free medium. A lethal dose of whole-body irradiation (900 
rads X-Ray) was applied to recipient mice. 6 h later, chimeric mice were established 
via bone marrow transplantation in which 5×106 unfractionated donor bone marrow 
cells were injected into the tail veins of irradiated recipient mice. An animal model for 
further use was acquired following tamoxifen induction of the similar strategy 
described above, on chimeric mice two weeks after bone marrow transplantation. The 
efficiency of bone marrow transplantation was determined by RFP detection using flow 
cytometry described above. Allograft transplantation of aortic segments from Balb/c 
mice to chimeric mice was not performed until the full reconstitution of bone marrow 
in chimeric mice and establishment of animal model. 
2.8     Mouse Vascular Stem/Progenitor Cell Isolating and Culture 
The procedure used for mouse vascular stem/progenitor cell (SPCs) isolation and 
culture was performed as previously described. Briefly, isograft of vena cava to carotid 
artery of recipient was performed (both donor and recipient were C57/BL6J mice). 
Grafts were harvested two weeks after surgery and then cut open and spread onto 
one 0.2% gelatin (Sigma, G1393) coated T25 flask (culture conditions were set at 37°C 
with 5% CO2). To ensure cell growth, complete stem cell culture medium consisting 
of DMEM (ATCC, 30-2002), 10% EmbryoMax ES Cell Qualified FBS (Millipore, ES-
009-B), 10 ng/ml leukaemia inhibitory factor (Merck Millipore, LIF1050), 0.1 mM 2-
mercaptoethanol (GIBCO, 31350-010), 100 U/ml penicillin-streptomycin (GIBCO, 
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15140122) and 2 mM L-glutamine (GIBCO, 25030081) was used. SPCs labelling was 
achieved in sequence by using sca-1(Miltenyi Biotec, 130-092-529) and c-kit (Miltenyi 
Biotec, 130-091-224) microbeads kit according to manufacturer’s instruction. The 
culture medium was prepared following the recipe described above. Once at 80% 
confluence, SPCs were digested by trypsin (Glico, 25300-054) and passaged at a ratio 
of 1:3. The culture medium was changed every other day. 
2.9     Cell Sorting 
A sca-1+ population of cells was obtained using an anti-Sca-1 MicroBead kit (FITC) 
(Miltenyi Biotec, Germany) and following the manufacturer’s instructions. The cells 
were first harvested using trypsin-EDTA after they had been washed with PBS. After 
incubation at 37 °C for 2 min, complete medium was added. The resulting cell 
suspension was centrifuged at 300 g for 10 min after which the supernatant was 
aspirated and the cell pellet was resuspended in 90µl MACS buffer (PBS, 0.5% serum 
and 2 mM EDTA) plus 10 µl of Anti-Sca-1-FITC per 107 cells. The suspension was 
mixed well and incubated in a 4 °C refrigerator for 10 min. 2 ml MACS buffer was then 
mixed with the cell suspension before it was centrifuged once more at 300 g for 10 
min. After aspirating the supernatant, the cell pellet was resuspended in 80 µl of MACS 
buffer and 20 µl Anti-FITC microbeads per 107 cells. The suspension was mixed well 
and incubated at 4°C for 15 min. After mixing with 2 ml of MACS buffer the suspension 
was then centrifuged a final time at 300×g for 10 min. Once the supernatant had been 
aspirated and the cell pellet had been resuspended in 500 µL MACS buffer, the cell 
suspension was transferred to a pre-washed column in the magnetic field of a MACS 
Separator. After all the cells had passed through the column, the column was washed 
three times, each time with 500µl MACS buffer.  New buffer was added only when the 
column reservoir was empty. The column was removed from the magnetic field of the 
separator and placed in a suitable collection tube. Afterwards, 1 ml buffer was loaded 
into the column and then was pushed by the plunger to flush out the magnetically 
labelled cells. The cell suspension was centrifuged at 1000 rpm for 5 min. After the 
supernatant was fully aspirated the cell pellet was resuspended in complete medium 
and the Sca-1+ cells were transferred to 0.04% gelatin coated flasks. The c-kit+ cells 
were sorted using the CD117 microbead kit (Miltenyi Biotec, Germany). Briefly, the 
cells were harvested by using trypsin-EDTA as previously described. After the cell 
suspension had been centrifuged at 300 g for 10 min, the supernatant was aspirated. 
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The cell pellet was then resuspended in 80 µl MACS buffer and 20 µl of c-kit 
microbeads per 107 total cells. The suspension was mixed well and incubated at 4 °C 
in the refrigerator for 15 min. The suspension was then centrifuged at 300 g for 10 min 
after 2 ml MACS buffer had been added to the suspension. Once the supernatant had 
been aspirated and the cell pellet had been resuspended in 500 µl MACS buffer, the 
cell suspension was transferred to a column in the magnetic field of a MACS Separator. 
Then the magnetic sorting was carried as described for sca-1(Figure 2.9). 
 
Figure 2.9 Cell Sorting. Cell pellets were incubated with microbeads containing 
antibody coated magnetic microbeads in MACS buffer. After labelling, cells were 
passed through a column in a magnetic field to exclude non-labelled cells. 
Magnetically labelled cells were then pushed out from the column and these positive 
sca-1+ and/or c-kit+ cells were further cultured. 
 
2.10 Transwell Migration Assay 
Transwell migration assays were performed using transwell kits (Corning Costar, 3464) 




serum free medium in the upper chamber at 37 °C for 10 min was followed by loading 
gradients SCF (Pepro Technology, 250-03) (0, 1,10,100 ng/ml) or VEGF (Pepro 
Technology, 450-32)(25, 50,100ng/ml) in a total of 600 µl serum free medium into the 
lower chamber. In experiments concerning c-kit blocking antibody ACK2 (eBioscience, 
14-1172-85) or IgG antibody as control, antibody was loaded in both upper and lower 
chambers. AKT inhibitor X (Millipore, 124020) was loaded similarly. After 18h 
incubation, medium from both upper and lower chambers was discarded. The 
migrating cells on the reverse surface of the transwell filter were sequentially fixed in 
4% PFA for 10 min and then stained with 1% crystal violet solution (Sigma Aldrich, 
HT90132) for 15 min (both processes were at room temperature). Non-migrating cells 
remaining on the top of transwell filter were removed by cotton swabs ensuring the 
images recorded captured only migrated stained cells on the reverse surface. Cells 
were counted at 5 random fields of the view under the microscope (at 20×).  
 
Figure 2.10 in vitro Migration Assay. A, Transwell migration assay. Cells migrate 
through a pore in the membrane. B, Wound healing assay. Cells were scratched from 
a dense monolayer a pipette tip to produce a cell free area. Closure of the wound area 





M, Krupitza G, Hengstschlager M, Dolznig H. In vitro cell migration and invasion 
assays. Mutation research. 2013;752:10-24215.) 
2.11 Scratch-wound Healing Assay 
SPCs were seeded in culture medium in a 12-well plate (Figure 2.10). The density was 
1×105 cells per well. Once at 80% confluence, a scratch in the surface coverage of 
cells was made using a 1000 µl pipette tip and culture medium was removed. Images 
of the initial width of the gap were obtained under the microscope (at 20x) in 5 fields. 
A concentration gradient (0, 1, 10,100 ng/ml) of murine stem cell factor (SCF) 
(Peprotech, AF-250-03) in the serum free medium was added to the cells. After 16 h 
culture, images in 5 fields were recorded. Mean area change between the two sides 
of the scratch compared with that in the initial scratch was shown as data indicated.  
2.12 BrdU Proliferation ELISA Assay 
Cell proliferation was tested using the cell proliferation ELISA, BrdU (colorimetric) kit 
(Roche, USA). Briefly, 5000 VPCs and APCs were added to a 96 well plate (Sigma-
Aldrich, Corning-Costar, USA) which had been coated with 0.04% gelatin and 
incubated with complete medium overnight. After the complete medium was removed, 
100 µl serum free medium with various concentrations of SCF (0, 1, 10,100 ng/ml) 
was added into the wells to culture the cells for 18 h. Afterwards 10 µl BrdU labelling 
solution was added per well and the cells were incubated for an additional 2 h after 
which the medium was removed. 200 µl FixDenat was added per well for 30 min and 
then removed. Subsequently 100 µl anti-BrdU-POD working solution was added per 
well for extra 90min and then removed. Once every well had been washed with 300 µl 
washing solution 3 times, 100 µl substrate solution was added and then the 
absorbance of the samples measured at 450 nm (reference wavelength is 690 nm) in 
a platereader ( Life science, Tecan, Infinite M200 Pro, United Kingdom). 
2.13 Protein Extraction and Quantification 
Cells were lysed on ice for 40 min by a lysis buffer consisting of RIPA buffer (Thermo 
Fisher, 89901), phosphatase inhibitor tablets (Roche, 04906837001,) and protease 
inhibitor tablets (Roche, 05892970001). The resulting cell lysate was transferred to a 
1.5ml crystal clear microcentrifuge tube (Starlab, E1415-1500) and sonicated using a 
Branson Sonifier 150 at level 1 for twice, each time for 8 seconds. After 15 min 
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centrifugation at 15000 g speed at 4 ºC, supernatant was collected and transferred to 
a new 1.5ml microcentrifuge tube. Quantification of protein concentration was 
performed by DC Biorad protein assay according to manufacturer’s instruction. Briefly, 
reagent A and reagent B were sequentially mixed with sample, absorption was read 
at 750 nm and protein concentration was measured according to a resulting standard 
curve. 
2.14 Western Blot 
The loading buffer was prepared using 4 X LDS sample buffer (life-technologies, 
Thermo-Fisher, United Kingdom) supplemented with 10% 2-mercaptoethanol. The 
30µl sample volume was made of protein samples, loading buffer and distilled water. 
Specifically, the composition of the loading sample is that 30µg protein samples diluted 
with distilled water made up 3/4 and LDS buffer 1/4. Once loading samples had been 
prepared, they were centrifuged for a short time and incubated at 95°C for 10 min.  
NuPAGE 4-12% bis-tris Gels (life-technologies, Thermo-Fisher, United Kingdom) 
were loaded into a running gel tank, and the comb was carefully removed. First running 
buffer was added to the wells to remove excess acrylamide. After the running buffer 
(50 ml 20X running buffer + 950 ml PBS) had been added, the samples plus the ladder 
(Bio-rad, United Kingdom) were loaded into the wells. Any remaining wells were 
loaded with the 1X LDS to keep the pH balance within the gel. The electrophoresis 
apparatus was then attached to an electric power supply running at 140 V for 90 min, 
after which the gel was gently removed from the plastic plates. Transfer buffer 
consisting of 100 ml 100% methanol (life-technologies, Thermo-Fisher, United 
Kingdom), 25 ml 20X NuPAGE transfer buffer (life-technologies, Thermo-Fisher, 
United Kingdom), and 375 ml distilled water was prepared, and used to soak 
Amersham nitrocellulose Blotting membrane (GE healthcare life science, United 
Kingdom)  and filter paper, which was laid across the gel to make the gel sandwich. 
Then the transfer process is at the power supply 35 V for 90 min.  
After washing with TBST (prepared from tris buffered saline (TBS) tablet (AMERCO, 
United Kingdom), 0.1% Tween-20 (Sigma-Aldrich, USA) and 100 ml distilled water), 
the membrane was blocked with 5% non-fat dried milk in TBST for 1 h at 4 °C with 
shaking. Afterwards the membrane was washed in TBST 3x5 min. The membrane 
was incubated with primary antibody in TBST overnight at 4 °C with shaking after 
93 
 
which the membrane was washed in TBST, 3x5 min. The membrane was then 
incubated with secondary antibody for 1h, before it was washed in TBST 3x5 min. To 
develop the membrane Amersham ECL Western Blotting Detection reagent (GE 
healthcare life science, RPN2106, United Kingdom) was applied for 2 min at room 
temperature, the membrane was then put inside plastic film in a hypercassette and 
developed using Amersham hyperfilm (GE healthcare life science, United Kingdom) 
in the developing machine (Ecomax, Protech, United Kingdom). Primary antibodies 
applied in this project are listed in table 2.14. 
Table 2.14 Primary antibodies used for western blot 
Antibody Dilution used Provider Code 
anti-p-ckit  1:200 Cell Signaling 3391S 
Anti-c-Kit  1:50 Santa Cruz sc-5535 
anti-MEK1/2 1:200 Cell Signaling 4694S 
anti-p-ERK 1/2  1:500 Santa Cruz sc-16982-R 
anti-p-MEK1/2 1:200 Cell Signaling 9154S 
anti-ERK 1/2  1:1000 Cell Signaling 4695P 
anti-p-JNK  1:200 Santa Cruz sc-6254 
anti-JNK 1:200 Santa Cruz sc-474 
anti-p-c-jun 1:100 Santa Cruz sc-16312 
anti-c-jun 1:100 Santa Cruz sc74543 
anti-p-MLC 1:200 Cell Signaling 3675S 
anti-MLC 1:500 Cell Signaling 3672S 
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anti-p-AKT1/2/3 1:200 Santa Cruz sc-7985-R 
Anti-AKT1/2/3 1:500 Santa Cruz sc-8312 
anti-p-FAK 1:200 Abcam ab81298 
anti-GAPDH  1:1000 Santa Cruz sc25778 
 
2.15 G-LISA RhoA/Rac1/Cdc42 Activation Assay  
GTPase family activation was measured using a G-LISA activation assay kit 
(Cytoskeleton) including RhoA (BK124-S) / Rac1 (BK128-S) / Cdc42 (BK127-S) 
according to the manufacturer’s instructions. G-LISA was developed to detect small 
GTPases activity. Similar to ELISA assay, small GTPases effect proteins were coated 
in the plate. Only GTP but not GDP bounded G protein could bind on the plate. After 
luminescence reaction, amount of specific GTP bounded G protein could be detected 
from absorbance number. Briefly, cell lysate was collected from SCF treated SPCs 
and protein extraction was performed as in 2.13. Measurement of the protein 
concentration was using detection solution followed manufacturer’s instructions. For 
GTPase family activation measurement study, loading of equalized lysate to one 96 
well plate was performed (assay blank was acquired by loading lysis buffer only in 
some wells). For the purpose of mixing the samples in each well, the plate was placed 
on an orbital shaker at a speed of 400 rpm for 45 min at 4 ºC. After samples were 
mixed with antigen presenting buffer for 2 min and cultured with diluted anti-
RhoA/Rac1/Cdc42 primary antibody at 400 rpm speed on shaker for 45min. 
Secondary antibody and HRP detection reagent was then sequentially added to 
samples. Reactions were terminated by HRP Stop Buffer. Absorbance was read at 
490 nm. 
2.16 Cellular Cytoskeleton Immunostaining 
SCF was loaded on SPCs in 8-well slide. Samples were collected at specific time 
points and fixed with 4% PFA for 10 min. 0.1% Triton X-100 blocking buffer was 
applied to samples 1h for blocking and permeabilisation. Staining was achieved by 
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sequential incubation of samples with focal adhesion primary antibodies including 
vinculin (Abcam,ab18058,1:50) and p-FAK (Abcam,ab81298,1:100) overnight at 4 °C, 
secondary antibodies  plus phaloidin-488 (Invitrogen, A12379) a high-affinity 
filamentous actin (F-actin) probe 1h at room temperature and  DAPI on slides 8 min 
for nuclei staining. All slides were mounted with anti-fade mounting medium. 
2.17 Mouse ELISA Assay 
Concentration measurement of SCF and TGFβ from serum of C57/6J mice or MMP2 
and MMP9 from SPCs culture supernatant was achieved via quantification ELISA kit 
according to the standard protocol provided by manufacturer, respectively. The ELISA 
kits applied were including Mouse/Rat SCF Quantikine ELISA Kit (R&D, MCK00), 
Mouse TGF beta1 ELISA Kit (Abcam, ab119557), Total MMP-2 Quantikine ELISA Kit 
(R&D, MMP200), and Mouse Total MMP-9 Quantikine ELISA kit (R&D, MMPT90). 
Briefly, in purpose of collecting serum samples, sacrifice of mice was performed by 
over dose of phenobarbital. Blood from vena cava of mice was collected and blood 
serum was transferred to a new 1.5 ml vial tube. In terms of cultured cells, supernatant 
was collected from post-treatment medium. Dilution of collected serum or supernatant 
was according to each assay. Following each kit protocol, absorbance was read at 
450 nm and that at 540 nm or 570 nm was used as wavelength correction. 
2.18 RNA Extraction 
Total RNA was isolated from SPCs, which had been treated with 100 ng/ml SCF in 
serum free medium for different time periods (2, 5, 15, 30, 60 min), using the RNeasy 
Mini kit (QIAGEN, United Kingdom). Briefly, after the cells had been washed with PBS 
to thoroughly remove the culture medium, 350 µl RLT buffer was added to disrupt the 
cells. Lysate was then pipetted into a QIAshredder spin column placed in a 2 ml 
collection tube and centrifuged for 2 min at full speed. Subsequently 350µl ethanol 
was added to the homogenized lysate and mixed well by pipetting.  The sample was 
then transferred to an RNeasy spin column placed in a 2 ml collection tube and 
centrifuged at 8000g for 15s. After the flow-through had been discarded, 700µl RW1 
buffer was added to the RNeasy spin column and afterwards the sample was 
centrifuged at 8000g for 15 s to wash the spin column membrane. Once the flow-
through had been discarded, 500 µl RPE buffer was added to RNeasy spin column 
and the sample was centrifuged at 8000g for 2min. This process was repeated twice. 
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After the flow-through had been discarded, the RNeasy spin column was placed in a 
new 1.5 ml collection tube and 30µl RNase-free water was added to the RNeasy spin 
column. After the sample was centrifuged at 8000g for 1min, the RNA was diluted into 
the solution collected in the collection tube. The RNA concentration was detected 
using the NanoDrop 1000 Spectrophotometer (Thermo scientific, United Kingdom). 
Quality of RNA was controlled according to A260/280 ratio. Absorbance at 260 nm 
measures the RNA concentration and 280 nm measures the protein concentration in 
the sample. Proper RNA A260/280 ratio ranges between 1.8 and 2.2. The RNA sample 
was then ready to be used for reverse transcription and polymerase chain reaction 
(RT-PCR). 
2.19 Reverse Transcription (RT) and Quantitative Real-Time Polymerase Chain 
Reaction (qPCR) 
Reverse transcription was performed using the Qiagen kit following the manufacturer’s 
instructions. 14 µl solution including 1 µg RNA sample, with 2 µl gDNA wipeout buffer 
(QIAGEN, United Kingdom) and distilled water was incubated at 42 °C for 2min in a 
thermal cycler (Techne, United Kingdom) to eliminate contaminating gDNA in the RNA 
sample. This 14µl sample was combined with 4 µl reverse transcription buffer 
(QIAGEN, United Kingdom), 1µl RT primer mix (QIAGEN, United Kingdom) and 1µl 
quantitative reverse transcriptase (QIAGEN, United Kingdom). The total 20µl reaction 
solution was incubated in the thermal cycler at 42 °C for 15min and then at 93°C for 
3min. After the reverse transcription reaction process, 80 µl RNAse-free water was 
added to dilute the sample. Afterwards, 2 µl of cDNA samples were added to 10µl 
sybergreen mix (ThermoFisher, United Kingdom), 1.5 µl primer plus 6.5 µl RNAse-free 
water. The total cocktail was loaded into a 96 well plate after which the plate was 
centrifuged at 800 rpm for 1min to mix the sample well. The plate was loaded into the 
polymerase chain reaction (PCR) machine (Eppendorf, Mastercycler, United Kingdom) 
to react.  
2.20 Conventional Polymerase Chain Reaction (PCR) 
Genotyping for the target genes in Kit-CreER; Rosa26-RFP mice, employed 
polymerase chain reaction (PCR). Amplification of target DNA was achieved by 
mixture of cDNA with target primers and taq DNA polymerase. After transferring and 
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running resulting products on 2% agarose gel (Invitrogen, 16500-500), observations 
of target bands were acquired using a Biospectrum AC Imaging system.  
2.21 Agarose Gel Preparation and Observation  
2 g of agarose powder (#16500500, Invitrogen) was added to 100 mL 1x TAE buffer 
(#EC872, National Diagnostic). The mixture was heated to boiling point in a microwave 
for two minutes. Once the agarose had cooled down to around 60°C, 10 μl of SafeView 
nucleic acid stain (#NBSSV, NBS Biologicals) was added into the solution. The gel 
mixture was carefully poured into a Horizon horizontal gel cast electrophoresis 
apparatus with the well comb inside. Once the gel had reached room temperature and 
solidified, the gel was gently placed into 1x TAE buffer and the comb was carefully 
removed. 25 μl of amplified DNA samples together with 5 μl of 6x loading buffer were 
loaded into each well. Electrophoresis was performed at 160 V for 20 minutes. DNA 
fragments were visualized under UV light using a Biospectrum Imaging System 500. 
2.22 Statistics 
All data are presented as mean±standard error of the mean (SEM). Statistical analysis 
was performed using Graphpad Prism 6 software. Two-group comparisons were 
conducted via t-test, while more than two-groups were assessed via analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparison tests. p<0.05 was 




Chapter 3: Results 
 
3.1      Stem/Progenitor Cells (SPCs) Distribution in Aorta  
For detecting SPCs in mouse aorta, immunostaining of SPC markers including sca-1, 
CD34 and c-kit on aortic cryosection was performed (Figure 3.1A). SPCs were shown 
to be mainly distributed in adventitial and endothelial layers. Bone marrow cells were 
reported to harbour SPCs. Immunostaining in our study showed that bone marrow 
source of cells also expressed these three markers (Figure 3.1B). En-face 
immunostaining determined the distribution of SPCs in intima layer (Figure 3.1C). 
Further confirmation of the presence of SPCs in the adventitia layer was via adventitia 















Figure 3.1 SPCs distribution in aorta and bone marrow. Representative images of 
normal aorta (A) and bone marrow (B) from wildtype mice stained for c-Kit, Sca-1 and 
CD34 (n=3 experiments). Arrows indicate vascular SPCs. En-face staining of aortic 
intima (C) and adventitial (D) layers showing SPCs stained with c-Kit, Sca-1 and CD34 
from wildtype mice (n=3).  VE-cadherin, an endothelial marker is used to establish the 
presence of the intima. Scale bars, 100 μm, and 20 μm in the enlarged images. A, 
adventitia; M, media; I, intima; Ctr, control.  
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3.2     SPCs in c-kitkit/CreER; ROSA26-RFP Mouse 
To further address the role of SPCs in vivo, a c-kitkit/CreER; ROSA26-RFP mouse was 
employed61. Gene construct of this knock-in mouse was achieved through insertion of 
one piece of cDNA sequenced for Cre recombinase (Cre) combines with a mutant 
estrogen receptor (ER), into one allele of wild type C57/6J DNA strand, in the frame 
of promoter sequence of c-kit gene (in this way generation of CreER were acquired 
under control of c-kit promoter sequence). Rosa26-RFP or Rosa26-CAG-loxP-stop-
loxP-tdTomato-WPRE transgenic mice were constructed by gene trap technique. In 
this animal model, stop codon is flanked by loxP sites. Cross breeding was then 
performed between c-kitkit/CreER mice and ROSA26-RFP fluorescent reporter mice 
(Figure 3.2A). Upon tamoxifen injection (five pulses of tamoxifen intraperitoneal 
injection in five consecutive days), ER component is activated to drive CreER from the 
cytoplasm into the nucleus and this process only occurs when the cells expressed the 
c-kit promoter gene. The stop codon framed by a loxP sequence being cut by Cre 
therefore resulted in red fluorescent protein (RFP) labelling. Since RFP specifically 
labelled c-Kit+ cells in these mice, we were able to use this mouse model to trace the 
fate of c-Kit+ SPCs in vivo. It should be noted that RFP labelling is permanent in these 
cells once labelled, regardless of further changes in c-Kit expression, as most SPCs 
will lose their SPC markers once they differentiate. Kit-CreER; Rosa26-RFP mice were 
pulsed with tamoxifen and analysed for RFP expression one week later (Figure 3.2A). 
Flow cytometric analysis showed successful labelling of RFP in cells from bone 
marrow as well as aorta (Figure 3.2B). We also observed a population of cells 
expressing both RFP and c-Kit in the aortic adventitia, with a large portion of these 
RFP+ cells co-staining with Sca-1 and/or CD34, whereas some RFP+ cells were also 
found to reside in the medial and endothelial layers (Figure 3.2C). Interestingly, few 
resident c-Kit+ SPCs-derived RFP+ cells were found to co-express smooth muscle 
marker α-smooth muscle actin (α-SMA) in the media (Figure 3.2D). RFP labelling of 
c-Kit+ cells was also observed in lung, spleen and liver (Figure 3.2E). Collectively, 
these data showed that tamoxifen administration in Kit-CreER; Rosa26-RFP mice 









Figure 3.2 Establishment of Kit-CreER; Rosa26-RFP mouse model. A, Strategy 
for Kit-CreER; Rosa26-RFP mice generation and experimental schedule of tamoxifen-
induced RFP labelling of c-Kit+ cells and analysis. B, Representative flow cytometric 
analysis of RFP+ cells in bone marrow and aorta (n=3 experiments). C, Representative 
images showing RFP labelling in vascular SPCs staining for RFP, c-Kit. Scale bars, 
100 μm. n=3 experiments. D, Representative immunostaining images showing normal 
aorta from Kit-CreER; Rosa26-RFP mice (n=3) stained with RFP and α-SMA. Scale 
bars, 50 μm. E, Representative images showing RFP+ labelling of c-Kit+ cells in lung, 
spleen and liver (n=6 mice per group). Scale bars, 100 μm. A, adventitia; M, media; I, 
neointima; CTR, corn oil control; TAM, tamoxifen. 
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3.3     C-kit+ SPCs in Aortic Intima Layer were not Derived from Bone Marrow 
To determine if c-kit+ SPCs distribution in endothelial layer, we employed en-face 
immunostaining of c-kitkit/CreER; ROSA26-RFP mouse for the full length of aorta, which 
began from the aortic root and extended to the bifurcation of the abdominal aorta into 
the common iliac arteries, focusing on the tissue intima (Figure 3.3A). According to 
aorta anatomy, the artery was divided into five parts. Data showed that positive RFP 
staining within the intima mainly located at the sites above descending aorta, whereas 
at the location below the thoracic aorta, no c-kit+ SPCs were distributed within the EC 
layer (Figure 3.3A). Then chimeric mice were developed to detect whether these c-kit+ 
SPCs were derived from bone marrow. Chimeric mice were generated in which bone 
marrow cells from Kit-CreER; Rosa26-RFP mice were transferred to irradiated wildtype 
C57BL/6J mice. These chimeric mice were then pulsed with tamoxifen, subjected to 
allograft transplantation and further graft analysis (Figure 3.3B). Reconstitution of bone 
marrow was shown after transplantation and was determined via flow cytometry and 
immunostaining in bone marrow and blood cells (Figure 3.3C). En-face staining was 
then performed on these chimeric animals. Data showed that few aortic ECs contained 
RFP (Figure 3.3D). This result indicated that c-kit+ SPCs in the intima were not derived 
from bone marrow. Counting of c-kit+ SPCs derived ECs in both c-kitkit/CreER; ROSA26-






























Figure 3.3 C-kit+ SPCs in intima layer were not derived from bone marrow. A, En 
-face staining of aortic intima showing SPCs stained with c-Kit+ SPC derived cells 
distribution according to aorta anatomy in Kit-CreER; Rosa26-RFP mice. VE-cadherin 
was shown as intima marker. Scale bars, 100 μm. Representative flow cytometric 
analysis of bone marrow cells from chimeric mice (n=6 mice per group). B, Strategy 
for chimeric mouse model in which bone marrow from Kit-CreER; Rosa26-RFP mice 
were transplanted to irradiated C57BL/6J mice, followed by tamoxifen treatment. C, 
Representative immunostaining images of peripheral blood cells stained with RFP 
from chimeric mice (n=6 mice per group). Scale bars, 25 μm. D, En-face staining of 
aortic intima showing SPCs stained with c-Kit+ SPCs derived cells distribution in 
chimeric mice (n=3 experiments). E, c-kit+ SPCs derived ECs counting in both c-








3.4     c-kit+ SPCs Identification in Allograft Induced Lesion  
We further explored whether SPCs contribute to neointima formation in a mouse 
allograft model as described previously34, in which aortic segments from BALB/c mice 
were transplanted to C56BL/6J mice (Figure 3.4A). Immunostaining of aortic allografts 
showed neointima formation after allograft transplantation (Figure 3.4B). Importantly a 
small number of cells expressing c-Kit, Sca-1 and/or CD34 were found in neointimal 
layers (Figure 3.4B), suggesting a possible role for SPCs in allograft-induced 
neointima formation. We next asked whether c-Kit+ SPCs contribute to allograft-
induced neointima formation. Kit-CreER; Rosa26-RFP mice pulsed with tamoxifen 
were subject to an allograft transplantation surgery, in which aorta segments from 
BALB/c mice were transplanted to Kit-CreER; Rosa26-RFP mice. Grafts were 
collected four weeks after transplantation (Figure 3.4C). Immunostaining of aortic 
allografts revealed a large number of RFP+ cells accumulated in the neointimal lesions 















Figure 3.4 C-kit+ SPCs involved in allograft induced lesion formation. A, 
Schematic showing allograft transplantation experiments. Aortas from BALB/c mice 
were transplanted to C57/6J mice and grafts were collected 4 weeks after surgery. B, 
Representative images of aortic allograft from allograft mice stained for c-Kit, Sca-1 
and CD34 (n=3 experiments). Arrows indicate vascular SPCs. Scale bars, 100 μm, 
and 20 μm in the enlarged images. C, Schematic showing allograft transplantation 
experiments. After Kit-CreER; Rosa26-RFP mice received tamoxifen injection, aortas 
from BALB/c mice were transplanted to these mice and grafts were collected 4 weeks 
after surgery.  D, Representative images showing aortic grafts from Kit-CreER; 
Rosa26-RFP mice stained with RFP antibody (n=6 mice per group). A, adventitia; M, 
media; I, intima or neointima; TAM, tamoxifen. 
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3.5 Recipient c-Kit+ SPCs Differentiated into SMCs in Neointima and were of 
Non-Bone Marrow Source 
As smooth muscle cells are the major component of neointima, we further explored 
whether c-Kit+ SPCs may give rise to neointimal SMCs. Immunofluorescence analysis 
showed that SM22+ and α-SMA+ SMCs were abundant in neointimal lesions. 
Subsequently, we counted the whole numbers of RFP+ cells, SMCs and the cells which 
co-expressed both RFP and SMCs markers in the slides. After calculation, we found 
that   53.54 ± 1.92% of SM22+ and 37.31 ± 1.55% of α-SMA+ SMCs in neointimal 
lesions were labelled with RFP, whereas 63.57 ± 2.39% and 30.18 ± 1.04% of RFP+ 
cells showed expression of SM22 and α-SMA, respectively (Figure 3.5A). These data 
suggest that a large number of neointimal SMCs originate from c-Kit+ SPCs. As RFP 
only labelled recipient cells in this model, our results also indicate that c-Kit+ SPCs 
from recipient mice can differentiate into neointimal SMCs in vivo and contribute to 
neointima formation in allograft mouse model. We next sought to address whether 
these recipient c-Kit+ SPCs originate from bone marrow or non-bone marrow tissues. 
Aortic graft was allotransplanted from BALB/c mice to chimeric mice (Figure 3.5 B). 
RFP+ cells were detected in neointimal lesions (Figure 3.5C). However, few RFP+ cells 
co-expressed SMC markers SM22 and α-SMA (Figure 3.5C), indicating that the origin 












Figure 3.5 Recipient non-bone marrow source of c-kit+ SPCs differentiated into 
SMCs in neointima. A, Representative images showing aortic allograft from Kit-
CreER; Rosa26-RFP mice stained with RFP, SM22 and α-SMA. Scale bars, 50 μm, 
and 20 μm in enlarged images. Arrows indicate RFP+SM22+ or RFP+α-SMA+ cells. 
The graphs indicate percentage of RFP expression in SMCs or SMC marker 
expression in RFP+ cells. Data are mean ± SEM, ***P<0.001, unpaired two-tailed t test, 
n=10 per group. B, Strategy for chimeric mouse model in which bone marrow from Kit-
CreER; Rosa26-RFP mice were transplanted to irradiated C57BL/6J mice, followed 
by tamoxifen treatment and allograft transplantation. C, Representative 
immunostaining images showing aortic graft of chimeric mice with RFP, SM22 and α-
SMA staining. n=6 mice per group. Scale bars, 50 μm, and 20 μm in enlarged images. 




3.6 Recipient c-Kit+ SPCs Differentiated into ECs for Both Luminal ECs 
Regeneration in Neointima and Microveseels Remodelling in Adventitia   
We further explored whether c-Kit+ SPCs might give rise to ECs. Immunofluorescence 
analysis on the animals same as Figure 3.4C showed that ECs were abundant in 
neointimal and adventitia lesions in the graft (Figure 3.6A and Figure 3.6B). These 
ECs were positive for markers including CD31 and VE-cadherin. Since ECs in the graft 
are responsible for both intima layer regeneration and adventitial layer 
neovasculogenesis, we therefore tried to detect the role of c-Kit+ SPCs in both luminal 
ECs regeneration and adventitial microvessel remodelling. Firstly, we analysed ECs 
in neointima. Similar to the methods before, we count all the numbers of CD31+ cells, 
RFP+ cells, and the cells which co-expressed with CD31 and RFP. Data showed that 
49.37 ± 4.06% of CD31+ cells were labelled with RFP, whereas 27.34 ± 2.58% of RFP+ 
cells showed expression of CD31 (Figure 3.6A). Then, we analysed ECs in graft 
adventitial layer. Data showed that 38.47 ± 4.87 % of CD31+ cells were labelled with 
RFP, whereas 27.21 ± 2.61% of RFP+ cells showed expression of CD31 (Figure 3.6B). 
These data suggest that c-Kit+ SPCs contributed to both luminal ECs regeneration in 
neointima and adventitial microvessel ECs remodelling. We next addressed whether 
bone marrow derived c-Kit+ SPCs contribute to ECs commitment. The aortic graft 
tissues were collected from the same animals as Figure 3.5B. RFP+ cells and ECs 
were also detected in both neointimal lesions and adventitial layers in the grafts. In 
neointima layer, few luminal ECs were labelled with RFP (Figure 3.6C), indicating that 
the origin of c-Kit+ SPCs-derived luminal ECs was not bone marrow. In adventitial 
microvessels, some of RFP+ cells co-expressed with ECs marker CD31 (Figure 3.6D). 
However, none of these RFP+ cells in adventitial microvessels co-expressed with VE-
cadherin. Instead large number of these RFP+ cells co-expressed with inflammatory 
ECs marker VCAM (Figure 3.6D). This result indicated that c-Kit+ SPCs derived from 
bone marrow were involved in adventitial microvessels remodelling by differentiating 




















Figure 3.6 Recipient c-Kit+ SPCs differentiated into ECs for both luminal ECs 
regeneration in neointima and microveseels remodelling in adventitia.  A, 
Representative images showing luminal ECs regeneration in the neointima of aortic 
allograft from Kit-CreER; Rosa26-RFP mice stained with RFP, CD31 and VE-cadherin. 
Scale bars, 50 μm and 20 μm in enlarged images. The graphs indicate percentage of 
RFP expression in CD31+ cells or CD31 expression in RFP+ cells. Data are mean ± 
SEM, ***P<0.001, unpaired two-tailed t test, n=10 per group.  B, Representative 
immunostaining images showing adventitial microvessel remodelling of allograft from 
Kit-CreER; Rosa26-RFP mice stained with RFP, CD31, VE-cadherin and VCAM. 
Scale bars, 50 μm and 20 μm in enlarged images. The graphs indicate percentage of 
RFP expression in CD31+ cells or CD31 expression in RFP+ cells. Data are mean ± 
SEM, ***P<0.001, unpaired two-tailed t test, n=10 per group.C, Representative images 
showing ECs regeneration in the neointima of aortic allograft from chimeric mice 
stained with RFP, CD31 and VE-cadherin. Scale bars, 50 μm and 20 μm in enlarged 
images. D, Representative immunostaining images showing adventitial microvessel 
remodelling of allograft from chimeric mice stained with RFP, CD31, VE-cadherin and 
VCAM. n=6 mice per group. Scale bars, 50 μm, and 20 μm in enlarged images. M 




3.7     Donor c-Kit+ SPCs Did Not Involve in Neointima Formation 
To further investigate whether neointimal SMCs may arise from c-Kit+ SPCs within 
donor graft, aortic segments from Kit-CreER; Rosa26-RFP mice were transplanted into 
BALB/c mice (Figure 3.7A). One week after transplantation, BALB/c mice were pulsed 
with tamoxifen and grafts were collected for analysis two weeks later (Figure 3.7A). 
Interestingly, although we observed neointimal SMCs accumulation in aortic grafts, no 
RFP+ cells were detected (Figure 3.7B), in contrast to grafts harvested from recipient 
Kit-CreER; Rosa26-RFP mice. Meanwhile, ECs regeneration was detected but these 
ECs were not labelled with RFP fluorescence (Figure 3.7C). Collectively, these results 
demonstrate that c-Kit+ SPCs from recipient, but not donor mice, are important 












Figure 3.7 c-Kit+ SPCs from donor aorta did not contribute to neointima 
formation.  A, Schematic showing allograft transplantation experiment in which aortic 
segment from Kit-CreER; Rosa26-RFP mice was transplanted to BALB/c mice, 
followed by tamoxifen treatment. Graft tissues were collected two weeks after the last 
pulse of tamoxifen. B, Representative images showing aortic grafts stained with RFP 
and α-SMA from mice described in A (n=6 mice per group). B, Representative images 
showing aortic grafts stained with RFP and CD31 or eNOS from mice described in A 











3.8   SCF Induced c-Kit+ SPCs Migration 
We next sought to examine possible mechanisms underlying c-Kit+ SPCs migration to 
the lesions and differentiation into neointimal SMCs. Previous reports have shown that 
SCF, a specific ligand for c-Kit, can mediate cell survival, proliferation as well as cell 
migration216. Significant increase of SCF concentrations in peripheral blood was 
observed after allograft transplantation (277.9 ± 15.45 vs 114.8 ± 12.80 pg/ml, Graft 
vs Control, Figure3.8A). More importantly, compared to control aorta, SCF was 
significantly increased in neointimal lesions of allografts where co-staining of SCF with 
RFP+ cells was also observed (Figure 3.8A). These data suggest a possibility that 
accumulation of SCF in blood and neointima may induce migration of c-Kit+ SPCs to 
the lesion sites.  
To further prove our hypothesis, we isolated resident c-Kit+ SPCs from vessel grafts. 
We first performed phenotyping of these c-Kit+ SPCs and flow cytometric analysis 
showed that these cells expressed multiple SPCs markers including c-Kit, Sca-1, 
CD34, CD140, CD105, CD29, CD44 and CD201 (Figure 3.8B), confirming that these 
isolated c-Kit+ cells displayed SPCs properties. We next determined whether SCF 
could induce migration of these c-Kit+ SPCs in vitro. Both transwell migration assay 
(Figure 3.8C) and scratch wound healing assay (Figure 3.8D) showed that SCF 
significantly increased migration of SPCs in a dose-dependent manner, with a dosage 
of 100 ng/ml SCF resulting in the peak of cell migration. This dosage was therefore 
used in our subsequent experiments.  
ACK2 is an antibody which has been reported to specifically target c-Kit+ cells and 
block c-Kit function217. We next determined if AKC2 could also reduce SCF-induced 
c-Kit+ SPCs migration in vitro. As expected, ACK2-treated cells showed a significantly 
lower migration rate than a control IgG group in response to SCF stimulation (Figure 
3.8E). However, we noticed that blocking effects were partial. We speculated that 
other feedback signalling pathways could be activated after c-kit receptor kinase was 
blocked. However, this still needs further study to demonstrate. SCF or ACK2 
treatment did not affect cell proliferation in c-Kit+ SPCs (Figure 3.8F), indicating that 
the effect of SCF or ACK2 on cell migration did not result from cell proliferation. Taken 
together, our data provide evidence that SCF is a chemotactic factor that induces c-
Kit+ SPC migration.  
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Our data so far suggested that recipient c-Kit+ SPCs mainly from non-bone marrow 
tissues contributed to neointima formation. We next asked whether blocking of c-Kit 
could abrogate neointima formation in our model. Therefore, ACK2 was further used 
in our in vivo experiments. Immediately after aortic graft transplantation from BALB/c 
mice to C57BL/6J mice, ACK2 or control IgG dissolved in pluronic F-127 gel was 
applied to the adventitial side of the aortic grafts (Figure 3.8G). The application of 
pluronic F-127 gel allows a slow release of ACK2 to the local graft microenvironment218. 
Our results showed mice that received IgG treatment developed severe neointimal 
formation (Figure 3.8H). In contrast, neointimal lesions were significantly reduced in 
ACK2-treated aortic grafts, with significant lower neointima areas and higher lumen 
areas (Figure 3.8H). Furthermore, the number of neointimal SMCs was much lower in 
ACK2-treated mice than in control mice (Figure 3.8I), suggesting that blocking of c-
Kit+ cells effectively impaired neointimal SMC formation. The percentage of SMCs in 
neointimal lesions was comparable between both groups (Figure 3.8I). Taken together, 
these results further demonstrate the importance of c-Kit+ SPCs in neointima formation 









Figure 3.8 SCF induces migration of c-Kit+ SPCs in vitro. A, Representative 
images showing RFP and SCF staining in control and allografts (n=6 mice per group). 
Arrows indicate co-staining of RFP and SCF. Scale bars, 50 μm, and 20 μm in 
enlarged images. The graphs indicated concentration of SCF in blood plasma of 
control and allograft mice. Data shown are mean ± SEM, **P<0.01, ***P<0.001, 
unpaired two-tailed t test, n=6-7 mice per group. Ctr indicates control group. B. Cells 
were analysed by flow cytometry for their expression of surface markers including c-
Kit, Sca-1, CD34, CD140, CD105, CD29, CD44, CD201, CD146 and CD31. 
Corresponding IgG was used as isotype controls, as indicated by tinted grey areas 
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(n=3 experiments). C, Representative images showing SCF-induced c-Kit+ SPC 
migration, by Transwell migration assay. Scale bars, 100 μm. Graphs shown are 
relative cell number normalised to control. **P<0.01, ***P<0.001, one-way ANOVA 
with Dunnett’s test, n=3 experiments, 10 fields per sample. D, Representative images 
showing migration of c-Kit+ SPCs in response SCF using a scratch-wound assay. 
Scale bars, 100 μm. Graph are shown as fold change normalised to 0 h time point. 
***P<0.005, one-way ANOVA with Dunnett’s test, n=5 per group. E, Representative 
images showing SCF-induced c-Kit+ SPC migration with ACK2 or control IgG by 
transwell migration assay. Scale bars, 100 μm. Graphs shown are relative cell number 
normalized to control. **P<0.01, ***P<0.001, two-way ANOVA with Bonferroni’s test, 
n=3 experiments, 5 fields per sample. F, Cell proliferation was measured by BrdU 
assay and Ki-67 staining in SCF-treated c-Kit+ SPCs in the presence of ACK2 or IgG 
(n=3 experiments).  G, Schematic showing ACK2 or IgG treatment in mouse allograft 
model (n=6 mice per group). H, Representative HE staining of aortic grafts was shown. 
Arrows indicate neointima lesions. Scale bars, 100 μm, and 50 μm in enlarged images. 
Graphs showing quantification of neointima areas and lumen areas. **P<0.01, 
unpaired two-tailed t test, n=6 per group. I, Representative images showing allograft 
stained with α-SMA. Arrows indicate neointimal lesions. Scale bars, 50 μm. Graphs 
showing quantification of SMC numbers per 100 μm of neointimal lesions. **P<0.01, 
unpaired two-tailed t test, n=6 per group. F, Percentage of SMCs in total cells was 












3.9     The SCF/c-Kit Signalling Pathway Regulated c-Kit+ SPC Migration 
 Considering that reorganisation of the actin cytoskeleton is critical in triggering cell 
migration219, to investigate the possible mechanisms behind this migration we first 
performed immunostaining to observe actin cytoskeleton and focal adhesion in c-Kit+ 
SPCs, as phalloidin specifically binds actin, whereas phosphorylated focal adhesion 
kinase (p-FAK) and vinculin stain focal adhesion assembly. SCF immediately induced 
formation of parallel elongated stress fibres and cell spreading in cultured graft derived 
c-Kit+ SPCs, compared to untreated cells (Figure 3.9A). Filopodia and lamellipodia 
were formed at the leading edge of c-Kit+ SPCs within 2 min after SCF treatment. 
Moreover, co-staining of p-FAK, vinculin and filamentous actin (F-actin) was also 
observed at the leading edge (Figure 3.9A), which is indicative of cell migration. These 
data suggest that SCF may trigger cell migration at a very early time point. As SCF 
has been reported to specifically bind and activate c-Kit, we next sought to investigate 
whether c-Kit signalling pathways regulate this early process. Phosphorylation of c-Kit 
was increased by SCF within minutes (Figure 3.9B), indicating that early activation of 
c-Kit signalling may regulate this process. Small GTPases, which can be activated by 
tyrosine kinase, have been shown to be pivotal in regulating cytoskeleton 
reorganisation and cell migration219. As c-Kit is a receptor tyrosine kinase, we further 
performed G-LISA activation assay to test the activation of GTPases. We showed that 
SCF treatment led to early activation of small GTPases including cell division cell 
division cycle 42 (Cdc42), Ras homolog family member A (RhoA) and Rac family small 
GTPase 1 (Rac1) within 2 min (Figure 3.9C). Possible downstream pathways of c-Kit 
signalling and/or GTPases including phosphorylation of mitogen-activated protein 
kinase kinase 1/2 (MEK1/2), extracellular signal-regulated kinase 1/2 (ERK1/2) and 
myosin light chain (MLC) were also elevated shortly after SCF stimulation (Figure 
3.9B). Activation of MLC may further promote cell contractility and cell motility220. 
Phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun was also observed to 
increase and peak at a later time point of 30 min (Figure 3.9B). Notably, ACK2 could 
completely or at least partially blocked the activation of c-Kit signalling, as well as 
migration-related pathways including MEK/ERK/MLC, JNK/c-Jun pathways (Figure 
3.9D), consistent with the inhibitory effect of ACK2 on SPC migration (Figure 3.8), 
indicating that SCF/c-Kit signaling, upstream of MEK/ERK and JNK pathways, is 
critical for cell migration in c-Kit+ SPCs. Because both MEK/ERK and JNK/c-Jun have 
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been reported to regulate expression of matrix metalloproteinase (MMP) to degrade 
extracellular matrix and ease cell migration221, we further measured secretion of MMPs 
in cell culture supernatants. A significant increase in MMP-2, but not MMP-9, was 
detected after SCF treatment for 24 h and 48 h (Figure 3.9E), suggesting a possible 
role of MMP-2 in regulating cell migration at a later time.  





Figure 3.9 SCF/c-Kit signalling pathway in c-Kit+ SPCs migration. A, 
Representative images showing SCF-treated c-Kit+ SPCs stained with p-FAK, F-actin 
and vinculin (n=3 experiments). Scale bars, 10 μm. B, Representative western blot 
showing activation of c-Kit, MEK-ERK-MLC and JNK/C-Jun pathways in response to 
SCF (n=3 experiments). C, Graphs showing activation of small GTPase including 
Cdc42, Rac1 and RhoA in SCF-treated SPCs. *P<0.05, **P<0.01, ***P<0.001, one-
way ANOVA with Dunnett’s test, n=3 experiments. D, Representative western blot 
indicating signalling pathways in response to SCF for indicated times, in the presence 
of ACK2 or IgG (n=3 experiments). E, Quantification of MMP-2 and MMP-9 in cell 
culture supernatant from SCF-treated cells. ***P<0.005, two-way ANOVA with 




3.10 VEGF Induced c-Kit+ SPCs Migration 
VEGF is another crucial molecule in vascular biology. Immunostaining results showed 
that VEGF co-stained with RFP+ cells in neointimal lesions of allografts (Figure 3.10A). 
These data suggest the possibility that VEGF is involved in of c-Kit+ SPCs regulation. 
We next determined whether VEGF could induce migration of these c-Kit+ SPCs in 
vitro. Transwell migration assay showed that SCF significantly increased migration of 
SPCs, with a dosage of 50 ng/ml SCF resulting in the peak of cell migration (Figure 
3.10B). This dosage was therefore used in our subsequent experiments. Cytoskeleton 
immunostaining was then performed to detect cell migration at a single cell level. Data 
showed that VEGF immediately induced formation of parallel elongated stress fibres 
and cell spreading in c-Kit+ SPCs, compared to untreated cells (Figure 3.10C). 
Filopodia and lamellipodia were formed at the leading edge of c-Kit+ SPCs within 2 min 
after VEGF treatment. Moreover, co-staining of p-FAK, vinculin and filamentous actin 
(F-actin) was also observed at the leading edge (Figure 3.10C), which is indicative of 
cell migration. These data suggest that VEGF triggered cell migration at a very early 
time point. The mechanism underlying VEGF-mediated cell migration was further 
investigated. Protein kinase B (AKT) activity is reported downstream of VEGF 
signalling and its expression was shown elevated shortly after VEGF stimulation 
(Figure 3.10D).  Downstream, FAK was also found activated (Figure 3.10D) and FAK 
is correlated with focal adhesion digestion. An AKT inhibitor was used, and it was 
found that the AKT/FAK pathway can be blocked (Figure 3.10D). We next determined 
whether AKT inhibition could also reduce SCF-induced c-Kit+ SPCs migration in vitro. 
As expected, AKT inhibitor-treated cells showed a significantly lower migration rate 












Figure 3.10. VEGF induced migration of c-Kit+ SPCs in vitro. A, Representative 
images showing RFP and SCF staining in allografts (n=6 mice per group). Arrows 
indicate co-staining of RFP and SCF. Scale bars, 50 μm, and 20 μm in enlarged 
images. B, Representative images showing VEGF-induced c-Kit+ SPC migration, by 
transwell migration assay. Scale bars, 100 μm. Graphs shown are relative cell number 
normalized to control. **P<0.01, ***P<0.001, one-way ANOVA with Dunnett’s test, n=3 
experiments, 10 fields per sample. C, Representative images showing VEGF-treated 
c-Kit+ SPCs stained with p-FAK, F-actin and vinculin (n=3 experiments). Scale bars, 
10 μm. D, Representative western blot showing activation of AKT/FAK pathways in 
response to VEGF (n=3 experiments) or in the presence of AKT inhibitor or DMSP 
(n=3 experiments). AKTi, AKT inhibitor; DMSO Dimethy sulfoxide. E, Representative 
images showing VEGFF-induced c-Kit+ SPC migration with AKT inhibitor or control 





Chaper 4: Discussion  
 
4.1    Summary 
This study answers several important questions about vascular allograft induced 
arteriosclerosis.  Firstly, immunostaining of wild type mice identified the location of 
SPCs to be both aorta and bone marrow. Additional findings from the c-kitkit/CreER; 
ROSA26-RFP transgenic lineage tracing mouse model further supported this 
conclusion. Secondly, in an allo-transplantation study, the sources of vascular cells 
mainly including ECs and SMCs were determined. The results showed that 4 weeks 
post-transplantation, all donor derived c-kit+ vascular cells were absent from the graft. 
Meanwhile, the graft lesion was formed of c-kit+ vascular cells derived from the 
recipient mouse. When analysing cell fate using double marker staining, data showed 
that c-kit+ SPCs differentiated into both ECs and SMCs. Further analysis of the source 
of recipient vascular cells was performed using a bone marrow chimeric animal. It was 
shown that only non-bone marrow derived c-kit+ SPCs differentiated into SMCs. For 
ECs, non-bone marrow source of c-Kit+ SPCs differentiated into ECs for luminal ECs 
regeneration in the neointima, whereas bone marrow source of c-Kit+ SPCs mainly 
differentiated into inflammatory ECs for microveseels remodelling in graft adventitia. 
Thirdly, the pattern and underlying mechanism of cytokine inducing c-kit+ SPCs 
migration was also evaluated in vitro. Vascular graft related cytokines were analysed 
by immunostaining. Data showed that expression of SCF and VEGF were upregulated. 
However, the control mice we used were only those without surgery. This is not a 
standard control. In the future study, standard control groups such as sham surgery 
or autografting mice need to be established to compare with the allograft animal 
groups to acquire more convincing result. Using transwell and scratch wound healing 
assays, it was demonstrated that under the influence of these two cytokines, c-kit+ 
SPCs migration is increased. Finally, a combination of G-LISA assays, 
immunostaining and western blots showed that migration of c-kit+ SPCs can be 
triggered by SCF via downstream activation of small GTPases, MEK/ERK/MLC and 
JNK/c-Jun signalling pathways, whereas VEGF can facilitate c-kit+ SPCs migration via 
AKT/FAK pathway. These in vitro studies provided us the clues about on how the 
recruitment of c-kit+ SPCs within the graft tissues were regulated. However, these 
mechanisms still need further in vivo work to demonstrate in the future. 
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4.2    Stem/Progenitor Cells (SPCs) Distribution  
SPCs are a cluster of cells with the potential for proliferation and differentiation. SPCs 
possess two important characteristics, which are self-renewal and differentiation 
potency. Self-renewal refers to the ability of cells to go through cell division while 
maintaining their undifferentiated state, while differentiation potency indicates that 
SPCs can differentiate into mature terminal cell types. Specifically, stem cells can 
differentiate into multiple terminally differentiated cell types, whereas progenitor cells 
can only transform into one (Table 4.2-1).  From the point of view of replication capacity, 
stem cells have a nearly unlimited potential for self-renewal, whereas progenitor cells 
can only divide for a finite number of times. In the adult body, adult SPCs act to repair 
injured tissue. Several methods have been used to identify SPCs, such as cell 
transplantation assay, clonogenic assays and functional assays. In the above methods, 
several makers such as CD34, Sca-1 and c-kit are used to label the vascular SPC 
population. For example, c-kit or CD117 is a tyrosine kinase receptor expressed on 
the surface of various types of SPC. Data has shown that c-kit is an important marker 
for hematopoietic stem cells (HSCs). Several tissues including the skin, the 
reproductive organs, the gastrointestinal tract, the nervous system and the cardiac and 
respiratory systems have been shown to contain c-kit+ cells.  However, there are only 
few studies investigating c-kit expression and function in the vascular system. One 
important issue, which hinders SPC research, is that though various markers have 
been used to identify SPCs, a uniquely specific marker is still lacking. For example, 
though c-kit is widely used to represent a cluster of SPCs, other cell types such as 
pericytes, ECs, hematopoietic cells, mast cells and interstitial cells also express c-kit. 
This can severely complicate result interpretation. The study in our lab previously 
identified vascular SPCs with the markers including Sca-1, CD34 and c-kit95. Therefore, 








Table 4.2-1 Comparison between stem cells and progenitor cells 
 Stem cells Progenitor cells 






To identify localised target gene or protein expression, several techniques are 
normally used (Table 4.2-2). To study expression of DNA or RNA sequences, labelled 
complementary DNA or RNA is used as a probe to bind to and identify target gene 
expression, this process is referred to as in situ hybridization. To identify specific 
proteins immunofluorescence (IF) or immunohistochemistry (IHC) techniques are 
employed to detect target antigen. In this way, antigen distribution can be visualised 
in the sample. Both IF and IHC are based on antigen-antibody interactions. The 
difference between IF and IHC are the reporter molecules; IF uses fluorochromes, 
whereas IHC uses chromogenic molecules as the reporter. Alexa Fluors and Dylight 
Fluors are popular commercial fluorescent reporters. In IHC, a colourless substrate is 
converted into a coloured product after use of enzymes such as alkaline phosphatase 
(AP) or horseradish peroxidase (HRP). For example, when DAB is catalysed by HRP, 
it generates a brown pigment, which can be visualised under the microscope. IF and 
IHC methods can be classified as direct or indirect methods. When the primary 
antibody is directly linked to a fluorophore and is bound to target molecules, the 
antigen can be recognised. This is called a direct method.  In contrast, indirect method 
uses the primary antibody without the fluorophore to be firstly applied to bind to the 
target antigen followed by a secondary antibody incubation, which carries fluorophore 
and binds to the primary antibody. As multiple secondary antibody molecules may bind 
to a single primary antibody molecule, the fluorescence signal can be amplified using 
this method, which facilitates sensitivity improvement. In our study, we employed 
indirect IF to detect target antigen expression because of its high sensitivity and 
specificity.  However, in our study we only used PBS with secondary antibodies as the 
negative control. This is not appropriated. In the future, IgG primary antibodies along 




Table 4.2-2 Target gene/antigen localisation 
















Fluorochrome Chromogenic  
Enzyme Yes/No No Yes 
 
The stem cell niche refers to the cellular microenvironment in the specific location 
where stem cells are found. It maintains adult stem cells in a quiescent state. However, 
after stimulations such as injury, SPCs exit from this quiescent state into a self-renewal 
or differentiation state. Various factors contribute to the stem cell niche, including 
stromal cells, ECM proteins, cytokines, adhesion molecules and specific metabolic 
environment. The SPC niche plays an important role in the cell physiological balance. 
If the SPCs niche is damaged, this cell physiological balance could be broken leading 
to tissue/organ failure. The bone marrow was the first niche described to harbour 
vascular cells including SPCs222. According to position and function, the bone marrow 
niche can be subdivided into the osteoblastic niche and the vascular niche. The 
osteoblastic niche is located at inner part of the bone, with a hypoxic environment for 
SPCs quiescence. The vascular niche is located near the artery, providing a higher 
concentration of nutrients and oxygen for SPC mobilisation. In the bone marrow niche, 
SPCs do not exist in isolation. In fact, they are under the regulation of surrounding 
cells such as ECs and stromal pericytes. Via a paracrine effect, surrounding cells 
secrete growth factors facilitating SPCs homeostasis. Meanwhile, ECs and stromal 
cells can also directly interact with SPCs. For example, Jagged and Delta like ligand 
expressed on the EC surface can regulate HSCs function through the Notch/Wnt 
pathway. Furthermore, mobilisation of SPCs from the bone marrow niche is also 
regulated by signalling such as SDF/CXCR4 and SCF/c-kit axis. By repeated flushing 
of the whole murine femur and tibia bones with PBS, we harvested SPCs attached to 
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bone marrow. Co-localisation of markers including CD34, Sca-1 and c-kit markers, 
indicated that a large proportion of harvested bone marrow cells were SPCs. 
The vascular wall is largely composed of vascular cells and ECM proteins. It was 
initially thought that the vessel wall environment solely played a structural role in 
supporting SMCs and ECs, until the identification of SPCs. Multiple studies have 
indicated an important role for these SPCs in vascular wall function and disease. 
Evidence from various groups suggests that SPCs are involved in atherosclerosis 
lesion formation as well as tissue regeneration. To acquire aorta specimens, cryo or 
frozen sectioning was performed (Table 4.2-3). Cryosectioning is a widely used 
technique for rapid microscope pathological diagnosis during surgery. Cryosections 
are also prepared in the lab for cytological analysis. Compared with paraffin sections, 
cryosectioning is comparatively timesaving because the tissues do not need pre-
paraffin embedding. Cryosectioning is additionally beneficial for preserving antigen 
function. In our study PFA, instead of formalin was used. This further improves antigen 
preservation. However, some information can be lost if cryosectioning alone is used 
to detect target cell distribution in the vessel. Although aortic cryosections provides us 
the opportunity to study the distribution of SPCs transversely across aortic wall, the 
less than 20μm thickness of the specimen could easily mean we miss the target cells 
and restrict the view of whole vessel. Though it may be possible to reconstitute the 
whole aorta using many sections and a computer-based technique, this work is time-
consuming and difficult to carry out. Therefore, whole mount en-face staining was 
performed, which assisted us in determining the distribution of SPCs in the whole aorta 
while focusing on specific layers. In our study, endothelial and adventitial layer en-face 
staining was performed. In endothelial layer en-face staining, the whole aortic tissue 
was carefully harvested. Because ECs are prone to apoptosis after animal death, 
perfusion fixation during harvest is necessary for cell and antigen preservation. 
Though some studies report that the EC layer can be distinguished from the SMC layer 
based on nucleus morphology, our study employed ECs specific cell surface marker 
VE-cadherin to distinguish ECs by their specific cobblestone structure under the 
microscope (as shown above). Distinct to ECs, cells within the adventitial layer are 
embedded in the ECM and comparatively resistant to apoptosis. Therefore, 
collagenase was used to digest the whole vessel and the adventitia was then carefully 
dissected from media layer. We found that maintaining the whole adventitial layer 
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intact was practically speaking rather difficult despite the tensile characteristics of this 
layer. 
Table 4.2-3 Aortic tissue preparation 
 Paraffin section Frozen tissue En-face 
Fixation Before embedding After sectioning Before Harvest 
Fixing Reagent Ice cold acetone Ice cold acetone/PFA PFA 
Section  Microtome Cryostat N/A 
Storage  Long term, RT Mild, -80°C Short, 4°C 
Time 
Consuming 
Long Short Intermediate 
Direction Cross  Cross Vertical 
Antibody 
Penetration 
Three layers Three layers Single layer 
 
 
The aorta is the largest vessel, originating from the cardiac left ventricle and extending 
down to the abdomen. Based on anatomy, the aorta can be divided into ascending 
aorta, aortic arch, descending aorta, thoracic aorta and abdominal aorta. In the current 
study, IF staining of SPC markers on aortic cryosections were performed. It was found 
that CD34+ and Sca-1+ cells were distributed throughout the whole aorta, whereas c-
kit staining was limited to the ascending aorta and aortic arch (Figure 3.1A). This is 
verified by en-face staining as c-kit marker were solely expressed in ascending aorta 
(Figure3.1C and Figure 3.1D). These results firstly embodied asymmetry of SPCs 
markers in spatiality, which indicates that although surface antigens such as CD34, 
Sca-1 and c-kit are traditionally regarded as SPC surface markers, they represent 
distinct cell lineages which may exert functionally distinct effects on vascular wall 
homeostasis. Secondly, when analysing these three markers together, data showed 
that a certain proportion of aortic cells express triple positive staining. When studying 
location (Figure 4.2A), we observed a distinct distribution pattern, in which most SPCs 
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are distributed in the ascending aorta and aortic arch, whereas in the descending aorta, 
thoracic aorta and abdominal aorta we see only sporadic SPCs. This asymmetric 
distribution might result from distinct aortic segment origin since the embryonic stage 
(Figure 4.2B). In the human prenatal aorta, the ascending aorta derives from the aortic 
sac or truncus arteriosus, which serves as a ventricular outflow tract after birth. 
Meanwhile, part of the truncus arteriosus would make up the aortic arch. In total seven 
aortic arches form during embryonic development. The first and second aortic arch 
disappear with further aortic development. The third aortic arch forms the carotid artery, 
and the fifth aortic arch regresses very early during development or does not form at 
all. The sixth forms in pulmonary arch and develops into the pulmonary artery during 
maturation, but the connection to the dorsal aorta either disappears on the right side 
or becomes ductus arteriosus on the left side. Only the left fourth aortic arch persists 
postnatally and serves as the aortic arch. The descending aorta, thoracic aorta and 
abdominal aorta derive from the dorsal aorta. Separate origins of aorta segments lead 
to distinct microenvironments, which could partly explain the asymmetric distribution 
of SPCs. In addition, structure distinction in aortic segments could also be a factor, 
which affects SPCs distribution. From direct observation, it is easily to see that the 
aortic arch has more curve and branches, whereas the descending aorta is relatively 
straight and branchless. This morphological change influences blood flow patterns and 
the resulting fluid shear stress felt by the vessel wall. Curvatures and branch points 
experience low levels of shear stress which is thought to cause inflammation in vessel 
tissue. This inflammation may trigger SPC recruitment and homing to this area and 





Figure 4.2 Aorta. A, aortic anatomy. The aorta can be divided into ascending aorta, 
aortic arch, descending aorta, thoracic aorta and abdominal aorta. B, aortic 
embryology. The ascending aorta derives from the aortic sac or truncus arteriosus. 
The truncus arteriosus consist of aortic arch. In total seven aortic arches form during 
embryo stage. The first and second aortic arch disappear in adult. The third aortic arch 
forms the carotid artery, and the fifth aortic arch never forms or regresses. The sixth 
aortic arch forms in pulmonary arch. Only the left fourth aortic arch persists until 
postnatal and serves as aortic arch. Descending aorta, thoracic and abdominal aorta 




4.3    SPCs in c-kitkit/CreER; ROSA26-RFP Mouse 
To answer questions in terms of the fate of SPCs, c-kitkit/CreER; ROSA26-RFP knock-in 
and transgenic animal models were employed (Figure 3.2A). The C-kitkit/CreER mouse 
is one type of knock-in animal, in which a CreER sequence flanks a c-kit promoter. 
This means that once the cellular c-kit promoter is activated, the CreER sequence is 
transcribed to produce mRNA, which can then exert function at a protein level. The 










tdTomato-WPRE transgenic mouse, in which the stop codon is flanked by loxP sites. 
By crossing these two transgenic or knock in mice, c-kitkit/CreER; ROSA26-RFP mice 
were generated. Within quiescent c-kit+ cells, mature Cre is contained by the ER in 
cytoplasm.  Once the animals are injected with tamoxifen, Cre is guided by ER 
components to translocate into the nucleus and recombines the loxp flanked stop 
codon sequence. C-kit+ cells are labelled with tdTomato/RFP signal, which is 
permanent regardless of cellular differentiation state. Thus, the progeny of c-kit+ cells 
maintain RFP signal even though expression of c-kit has been lost, permitting us to 
trace the fate of c-kit+ cells. We made a number of observations in this conditional 
inducible animal model, which have been previously reported in other studies. For 
example, c-kit+ cells were found to differentiate into ECs with lung and heart by using 
this animal models. However, in this animal model the role of c-kit+ cells in the vascular 
tissues is still unknown. Both c-kitkit/CreER and ROSA26-RFP transgenic mice were 
designed based on C57/6J background. Several studies have indicated that these 
transgenic animals including hybrid c-kitkit/CreER; ROSA26-RFP mice share similarity 
with C57/6J wild type animals, in every basic aspect such as shape, fur colour, body 
weight and daily diet and we also found this to be the case. As c-kitkit/CreER; ROSA26-
RFP mice are used as lineage tracing mouse model therefore specification in the 
recombination system is crucial to the final result. In our study, two strategies were 
applied to ensure system reliability. C-kitkit/CreER is known as a one knock-in mouse 
model, in which the CreER sequence replaces the c-kit exosome in a one to one 
pattern. This means that CreER expression accurately depends on c-kit activation 
level. This knock in mouse model is an improved technique, compared with random 
integration based traditional transgenic mouse models. In traditional random 
integration transgenic mouse models, the designed gene would be placed in a random 
place within the host genome. Meanwhile, transgenic gene expression can be affected 
by its own exogenous promoter, which could lead to unfaithful expression of the 
inserted gene. Therefore, our c-kitkit/CreER model insures that CreER replicates c-kit 
gene expression to a large extent. Another issue affecting the CreER recombination 
model is endogenous leak. As described previously, in traditional CreER 
recombination mouse models, in addition to tamoxifen, endogenous oestrogen may 
also stimulate the ER component, inducing CreER translocation, and leading to 
endogenous leak. In our study, the CreERT2 sequence which is designed based on a 
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mutant ER component, was used in c-kitkit/CreER animal. In this strategy, a mutant ER 
component which solely recognises tamoxifen, but not endogenous oestrogen was 
used. This has been shown sufficient to solve this endogenous leak issue in other 
studies. Another issue that must be monitored in this animal model is recombination 
efficiency. As described before, tamoxifen injection would ensure Cre recombination, 
which assists cell labelling. However, tamoxifen used as breast cancer medication has 
been reported to induce severe side effects including osteoporosis, thromboembolism 
and reduced cognition. In fact, murine mortality post tamoxifen injection was observed. 
In our study, 5 doses of 150 µg/g (mouse weight) on five consecutive days was used 
in consideration of both Cre recombination efficiency and mice survival rate (Figure 
3.2A). Our data showed that RFP signal could efficiently and specifically label the c-
kit+ cells in target tissues including aorta, lung, liver and bone marrow (Figure 3.2 C 
and Figure 3.2E).  
 
Table 4.2-3 Transgenic mouse 
 
4.4   C-kit+ SPCs in Aortic Intima Layer were not Derived from Bone Marrow 
In Figure3.1C, we showed that c-kit+ cells were distributed in the endothelial layer of 
WT C57/6J mouse. Therefore, endothelial en-face staining was also performed in c-
 Traditional Transgenic Knock In  
Gene 
manipulation 
Random integration Point to point replacement 
Off-target High Low 
Specification Low High 









kitkit/CreER; ROSA26-RFP animals to identify c-kit+ SPCs. Further, to better represent 
the vascular structure, we divided the whole aorta into five parts following anatomy. 
From these results, it was shown that RFP signal can be observed in certain parts of 
the ascending aorta, aortic arch and descending aorta, but not in thoracic and 
abdominal aorta (Figure 3.3A). This result indicated that c-kit+ cells were distributed in 
the vascular intima layer and could potentially be involved in vascular ECs 
regeneration. Two theories could explain c-kit+ cells involvement in vascular ECs 
regeneration. The first theory is through angiogenesis, in which new blood vessels are 
formed from pre-existing ECs. Angiogenesis is a vital process in both physiology and 
pathology. Once stimulated, cell surface receptors can be activated for ECs to sprout. 
Several factors are reported to initiate angiogenesis. For example, data has shown 
that shear stress can act on ECs leading to ECs mobilisation. In addition, growth 
factors such as VEGF and FGF can increase ECs permeability and proliferation to 
facilitate angiogenesis. Under these stimuli, ECs could first release proteases to 
degrade the ECMs for cell mobilisation. Then with the adhesion molecules, ECs fuse 
into neighbouring vessels. In our study, c-kit antigen was shown to be expressed within 
the ECs layer and thus suggesting that these c-kit+ cells represent a novel population 
of ECs that are activated under stimulation. In fact, the shear stress pattern within 
aorta segments is quite distinct. For example, because several branches are within 
aortic arch area, disturbed and low shear stress are observed in this region. In contrast, 
unidirectional and high laminar blood flow are detected in the descending aorta. 
Various studies have shown that distinct blood flow patterns have opposite effects on 
ECs biology, in which disturbed flow could increase angiogenesis and high shear 
stress decrease ECs sprouting. This could partly explain the distinct pattern of c-kit+ 
cells observed in within different aortic regions within the endothelial layer. The second 
theory for c-kit+ cell involvement in ECs regeneration is vasculogenesis. 
Vasculogenesis is a process, in which de novo ECs are formed from ESPCs. This 
process along with angiogenesis dominates blood vessel formation during embryonic 
stages.  In postnatal stages, vasculogenesis was also shown to form small vessels 
such as capillaries and tumour vessels. However, the role of vasculogenesis in large 
vessels is still unknown. In our study, the expression of c-kit+ cells and their progenies 
in endothelial layers indicate their potential as SPCs in ECs regeneration. Possibly c-
kit+ SPCs are activated and then fuse into monolayers of ECs similar to angiogenesis. 
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Several populations of EPs are reported harboured in the vessel wall. However, the 
role of these EPs in ECs homeostasis requires further study. In summary, the results 
of en-face staining indicate that c-kit+ cells were distributed in the vascular intima layer. 
However, whether these cells participate into angiogenesis or vasculogenesis cannot 
be confirmed by our in vivo work. Thus, in vitro work such as endothelial colony-
forming cells (ECFCs) culture assay is still needed to demonstrate the stemness of 
these c-kit+ cells.   
Another issue was whether these c-kit+ SPCs cells were derived from the bone marrow, 
a site which is known to harbour the SPCs. Therefore, chimeric mice which contain 
two populations of genetically distinct cells were created by transplanting the bone 
marrow cells from c-kitkit/CreER; ROSA26-RFP to WT C57/6J irradiated mice (Figure 
3.3B). This allowed us to examine the role of bone marrow derived c-kit+ cells. Two 
steps are required to produce chimeric mice. The first step is irradiation of WT C57/6J 
animals. Although the c-kitkit/CreER; ROSA26-RFP mice in our study have a C57/6J 
background. Immune response can still be activated because the bone marrow 
transplantation was performed between different individuals. If bone marrow cells are 
directly transplanted into a non-irradiated mouse, transplantation failure would occur. 
Irradiation is required to clear recipient inflammatory cells to prevent transplant 
immune response. Irradiation exerts injury on dividing cells such as HSCs within bone 
marrow. The most commonly used techniques are Gamma and X-ray irradiation. X-
ray irradiation was used in our study and the dose used was 900rad, which ensured 
total myeloablation223. After irradiation, immunosuppressed mice were produced, 
which are suitable for cell transplantation. The second process in generating chimeric 
mice is transplantation of bone marrow cells. After transplantation, 
immunosuppressed mice were rescued due to cell replenishment with the transplant 
cells. In the clinic, bone marrow cell transplantation is a vital treatment for malignant 
blood diseases such as leukaemia and multiple myeloma. In animal experiments, bone 
marrow transplantation can be used to obtain crucial information about bone marrow 
derived cells. In our study, bone marrow cells were flushed out of the femur and tibia 
of donor c-kitkit/CreER; ROSA26-RFP mice, and stored in sterile cell culture medium. 
Donor bone marrow cells were transplanted to recipient irradiated C57/6J mice 
through the tail vein. Guided by molecules such as SDF-1, donor cells could home to 
bone marrow from the circulation. The transplanted bone marrow SPCs can be divided 
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into the categories of short and long term lived HSCs. Immediately after 
transplantation, short lived SPCs reconstitute lymphoid and myeloid lineage, whereas 
long lived SPCs are responsible for long term haematopoietic cells reconstitution. 
Approximately 21 days after bone marrow transplantation, peripheral haematopoietic 
lineage is fully reconstituted224. Because the recipient mice were myeloablated by 
irradiation before bone marrow transplant, they were at high risk of infection or death 
if the donor bone marrow cells failed to reconstitute the immune system. Therefore, 
survival of the mice is one positive index indicating bone marrow transplantation 
success. Similar to c-kitkit/CreER; ROSA26-RFP mice, chimeric animals were given 5 
doses of tamoxifen, for Cre recombination (Figure 3.3B). Afterwards, bone marrow 
reconstitution was also verified by flow cytometry and immunofluorescence staining. 
Harvested cells from chimeric mice showed RFP signal (Figure 3.3C). This indicated 
that both bone marrow transplantation and tamoxifen induced CreER recombination 
were partially successful.  
After chimeric mice were created, aortic en-face staining was performed on collected 
tissue. However, no RFP signal was detected within ECs layers in all aorta tissues 
from aortic root to abdominal aorta. Several possible reasons could be behind this 
result. Failure of bone marrow transplantation is one possibility. However, our previous 
results (Figure 3.3C) which identified RFP in chimeric mice indicated that 
transplantation was partly successful. However, we also noticed that percentage of 
RFP+ cells in bone marrow were lower in chimeric mice(Figure 3.3C) than that in c-
kitkit/CreER; ROSA26-RFP mice(Figure 3.2B). In the future study, we still need to prolong 
the recovery time for chimeric mice after bone marrow transplantation. In addition, 
survival of the animals without infection or haematopoietic disease suggested that 
donor bone marrow has re-established the immune system within the recipient animal. 
Both these findings suggest no RFP signal within the ECs layer is not due to failed 
transplantation. Another potential reason for negative results is the failure of CreER 
recombination. However, positive staining in both IF and flow cytometry results 
demonstrated that our strategy could efficiently induce recombination and label the c-
kit+ cells in the chimeric animals. Low efficiency labelling of specific ECs because of 
the knock in lineage tracing animal model may be the culprit. However, previous en -
face staining data (Figure 3.3A) has shown positive staining of c-kit+ cells in c-kitkit/CreER; 
ROSA26-RFP animals. Both of these results indicated that the absence of RFP 
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staining in chimeric mouse en-face staining is not because of failure in labelling target 
cells. Therefore, our results (Figure 3.3E) indicated that bone marrow c-kit+ SPCs did 
not differentiate into luminal ECs in physiological state. This raised several areas of 
interest. The first is the true derivation of these c-kit+ SPCs during vascular 
regeneration. Resident vascular SPCs are one potential candidate. In fact, due to their 
location, resident vascular SPCs might rapidly sense the signals from surrounding 
vascular cells and contribute to ECs vascular homeostasis, but this still needs further 
study. Another point of interest is that although bone marrow derived c-kit+ SPCs do 
not contribute to vascular homeostasis, whether they are involved in disease was not 
clear. For this reason, a vascular allograft accelerated arteriosclerosis mouse model 
was designed. 
4.5   c-kit+ SPCs in Vascular Allograft lesion 
To study the role of SPCs in vascular allograft accelerated arteriosclerosis a mouse 
model was established (Figure 3.4A). The model used in this study has been 
developed in our lab since 2000 when carotid artery or aorta was allotransplanted34. 
Obviously, mice are much smaller than humans, and naturally murine vascular 
diameter is very small, increasing the difficulty level of the surgery. The carotid artery 
and the aorta are the largest blood vessels in mice and therefore the most accessible 
for use in vascular allograft accelerated arteriosclerosis surgery. In this surgery 1mm 
cuffs are applied to stabilise and ligate the vessel end. It is well known that long term 
donor graft ischaemia can easily result in graft fibrosis, which is an inducement for 
graft failure. Cuff usage greatly reduces the duration of surgery, increasing success 
rates of the transplantation.  Further transplantation between C57BL/6J (H2b) and 
Balb/c (H2d) mice ensues alloimmuno reaction occurrence because of mismatched 
MHC molecules (Figure 4.5 A). In this model, cell infiltration in both media and 
neointima can be observed within 2 weeks of transplantation. After 4 weeks, neointima 
enlargement leads to vascular stenosis. By 6 weeks, the whole lumen is occluded. In 
terms of specific cells, data from our lab has shown that the number of ECs derived 
from the donor decrease over time and entirely lost after 4 weeks66. In contrast, the 
number of host derived ECs increases and these ECs are shown to be involved in 
both ECs regeneration and microvessels formation (Figure 4.5 B). Similarly a recipient 
source of cells dominate de novo SMC formation in the neointima after 4 weeks98. For 
this reason, we collected the tissues 4 weeks after transplantation. In our study both 
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cell infiltration, lesion formation and lumen stenosis can be observed. When the 
tissues were further stained, SPCs were shown to be distributed in the lesion of the 
allograft (Figure 3.4B). However, more questions arose from this result. Firstly, 
although SPCs can be detected in the lesion, their fate was still left unknown. During 
this process, SPCs would home in and colonise the lesion, however, at the same time 
these cells undergo differentiation mediated by cytokines. When these SPCs 
terminally differentiate, they lose SPC marker expression. Because cellular marker 
expression is not stable during their differentiation process, lineage tracing in wild type 
animal cannot be realized. Furthermore, although SPCs markers including Sca-1, C-
kit and CD34 are observed in the lesion, the source of these SPCs in wild type mouse 
model cannot be detected. Understanding whether these SPCs derive from the donor 
or recipient cells is vital, because the result directly affect the strategy choice during 
and after allo-transplantation surgeries. If the SPCs are derive from the donor animal, 
anti-immune drugs that protect these cells would be vital for improving graft survival 
rate. In contrast, if the SPCs are from recipient sources, increasing SPCs mobilisation 
may be one important issue for graft long term maintenance. Additionally, the 
mechanisms behind migration and differentiation of these cells is hard to detect using 
only in vivo animal models. For this reason, these SPCs were harvested and the 







Figure 4.5 Allograft accelerated arteriosclerosis. A, HE-stained sections of mouse 
control artery and artery allografts. Common carotid arteries (a) of C57BL/6J mice, 
allografted 2 (b) and 4 (c) weeks after surgery. B, En-face staining of endothelial cells 
on aortic allografts. a through d, Freshly harvested aorta segments from TIE2-LacZ 
mice (a) were allografted into carotid arteries of Balb/c mice (b through d). e through 
h, Freshly harvested aortic segment from a Balb/c mouse (e) was allografted into 
carotid arteries of TIE2-LacZ mice (f through h). Blue indicates β-gal+ cells. (Figure 
Source: A, Dietrich H, Hu Y, Zou Y, Dirnhofer S, Kleindienst R, Wick G, Xu Q. Mouse 
model of transplant arteriosclerosis: Role of intercellular adhesion molecule-1. 
Arteriosclerosis, thrombosis, and vascular biology. 2000;20:343-35234; B, Hu Y, 
Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in 










4.6   Death Pathways were Induced in Donor Graft c-kit+ SPCs Derived Cells  
ECs can be damaged after vascular allograft because of immune cell attack. T cells 
may directly trigger ECs apoptosis or B cell dominated humoral immune activity may 
recruit antibodies and complement components, leading to attack on ECs. Immune 
system involvement results in EC barrier dysfunction and adhesion molecular 
exposure, both of which lead to ECMs, platelets, erythrocytes and other inflammatory 
cells infiltrating the graft intima layer. Previous results from our lab have shown that in 
animal models, donor derived ECs did not survive66 (Figure 4.5 B). In addition to 
immune responses, risk factors such as lipid accumulation and local infection can 
accelerate ECs apoptosis. In fact, acute graft failure is frequently observed after ECs 
dysfunction. Therefore, EC integrity and regeneration are key to graft survival rate. 
ESPCs are an important source of regenerated ECs. Once ECs are lost, ESPCs can 
be activated for vasculogenesis and form a de novo lumen within the lesion. However, 
the source of these ESPCs are still unclear (Table 4.6-1). Our results show that donor 
derived c-kit+ SPCs are not involved in ECs regeneration within allograft tissue (Figure 
3.7A and Figure 3.7C). Similar to our other in vivo work, procedures were performed 
to prevent mouse model failure. For example, after the graft c-kitkit/CreER; ROSA26-RFP 
was transplanted to Bab/c mice, tamoxifen was given to recipient animal. This ensured 
successful Cre recombination within the graft even after allo-transplantation. 
Therefore, there was no contribution of donor c-kit+ SPCs in allograft induced lesions. 
This agrees with our previous study that suggest regenerated ECs in allograft are not 
from donor origin66. However, studies in human tissue showed a different result. When 
Y-chromosome in situ hybridization was used to investigate female graft tissue that 
was transplanted into a male recipient, it was found that within transplanted coronary 
artery graft tissues, more than 95% ECs did not show a Y-chromosome. This indicates 
that in human graft tissue, most ECs are of donor origin225. Later, when similar 
protocols were performed on cardiac transplantation patients, the results showed the 
graft was of chimeric ECs, suggesting that only half of ECs were derived from donor 
resident ESPCs67. Contradictory conclusions observed in human and animal studies 
can be explained by several factors. Firstly, to increase patient survival rate post 
cardiac allo-transplantation, immunosuppressive drugs are regularly used. Therefore, 
donor ECs in human tissues may remain in the graft after markedly reduced intima 
injury. In contrast, to induce lesion formation, immunosuppressive drugs were not used 
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in a vascular allo-transplantation animal model. As shown previously, ECs were totally 
desquamated after allo-transplantation. Another potential source of donor derived ECs 
are resident ESPCs. Similar to ECs, after transplantation, SPCs could also be attacked. 
Immunosuppressive drugs assist to preserve function of local SPCs to differentiate to 
ECs. The animal model used in our study was c-kitkit/CreER; ROSA26-RFP mouse, 
which allows tracing of the fate of c-kit+ SPCs. Our results indicate that donor derived 
c-kit+ SPCs are not involved in EC regeneration. However, to determine whether other 
population of SPCs such as donor sca-1+ and CD34+ cells are involved in allograft 
arteriosclerosis would require other animal models.   
 
 






(Table Source:  Xu Q. Stem cells and transplant arteriosclerosis. Circulation research. 
2008;102:1011-1024226. ) 
After EC dysfunction, SMCs accumulate in the allograft lesion. However, the source 
of these SMCs is still under debate (Figure 4.6-2). It was firmly believed that SMCs in 
the lesion were derived from media vascular SMCs. When these SMCs go thorough 
phenotypic switching, cell potential of migration and proliferation are upregulated227, 
228. Increased ECM is secreted by SMCs, leading to neointima formation. However, 
results from our lab indicates another possible conclusion. Data show that after 
transplantation, no graft derived SMCs were preserved in the neointima98 and this 
suggests that after surgery, SMCs undergo cell death. Several studies support this 
result and in fact, SMCs death is one common hallmark of arteriosclerosis226. In the 
past 20 years, local vascular wall layers harbouring SPCs, were also reported to be 
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involved in SMCs formation after vascular injury87, 92. In our study however, we did not 
observe any local SPCs after allo-transplantation (Figure 3.7B). This result indicated 
that donor c-kit+ SPCs were also induced to death. Indeed, a relationship between 
vascular SMCs and SPCs within the vascular lesion has emerged after years of 
debate89. It was demonstrated that after mild atherosclerosis, vascular SMCs first 
undergo a phenotype change, to adopt vessel wall remodelling. When vascular 
injury becomes more severe, apoptosis of the original SMCs occurs and at the same 
time, SPCs are recruited to injury sites differentiating into SMCs. However, in our 
study, both donor SMCs and donor c-kit+ SPCs were induced to death because of 
the severe immuno response and were therefore not involved in SMCs regeneration.    
 
 







(Table Source:  Xu Q. Stem cells and transplant arteriosclerosis. Circulation research. 
2008;102:1011-1024226. ) 
Cell death can be divided into the pathways of apoptosis, necrosis, autophagy and 
pyroptosis (Figure 4.6-3). Apoptosis is a programmed cell death realised by a series 
processes including blebbing, cell shrinkage, and nucleus fragmentation. After the cell 
fragments are produced, phagocytic cells are recruited to engulf the post-apoptotic 
contents. Cellular apoptosis is mainly initiated by intrinsic and extrinsic pathways. 
Intracellular pathways are activated by stress sensed by the cells, whereas extrinsic 
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pathways are triggered when extracellular ligand binds with cell surface death receptor. 
After allograft transplantation, TNF-ɑ and Fas ligand (FasL) concentrations are both 
upregulated due to inflammatory cell activation. When they bind with their receptors 
on SMCs, death inducing signalling complex (DISC) is formed, which triggers caspase 
activity. Caspases such as caspase-8 are a group of cysteine-aspartic proteases, 
which attack target proteins facilitating programmed cell death.  
Extracellular pathways increase intracellular stress and stimulate intracellular 
apoptotic pathway. During this process, mitochondria are induced to swell under 
proapoptotic protein attack and are prone to rupture further promoting pro-apoptotic 
effectors to leak out. Then through mitochondrial apoptosis-induced channels, 
cytochrome C is released into the cytoplasm and forms the apoptosome when binding 
with caspase-9. With these components, organelles are digested into fragments and 
cleared by phagocyte without affecting nearby cells.  
Necrosis is a pathological process in which cells are induced to injury and death, under 
extracellular factors. Distinct from apoptosis, necrosis is always detrimental and fatal. 
Necrosis does not follow apoptotic signalling pathways and has a distinct underlying 
pattern. Cellular necrosis also starts from surface receptor activation when stimulated 
by external factors. For example, in the vascular graft, if the lesion area grows 
restricting the blood flow ischaemia would then initiate SMCs necrosis in a caspase 
independent manner. In addition, the immune response can also trigger necrosis. 
During this process, reactive oxygen species (ROS) are produce and the oxygen and 
glucose supply are depleted which further enhances necrotic lesion development. All 
these factors result in the breakup of SMCs membrane and thus uncontrolled necrotic 
cellular products are released into extracellular space. This further upregulates the 
inflammatory response and recruits more phagocytes to engulf dead cells. However, 
phagocytosis in necrotic lesions is inefficient. In addition, inflammatory cells could also 
secrete cytokines. Both the remaining SMCs debris and inflammatory molecules would 
then function on surrounding cells to promote necrotic lesion enlargement. Meanwhile, 
platelets, fibroblasts and osteoblasts can be attracted by cytokines. Remnant necrotic 
SMCs along with ECMs, serve as a nucleating structure or necrotic core, initiating 
formation of complex lesions, including thrombosis, fibrosis and calcification.  
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Autophagy is a destructive mechanism which disassembles dysfunctional cellular 
components. This is executed by the autophagosome, a double membraned vesicle. 
When the autophagosome fuses with lysosomes, target proteins can be degraded. In 
SMCs, autophagy is an adaptive response, when under external stress such as 
starvation and ischaemia. Autophagy ensures SMCs reserve their priority functions 
such as survival when stress is minor. When stress become more severe, autophagy 
could also lead to death of unhealthy SMCs to save the energy for comparatively 
functionally complete SMCs. The current consensus is that in physiological states 
regulated autophagy promotes SMCs survival, whereas in pathological condition such 
as atherosclerosis, defective autophagy induces SMCs death contributing to 
vulnerable lesion formation. Studies have shown that autophagy related genes are 
regulated by a balance between two protein kinases mTOR and AMPK.  
Table 4.6-3 c-kit+ SPCs death 
 Autophagy Apoptosis Necrosis 
Cell lysis No No Yes 
Cell swelling No Yes/No Yes 
DNA fragment  Yes/No Yes Yes 
Trigger Metabolism change  Apoptosis ligand Cell stress 






No Yes No 








Several questions remain unanswered in this mouse model. For example, although 
death of donor source of c-kit+ SPCs was observed in vascular allograft lesion, cells 
loss rate is unclear. The technique such as terminal UTP nick end-labelling (TUNEL) 
was used to detect DNA fragmentation in all dead cells. However, this technique 
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showed no distinct staining in specific cell types such as SMCs and SPCs. When cell 
death is induced, their specific cell markers are prone to be lost. When different types 
of cells show a similar profile within the neointma, results of SPCs death rate could be 
incorrectly estimated. Therefore, in further study, multiple time points and techniques 
are needed to observe SPCs death rate, which could provide more accurate 
information in in a comprehensive dynamic way.   
The role of SPCs death in arteriosclerosis is still unknown. As described above, 
autophagy is a protective process once cells are under external stress. Several 
methods could be used to serve as autophagy markers. Besides direct observation of 
the autophagosome and morphology under microscope, LC3 and p62 compartment 
staining could also be used to track autophagy occurrence229. In fact, autophagy has 
been shown to be involved in SPCs biology including homeostasis and differentiation 
within various tissues such as skeleton and cardiac muscle131. However, the role of 
autophagy in vascular SPCs are still unknown. Furthermore, cell autophagy in 
atherosclerotic lesions is commonly impaired. Therefore, the role of autophagy and its 
impaired form in SPCs regulation still needs further study.  
When graft injury further develops, SPCs apoptosis and necrosis could be induced. 
Propidium iodide (PI) and 7-aminoactinomycin D (7-AAD) are fluorescent chemical 
compounds with high affinity for double stranded DNA. Because they cannot cross live 
cell membranes, these agents could be used to distinguish live and dead cells. 
Phosphatidylserine (PS) staining can be used to distinguish between apoptosis and 
necrosis. PS is an apoptotic marker, which translocates from the cytosol to the surface 
under regulation of scramblase once the cells undergo programmed death. In addition, 
processes such as time-lapse morphology change, DNA fragmentation, caspase 
activation and cytochrome c release are all used to identify SPCs apoptosis. Currently, 
the link between SPCs death type and injury severity is also unknown. Therefore, in 
future it would be worth carefully identifying percentage of apoptotic and necrotic cells 
in different allograft stages. Our results showed that, similarly to SMCs and ECs, SPC 
derived cells were also induced to death under alloimmuno reaction. However, the role 
of SPCs death in allograft accelerated arteriosclerosis is still unknown. Though it is 
clear that ECs and SMCs apoptosis leads to vascular dysfunction and unstable lesion, 
apoptosis of bone marrow derived macrophages is beneficial for alleviating neointima 
formation. Meanwhile, when undergoing external stress such as inflammatory attack 
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after allograft, whether SPCs are directed towards cell death or differentiation still need 
further study to investigate. 
4.7   C-kit+ SPCs were from Recipient Source in Vascular Allograft 
Role of the recipient SPCs within the vascular graft lesion were determined in this 
study, in which aorta segment of Balb/c mice were allotransplanted to c-kitkit/CreER; 
ROSA26-RFP mouse (Figure 3.4C). Because the segment showed no transgenic 
signal, RFP fluorescence can all be regarded to derive from recipient animal. 
Expression of RFP signal indicated that recipient source of SPCs involved in neointima 
formation. In terms of specific cells type, we found that recipient source c-kit+ SPCs 
involved in endothelium regeneration (Figure 3.6A). In the literature, it was thought 
that after ECs dysfunction, the damaged ECs are replaced by donor preserved ECs 
or ESPCs. However, in our animal model, results showed that after transplantation, 
no donor derived c-kit+ SPCs were detected within neointima. Instead, recipient source 
of c-kit+ SPCs regenerated the endothelium. This result draws a structure of ECs 
regeneration in vascular allograft. After donor ECs and/or ESPCs were induced to cell 
death by alloimmune attack, recipient source of c-kit+ SPCs were recruited to the graft 
in a cytokine gradient dependent manner. Once induced to differentiate into ECs, 
these ESPCs replace original dysfunctional ECs. This result is crucial in understanding 
pathology of vascular allotransplantation arteriosclerosis. It provided the clues in 
refining therapeutic strategy. Combined with studies from lab before, it is currently 
clear that local ECs and ESPCs were rapidly lost after the surgery. Subendothlial layer 
was therefore exposed to the blood, risking for vascular injury. If more ESPCs 
attachment and ECs regeneration on ECs layer can be promoted at early stage, the 
graft failure rate can be possibly reduced. We hypothesized that the number of ESPCs 
in circulation is critical for endothelium regeneration. This is because our previous 
study reported that CD34+ progenitor cells are lower in apoE-/- mice230. This resulted 
in diminished ECs regeneration and partly explained the increased lesion area in 
apoE-/- mice. In fact, it has been shown that risk factors such as inflammation and 
oxidative stress are related to decreased number of ESPCs. ESPCs number has been 
regarded as one biomarker to predict cardiovascular risk because of its correlation to 
Framingham cardiovascular score231. Therefore, for further clinical application, 
increasing ESPCs number could be a potential target to prevent chronic vascular 
allograft failure. For example, data showed that although immunosuppressant drugs 
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such as cyclosporine and tacrolimus could inhibit inflammatory response which is 
beneficial to prevent acute graft failure, these drugs could also inhibit cell proliferation. 
When the inhibition is severe, the number of circulating ESPCs would be decreased, 
which could be a potential cause for chronic graft. This provided another factor for 
clinicians, in setting a balance between immunosuppressive drug dosage and duration.  
In addition, some studies also indicated that after stimulation with vascular risk factors, 
the number of ESPCs are increased instantly, which seems ambiguous to previous 
conclusion.  For example, it was shown that after some acute myocardial infarctions, 
ESPCs were increased. The explanation of this paradox is that at the beginning of 
disease, ESPCs are stimulated and mobilized from their niche to injured site for 
compensation. However, with continuous stimuli, ESPCs dysfunction occurs resulting 
in a decrease of proliferation and mobilization along with increased apoptosis. All of 
these factors contribute to decreased ESPCs number in the long term. Therefore, as 
a future work, it would be beneficial to investigate the importance of dynamic change 
in ESPCs cell number to allograft severity. In terms of clinical settings, increasing 
circulating ESPCs number may raise tumour risk. Therefore, any similar strategy used 
into post-allotransplantation patient to promote ESPCs regeneration need be 
appraised on malignant risk before putting into clinic.  
Our study also showed that c-kit+ SPCs were involved in microvessel remodelling in 
the adventitial layer (Figure 3.6B). Vasa vasorum is the small blood vessel network, 
which supplies the blood and nutrient for the vessel wall. Within the aorta, vasa 
vasorum normally locate at adventitia and outer part of media. Few vasa vasorum 
penetrate into intima layer. Study indicated that occlusion in vasa vasorum of 
abdominal aorta could lead to extensive medial necrosis232. In allograft arteriosclerosis 
pathology, vasa vasorum remodelling also play an important role. It was shown that 
shortly after ECs injury, de novo formed and proliferated vasa vasorum would 
penetrate from adventitia into intima layer in response to ECs loss. In fact, results from 
our group showed that microvessel remodelling is one of earliest events occurring after 
vascular allograft transplantation66. The function of these microvessels in 
arteriosclerosis formation varies in different studies. Some studies demonstrate that 
vasa vasorum penetration helps to maintain nutrients and growth factors supply which 
restrict cells death within the lesion. On the other hand, other opinion insists that these 
neo-vascularized microvessels always have permeable ECs, which are conductive to 
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inflammatory cells invasion and contribute to lesion enlargement. However, when the 
disease further proceeds and vasa vasorum occlusion occurs, cell necrosis would be 
induced because of nutrient shortage. This leads to atherosclerosis complications 
such as lesion rupture, aneurysm and angioma. In our study when the 
allotransplantation was performed in chimeric mice (Figure 3.5B), results showed that 
bone marrow derived c-kit+ SPCs were involved in adventitial microvessls formation 
(Figure 3.6D). This is not surprising because a study from our group has indicated 
before that bone marrow derived cells are responsible for neo-vacuolization66. After 
ECs were induced to death by alloimmune response, various molecules were released 
into circulation. Bone marrow harboured c-kit+ SPCs would be therefore mobilized by 
cytokines. Then under attracting of chemoattractant, bone marrow derived c-kit+ SPCs 
were recruited to the graft and when interacting with adhesion molecules expressed 
on graft cells, c-kit+ SPCs adhered into graft tissue. These bone marrow derived c-kit+ 
SPCs subsequently are involved in microvessels formation. Although in an early stage, 
newly formed microvessels could provide graft tissue the blood flow to some extent, 
final stage of inflammatory vasa vasorum would accelerate arteriosclerosis lesion 
formation. In our study, data showed that adventitial microvessels derived from bone 
marrow c-kit+ SPCs were mainly inflammatory ECs (Figure 3.6D).  
Although c-kit+ SPCs are a population of cells identified by their communal surface 
marker c-kit, they are indicated a heterogenic population of ESPCs. For instance, in 
our study they are divided into bone marrow and non-bone marrow source of c-kit+ 
SPCs. Data was shown that non-bone marrow source of c-kit+ SPCs mainly functioned 
in intima layer regeneration (Figure 3.6A and 3.6C), whereas bone marrow derived c-
kit+ SPCs involve in microvessels formation (Figure 3.6B and 3.6D). Therefore, further 
studies are still needed to detect variation in function of different source of c-kit+ SPCs. 
If different source of c-kit+ ESPCs could be harvested properly in the future, test could 
be proceeded to compare function such as permeability and neo-vascularized 
potential in their formed cluster of cells. In addition, gene profile is worth to be 
established in subsequent studies in different populations of c-kit+ ESPCs. When 
compared with regenerated c-kit+ ESPCs in the lesion, the true source regenerated 
ECs can be expected to be identified. This study also provides the clue for future 
clinical treatment. Data from previous work indicate that ECs layer regeneration is 
beneficial to restore vessel function, whereas microvessels development could 
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enhance lesion area. This means if future clinical trials could develop the treatment to 
upregulate non-bone marrow c-kit+ ESPCs mobilization, and at the same time 
decrease bone marrow origin of c-kit+ ESPCs attachment to the vessel wall, longer 
time survive of vascular graft could be expected. After allograft transplantation, 
inflammatory molecules such as TNF-α and IL-2 are released leading to recipient cell 
death. Data showed that these molecules could also impact the ESPCs function. 
Therefore, more future work is required to detect role of these cytokines in c-kit+ SPCs 
function especially in ECs layer regeneration. 
Using the same mouse model (Figure 3.4A), co-expression of RFP and SMCs markers 
including α-SMA and SM-22 indicates that recipient c-kit+ SPCs differentiated into 
SMCs in vascular allograft (Figure 3.5A). This accorded with previous study from our 
lab that, in same mouse model, SMCs within plaque lesion derive from recipient but 
not donor sources98. One possible explanation of this result is that, after donor graft 
SMCs death since alloimmuno response from recipient inflammatory cells, cytokines 
as the signal were secreted into circulation. Role of these cytokines in SPCs regulation 
would be further discussed below. Resulted cytokines or chemokines gradient 
recruited recipient SPCs into lesion site to replenish SMCs within graft neointima. 
Subsequently, graft structure can be maintained by newly formed SMCs. Since the 
bone marrow is important for harbouring c-kit+ SPCs, it is crucial to determine whether 
bone marrow was involved in SPCs replenishment and SMCs differentiation. Result 
from allo-transplantation surgery based on Balb/c mice to these chimeric mice (Figure 
3.5B) indicated that, bone marrow source of c-kit+ SPCs was not involved in SMCs 
differentiation (Figure 3.5C). The conclusion that SPCs derived SMCs were of non-
bone marrow source agreed to previous study from our lab98. This is also in line with 
results from other groups using injury233 and ApoE-/- 234 spontaneous atherosclerosis 
mouse models. However, one study demonstrated that bone marrow derived LacZ+ 
cells could co-express with α-SMA markers in allo-transplant induced neointima235. 
Later this conclusion was found to be misinterpreted. Instead of real SMCs 
differentiation in vivo, this co-staining was in fact caused from overlapping between 
SMCs and LacZ+ leukocytes. One possible reason for this false positive result, is 
lacking high resolution confocal microscope, a technique limitation at that moment. 
Other tissues need to be tested, on whether they are source smooth muscle SPCs. A 
possible source was presumed to be recipient local carotid artery which is close to 
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anastomoses. However, in our method, instead of directly stitching graft with recipient 
vessel, a cuff was used to anastomose donor and recipient ends, leaving no direct 
contact between graft and recipient vessel. Combining with the similar study from our 
lab98, local recipient SPCs seem impossible to pass anastomoses into grafts. Another 
possibility is the non-bone marrow tissues, such as vessel wall, spleen, liver and 
adipose tissues, all of which were suggested to harbour SPCs. It is rational to 
speculate that, once stimulated, SPCs from these tissues could be mobilized into 
circulation and then home to graft under chemokines. Among all of these tissues, 
vessel wall is the best studied. In fact, all of three vessel wall layers have been reported 
to harbour SPCs. For example, adventitia as one important perivascular structure, 
contains several population of SPCs87, 90, which are capable of differentiating into 
SMCs-like cells and therefore involved in neointima formation. Meanwhile, another 
study before, points out that  MHC- stem cells could give rise to SMCs in neointima92. 
In addition, ECs were also shown able to transdifferentiate into SMCs-like cells in 
atherosclerosis lesions, via endothelial to mesenchymal transition (EndMT) 
mechanism236.  Various sources of these stem cells could also partly explain 
heterogeneity of SMCs in vascular allograft lesions. From various studies, data 
indicated that SMCs, which account for the highest percentage of cell number in 
allograft lesions, showed high level of heterogeneity. Traditionally it was thought that 
this heterogeneity derived from mature donor media SMCs transdifferentiation and it 
reflects different stage of SMCs dedifferentiation. However, our work has proven that 
donor SMCs would be induced to death, and then recipient source of SPCs dominate 
SMCs repopulation. Different source of these SPCs could be the main reason, why 
the SMCs within the lesion showed distinct phenotypes and characters.  
Because the donor SMCs were induced to death after transplantation, recruited SPCs 
within the graft, could differentiate into SMCs and repopulate vessel wall. During this 
process SPCs and their derived SMCs would firstly proliferate and reorganize ECMs, 
which contribute to vessel wall repair and lesion stability in the early stage. When 
inflammatory injury persists, SPCs accumulation and proliferation would be 
uncontrolled, which would result in luminal narrowing. In the advanced stage these 
recipient source of SMCs also undergo programmed cell death under cytokines such 
as TNF-α and IL-2. Therefore, some targets are worth focusing in future treatment. 
Firstly, in early stage of transplantation, SPCs mobilization and SMCs commitment is 
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one potential target for vascular allograft regeneration. Secondly, in long term, 
accumulation and proliferation of SPCs derived SMCs need to be cautiously regulated 
to keep the lumen area. Apoptosis and/or necrosis prevention of these newly formed 
SMCs is another target to inhibit advanced lesion formation. Thirdly, when choosing 
the drugs, the balance between inflammatory cells inhibition and SPCs function 
reserve need to be noticed. Both uncontrolled inflammation and SPCs dysfunction 
could result in graft failure. Summary of source and role of c-kit+ SPCs is shown in   
 
Figure 4.7 Proposed source and role of c-kit+ SPCs in allograft accelerated 
arteriosclerosis. After vascular allo-transplantation. Donor cells were firstly induced 
to death. Recipient of c-kit+ SPCs were recruited to the vessel wall. Non-bone marrow 
source of c-kit+ SPCs were committed to both ECs and SMCs fate in the neointima. 
SPCs, stem/progenitor cells; ECs, endothelial cells; SMCs, smooth muscle cells. 
Figure 4.7  
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4.8   C-kit+ SPCs Isolation 
Our study required the harvesting of SPCs from vascular grafts. Because the graft was 
a transplant harvested from surgery, isolated cells in our study were from various 
sources and for this reason mimic the cell population derived from in vivo work. When 
graft vessels are cut open and applied to the surface of a cell culture flask cells migrate 
from the graft vessel and after several days form colonies in the flask. After extended 
culture, vascular stem cells persist and expand in the flasks because of their self-
renewal properties. Stem cell culture has been widely used in labs throughout the 
world, but various points need to be taken into consideration to ensure successful 
conservation of stem cells pluripotency potential. In vivo, stem cells are under 
quiescent maintenance within a microenvironment or niche, which are full of ECMs 
favouring stem cells adhesion. Therefore, in our study, the flasks to hold the cells were 
coated with 0.2% gelatin. When the flask is coated with gelatin, there is a supportive 
physical environment for cells to attach and grow. Cell to cell interaction is one 
character of stem cells in the niche. Intercellular interaction allows the cells to relay 
the signal, and could respond to experiment change when in stress. Our study put the 
30,000 cells in 75 cm2 area, which provide the cells a proper intensity to grow. The 
culture media used in our study was complete stem cells medium which consists of 
Dulbecco's Modified Eagle's Medium, 10% foetal bovine serum, 10 ng/mL leukemia 
inhibitory factor and 0.1 mM 2-mercaptoethanol. Dulbecco's Modified Eagle's Medium 
is one standard formula stem cell culture medium consist of necessary nutrient 
including amino acid, glucose, vitamin and ions. Foetal bovine serum could provide 
cells with growth factors supporting cells to survive and grow. Leukaemia inhibitory 
factor (LIF) is an IL-6 class cytokine, which inhibit cell differentiation. When binding 
with cell surface receptor GP130, LIF activates JAK/STAT signalling. This promotes 
stem cells renew while inhibit cells differentiation.  2-mercaptoethanol is a chemical 
reducing compound which provides a mercapto group which could scavenge oxygen 
or hydroxyl radicals for antioxidant. Therefore, adding 2-mercaptoethanol into the 
medium prevented cell from toxic radical attack. Because in vitro, the cells lack the 
protection of immune system, cells are prone to contamination. Fungi, bacterial, virus 
and mycoplasma are the common source of contamination which could lead to cell 
dysfunction or death, antibiotic was therefore loaded to ensure the SPCs were growing 
in a sterile environment. Meanwhile, because our cells were cultured alone, the risk of 
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false result from other contaminated cell lines can be avoided. When the cells grew 
full in the flask, cells were digested with trypsin. Trypsin belongs to serine protease 
family member and its optimum activity is at 37°C. Therefore, cells detachment was 
performed in the pre-warmed incubator. During trypsin digestion, long time touch to 
the cells were avoided to protect the cells from damage. After fully detachment, 
complete culture medium was added to inactivate trypsin. This inactivation is that the 
serum in the medium contains antitrypsin and macroglobulin which could stop trypsin 
activity. To freeze the remaining cells, dimethyl sulfoxide (DMSO) contained medium 
was used since DMSO can prevent water crystal to lyse the cells during 
cryopreservation. The reason to use the medium is considering to avoid cells staving 
during thawing.   
Graft SPCs outgrew from our culture condition. However, the cell proportion are still 
unknown. To separate the target cell population, cells were sorted out of origin cells. 
Cell sorting could be based on cell size, shape and surface markers. Currently, several 
methods are used in cell sorting. Single cells sorting such as microrafts and DEPArry 
lab-based chip technology provided methods to sort the cells based on intracellular 
and extracellular properties. Florescent activated cell sorting (FACS) is based on flow 
cytometry to select the cells which contain target surface markers. Magnetic cell 
sorting makes use of column to separate labelled cells. In recent studies, one 
technique called buoyancy activated cell sorting was developed, in which 
microbubbles were bound with cells surface antigens and then through flotation, these 
cells could be isolated from the samples. From cost-utility ratio point of view, magnetic 
cell sorting was used in our study. Meanwhile, although c-kit is regarded as a stem 
cells surface marker, it is also expressed on other cell types such as ECs, 
hematopoietic cells, mast cells and interstitial cells. Therefore, another cell surface 
marker sca-1 was also used in our study in cell sorting. Overlapping of these two 
population could ensure SPCs property to the largest extent, in our study. Flow 
cytometry study (Figure 3.8B) identified our isolated c-kit+ SPCs. From the result, 
positive staining of c-kit and sca-1 indicates that cell sorting was successful. 
Meanwhile, other cells markers were also tested in our cell population. Interestingly, 
several cell markers were found positively stained including CD34, CD140, CD105, 
CD29, CD44, and CD201. This indicates that c-kit+ SPCs isolated from graft are 
heterogeneous cell populations, consisting of various cell types including ECPCs, 
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fibroblast, MSCs and pericytes. All these cell types were reported to have SPCs 
potential and could be involved in vascular remodelling. Mesenchymal stem cells 
(MSCs) are multipotent stromal cells which showed potential to differentiate into 
several cell types including osteogenic cells, cartilage cells, myocytes and adipose 
cells. In recent years, MSCs have also been demonstrated to differentiate into both 
ECs and SMCs to assist in vessel regeneration. This indicated the c-kit+ SPCs in our 
study might be a population of MSCs. Several tissues were indicated to harbour MSCs 
including bone marrow, adipose tissue and resident vessel wall. Fibroblasts are typical 
biological cells which could synthesize ECMs and play critical role in vascular wound 
healing and fibrosis.  In the vessel wall, fibroblasts normally locate at the adventitial 
layer. Pericytes are a population of cells that located around ECs consisting small 
vessel in vascular system. In tradition, both fibroblasts and pericytes exert paracrine 
function for surrounding cells. In recent studies however, it was shown that these cells 
could transform into SPCs and contribute to both vascular biology and pathology 
processes. This result fits our expectation, because other similar studies have 
indicated a heterogeneous population in SPCs. However, more work still needs to be 
performed in the future to demonstrate unanswered questions. For example, it is 
important to address whether our isolated cells were distinct populations, or they are 
derived from an ancestor. Although these cells express various markers, some similar 
study points out they may come from the same source and the various markers could 
be explained by the different stage of the same cells. Alternatively, if these cells do 
derive from multiple sources, the distinction and their respective fates need to be 
compared.     
4.9   SCF Induced c-kit+ SPCs Migration  
Stem cell factor (SCF) is specific ligand for c-kit receptor. SCF exists two forms, a 
soluble and a membrane bound isoform. Soluble SCF is derived from membrane 
bound isoforms, which have been cleaved by a protease. Both soluble and membrane 
bound SCF can bind with c-kit to promote intracellular tyrosine kinase activation. As 
one typical cytokine, SCF expresses in ECs and fibroblasts. From our results (Figure 
3.8A), in physiological aorta SCF was mainly expressed in the intima layer and 
adventitial layers, coinciding with previous studies. After transplantation, results 
showed that SCF spread all over the graft (Figure 3.8A). The explanation is that, when 
graft cells were induced to death after transplantation, SCF was released from these 
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cells, which could then bind with c-kit receptor and attract the c-kit+ SPCs. However, 
from our previous studies, c-kit+ SPCs were circulating in the blood. It is rational to 
speculate that SCF would also be released into the circulation to mobilize these cells. 
Therefore, ELISA assay was used in our study to investigate the change of SCF in 
circulation. Enzyme-linked immunosorbent assay (ELISA) is one widely used 
technique in clinic to detect the antigen in the sample for diagnosis. The principle of 
ELISA is based on antigen-antibody reaction. Target antigen could interact with 
specific antibody. The antibody is pre-connected with the designed enzyme. After 
substrate for enzyme is added, substrate reaction would produce signal, which can be 
detected by spectrophotometry. Intensity under standard setting is correlated with 
antigen concentration. Therefore, ELISA assay could accurately quantify SCF content 
in plasma. According to detection mode, ELISA can be divided into direct, sandwich 
and competitive ELISA. In direct ELISA, antigen contained buffer is directly added to 
the surface. Subsequently the enzyme contained antibodies are added to detect the 
antigen. Within this method, the enzyme can be used as amplifier, which could transfer 
reaction signal in a recognized and quantitative level. However, a major disadvantage 
in this method is that antigen capture is non-specific, especially in serum or plasma 
samples, which contain large number of antigens competing with surface area and 
decrease the chance of target antigens to stick on the plate. Sandwich ELISA is one 
improved technique. In this method, specific capture antibody would be pre-bounded 
at surface. When the sample is added into the plate, target antigen can be specifically 
captured by the antibody. After detecting antibodies are applied, signal could be 
detected. In this way, unspecific binding antigen induced problems can be avoided. 
Competitive ELISA is one comparatively less common used method, to detect antigen 
in non-purified samples. In consideration of sensitivity and specificity, our study used 
sandwich ELISA and found that SCF concentration was upregulated after 
transplantation (Figure 3.8A). In summary, both ELISA and IF staining result indicated 
that SCF is upregulated both locally and in circulation after vascular injury caused allo-
transplantation. Also this result demonstrated that SCF could potentially mobilize c-
kit+ SPCs from the niche into circulation, and then attract these cells to lesion area. 
But this still needs in vitro work to demonstrate. 
Cell motility allows the cells to change their position. Cell accumulation is one 
character of neointima. In general, motility assays can be separated into migration and 
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invasion assay. In the biological field, migration is defined as direct cell position 
change on substrate such as ECMs and plastic plate on a 2D surface, whereas 
invasion is regarded as ability, with which cells could break through the complex 3D 
matrix during movement. During invasive processes, cells need to go through series 
steps including attachment to ECMs, shape modification and/or ECMs digestion. For 
example, when leucocytes are mobilized from the bone marrow under cytokines, they 
migrate first in the blood without attaching to ECMs. Once recruited by local vascular 
chemokines, they attach on lumen surface and then invade into the vascular wall. 
Migration is a pre-condition of invasion. In other words, cells could not invade without 
migration capability. Mode of cell motility can be divided into single cell and multiple 
cells migration. Single cells could migrate simply by cytoskeleton rearrangement with 
or without attaching to ECMs, whereas multiple or collective cells migration involves 
cell to cell interaction. Both motility models could occur simultaneously. Animal studies 
demonstrated that SCF would be upregulated after transplantation. The role of SCF in 
c-kit+ SPCs function is still unknown within in vivo work. Therefore, our study tested 
how SCF activated c-kit+ SPCs in different assays in regarding to study cells migration, 
proliferation and differentiation.  
In our study, two cell motility assays, transwell assay and wound healing assay were 
used to detect the effect of SCF on c-kit+ SPCs migration in vitro (Table 4.9). Transwell 
assay or Boyden chamber assay is one classic method to observe cell chemotaxis. In 
a transwell kit, two chambers are separated by a pore membrane. When the cells 
could translocate from inner/upper chamber into the outer/lower surface, they are 
regarded going through migration. Two chambers were loaded with medium with 
different concentration of cytokines. Normally, cytokines concentration in outer 
chamber is higher than that in the inner chamber. Then the cells loaded in upper 
chamber could migrate under the attraction of cytokines. The membrane pore size is 
lower than cell diameter and this ensure that cells would not drop because of its own 
gravity. Only when guided under cytokines, these cells could change their morphology 
and pass the membrane. In our study, because SPCs size is on average around 30μm, 
pore size at 8μm of transwell assay kit was employed. During the assay, several other 
points need to be noticed. Firstly, height of medium level need to be equal. Because 
the liquid pressure could also drive cell to migrate, different medium level could result 
in false end. In our study, 100 μl and 600 μl medium were put into the inner and outer 
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chamber, respectively. This ensured the medium height to keep in an even level. 
Second, incubation time needs to be carefully controlled. If incubation time is too short, 
the cells could have not initiate to migrate. Conversely, when incubation time is too 
long, cells would migrate too extensively beyond membrane surface area limitation, 
which makes comparison impossible. Therefore, from previous test results, our study 
decided to load 1,000,000 cells and incubate for 18h, from which the result is suitable 
to observe. After incubation, migrated cells were fixed and stained using crystal violet. 
The remaining cells on the upper chamber were removed by cotton swab and then 
migrated cells can be counted under microscope. The advantage in using transwell 
assay is that this experiment could easily detect the SPCs motility capability when in 
response to gradient of SCF. The disadvantage is that dynamic cell migratory pattern 
cannot be acquired because this assay could only observe and count the cell number 
once at the endpoint. Another migration study used in our study is scratch wound 
healing assay. This assay also provided us the chance to observe cell migration but 
in a dynamic pattern. In this experiment, confluent SPCs on a plate were wounded by 
a scrape exerted by pipette tips. The rate at which cells fill in the gap can be regarded 
as cell migrating speed. Under the microscope, speed of cell movement can be 
measured dynamically. With this method, cell migration in several time points can be 
observed. Because uneven thick scratch could affect the result, our study used the 
same pipette tips in different groups trying to reduce variation between groups. 
Meanwhile, because heavy scratch is an external stress which could induce the cells 
to death. Therefore, when performing scratch wound on the cells, gentle action was 
preferred which minimizes the injury to cells. By using these two migration assays, our 
study demonstrated that SCF induced c-kit+ SPCs in a dose dependent manner 
(Figure 3.8C and Figure 3.8D). ACK2 is a blocking antibody, which could inhibit c-kit 
kinase activity. When ACK2 was applied into the working medium, data showed that 
SCF induced increase in cell migration can be partially reversed (Figure 3.8E). This 
indicated that effect of SCF on SPCs is through c-kit activity. 
Cytoskeleton as cellular basic component is crucial in regulating cell migration (Table 
4.9). By using cytoskeleton assay, SPCs migration can be detected in a single cell 
level (Figure 3.9A). Phalloidin is a toxin found in death cap mushroom. When it is 
injected into the blood, it rapidly binds with F-actin. When binding with F-actin subunit, 
they showed higher affinity to actin monomers leading to decreased dissociated rate 
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of actin subunit and then harm to filament depolymerization. Meanwhile, phalloidin 
could inhibit ATP hydrolysis and trap ADP. Since its high affinity to F-actin, phalloidin 
carrying fluorescence substrate was used as to label F-actin. Because phalloidin 
cannot penetrate cell membrane, this tagged antibody is commonly used in dead fixed 
and permeabilised cells such as which in our study, instead of live cells. Our result 
showed that in untreated cells, F-actin locate across the whole cell body but in a 
rambling pattern. However, instantly after SCF treatment, F-actin accumulate at the 
leading edge of membrane forming in filopodia and lamellipodia structure to sense the 
signal and initiate cell migration. As stated before, vinculin is a cytoskeleton protein 
located at the cell membrane and involve in focal adhesion formation. Along with other 
focal adhesion proteins such as paxillin and ɑ-catenin, vinculin serves to bind F-actin 
with cell membrane. From our study, vinculin was recruited early to the cell protrusion. 
Unlike floating cells such as leucocyte in blood flow, SPCs migrate on ECMs in a 
scramble manner. Therefore, focal adhesion could serve as feet during the cell spread 
process. Meanwhile, FAK was also appeared at focal adhesion site. Previous data 
have indicated that FAK is pivotal for cell motility. FAK activation in a phosphorylation 
form could activate downstream proteins, which in one hand dissociate adhesion 
complex, and in other hand, promote further cell protrusion F-actin formation. Our 
result indicated that, migration of SPCs under SCF is rapidly initiated, because of 
cytoskeleton rearrangement (Figure 3.9A). This migration is not constant. Instead, 
they went through several stages, including protrusion formation, F-actin stabilization 
and adhesion dissociation which are series of classic migratory manners of scramble 
cells. 
Table 4.9 Migration assays 







Yes No No 
Cell injury No Yes No 
Measurement  Cell count 













Collective Single cell 
Measure 
timepoint 
Endpoint Dynamic Endpoint/Dynamic 
Cell state Live Live Dead 
 
In our study, incubation time of transwell assay and scratch wound healing assay were 
both 18h, which is long enough for cells expansion. Migratory assays result could be 
affected by uneven cell division. Therefore, proliferation assays were also performed 
in our study. Cell proliferation or division is one stem cell character. In quiescent state, 
cells stay in G0 phase without replication. However, once stimulated, quiescent stem 
cells are induced to divide. Cell division can be divided into four stages including G1, 
S, G2 and M phases (Figure 4.9). G1 phase is the first stage of cell division process. 
During G1 phase, cells enlarge in size and synthesize necessary substrate to prepare 
for DNA duplication. S phases is the stage when DNA duplication occurs. G2 phase 
continues to increase genetic materials. At the end, cells enter in M phase to divide 
one cells into two daughter cells.  
 
Figure 4.9 Cell cycle. Quiescent stay in G0 phase without replication. G1 phase 
synthesize necessary substrate for DNA duplication. S phases is responsible for DNA 
Figure 4.9  
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duplication occurs. G2 phase continues to increase genetic materials. Cell divide in M 
phase. (Figure Source: www2.le.ac.uk/projects/vgec/highereducation/topics/cellcycle-
mitosis-meiosis.) 
During the whole cell cycle, four points control the cell proliferation. The first point is 
called restriction point(R-point), which locates between G1 and s phases. R-point 
decides whether the cells would continue further cell cycle or turn back to G0 phase. 
Once the cells pass the R-point, they do not need persistent extracellular stimulation 
to maintain the cell cycle. Then three checkpoints are responsible for cell cycle. G1/S 
checkpoint is located at end of G1 phase. Some studies hold the opinion that G1/S 
checkpoint and R-point located at the same place, but the conclusion still needs further 
study to demonstrate. One major target of the G1/S checkpoint is to check cellular 
DNA integrity. If DNA damage is detected at this point, cell cycle would be delayed or 
arrested at G1 phase. After the cells pass G1/S checkpoint and S phase replication, 
S/G2 checkpoint functions to assess if proper chromosome duplication is ready and 
duplicated newly formed genetic material is defective. At the end whether the 
kinetochore has attached to spindle fibre would be evaluated at G2/M checkpoint. 
Once the cells pass this point, cellular division occurs. The whole cell cycle is under 
regulation of cyclin. Cyclin has no enzymatic activity but could provide binding sites 
for downstream substrates such as CDKs. Cyclin-dependent kinases (CDKs) are a 
group of kinase, which could activate cell cycle through phosphorylating other proteins. 
Only when cyclin-CDKs complex is formed, cell cycle could be initiated. Cyclin-CDKs 
complex activity can be inhibited by negative regulatory molecules such as 
retinoblastoma protein (RB), p53 and p21. When the cell DNA is damaged under 
stress, these molecules would be accumulated for repaired. If the damage is too heavy 
and cannot be repaired, they would induce cell to death. Therefore, these negative 
regulatory molecules function in cell mutant and if dysfunction occurs on these 
molecules, cell aberration occurs. Currently, several proliferation related indexes 
including DNA synthesis, metabolic activity, proliferation markers and ATP 
consumption were used to detect proliferation rate.  In our study, Brdu assay and ki67+ 
cell counting was used to detect the effect of SCF on c-kit+ SPCs proliferation. Brdu is 
a synthetic nucleoside which could function similar to thymidine. When the Brdu is 
loaded into the sample, it incorporates into newly synthesized DNA during S phase. 
After adding Brdu specific antibody, incorporated Brdu number can be detected which 
170 
 
represent cell proliferation rate. Ki67 is one nucleus protein associated with ribosomal 
RNA transcription. It locates at cell nucleus and is present in all cell cycle stages but 
not quiescent cells. It is a classic proliferative marker which could be used to detect 
percentage of proliferating cells. In our study, after 18h SCF incubation, both Brdu 
number in immunoassay and ki67+ cells percentage in flow cytometry showed no 
significant difference in c-kit+ SPCs (Figure 3.8F). This indicated that within 18h, SCF 
would not alter the rate of c-kit+ SPCs division rate. Also this meant that SCF effect on 
c-kit+ SPCs migration was not due to increase proliferation rate.  
4.10 ACK2 Reduced Arteriosclerosis Lesion 
SCF upregulated c-kit+ SPCs migration in vitro (Figure 3.8C and Figure 3.8D) and this 
can be partially inhibited by c-kit blocking antibody ACK2 (Figure 3.8E). Therefore, we 
wondered if ACK2 could also decrease lesion after vascular allo-transplantation. 
Artery stenotic lesion is one complex result during vascular adaptive remodelling. After 
ECs are injured from various factors, they are leaky to several cytokines or leucocyte. 
Meanwhile, SMCs within intima layer are induced to proliferate and secrete ECMs 
leading to intimal hyperplasia. During lesion development, SMCs derived from any 
sources would accumulate into the lesion sites forming neointima and occupying the 
vascular lumen. When the lesion proceeds with thrombosis accumulation in the end 
stage, they could obstruct the whole lumen with or without lesion rupture. Several 
histologic indexes are important to atherosclerosis diagnosis. Lumen area is a 
parameter, which is correlated to vascular ischemia. When the lumen area is large, 
blood is flowing fluently, whereas when it is small, blood flow is restricted due to vessel 
wall narrowing. Neointima area is another biomarker to diagnose atherosclerosis. 
Increased neointima area indicates higher risk of vascular events. Because our study 
mainly used collected vascular tissue, lumen area and neointima area were used as 
parameters to appraise vascular lesion. Vascular allograft was transplanted again from 
balb/c to C57/6J mice (Figure 3.8G). Meanwhile, the graft was encompassed by 
pluronic F127 gel with ACK2 or with igG (Figure 3.8G). Pluronic F127 gel is one triblock 
copolymers that maintains in gel structure at room temperature, but become liquid 
state at 4-5°C. Previous study indicates pluronic F127 gel is suitable for drug release. 
Because of these characters, pluronic F127 gel was used in our study for local 
antibody delivery and release. To analyse the collected tissues, H&E staining was 
used. Haematoxylin and eosin (H&E) stain is one principle histological method for 
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clinical diagnosis. In this method, haematoxylin bind with basophilic structure such as 
DNA and stain them in blue. Eosin tends to stain eosinophilic proteins within plasma 
or ECMs into red. From H&E staining, our result showed that ACK2 significantly 
decreased lesion area whereas increased lumen area (Figure 3.8H). In addition, there 
is also a significant decrease in cell number (Figure 3.8H). This can be explained by 
our migration result that ACK2 could inhibit SCF induced c-kit+ SPCs accumulation 
after the vascular allo-transplantation. Our previous result indicated that c-kit+ SPCs 
could differentiate into SMCs. Since SMCs accumulation is one well known culprit in 
arteriosclerosis formation, we therefore also performed IF staining to count the SMCs 
cell number. Our results showed that SMCs accumulation is also significantly 
decreased (Figure 3.8I). Combining with these result, we concluded that c-kit+ SPCs 
migration and SMCs differentiation were the cause of lesion formation in vivo. 
Therefore, ACK2 could be a potential treatment to allograft related arteriosclerosis in 
future clinical work. 
4.11 SCF/C-kit Axis Signalling 
Murine c-kit gene was cloned and sequenced in 1993237. When c-kit is translated into 
protein level, it serves as a tyrosine kinase receptor protein. C-kit, as the cell surface 
marker, belongs to type III receptor tyrosine kinase. On structure, c-kit is a 
transmembrane protein mainly consist of extracellular domain, which bind with its 
ligand and intracellular tyrosine domain, which is responsible for phosphate group 
transfer. Core size of c-kit protein is around 110kDa and when it is glycosylated, 
mature c-kit protein forms with the size at around 150kDa. C-kit is rapidly activated by 
dimerization. When two separate c-kit monomers bind with the ligand, they are brought 
together and the same time, structure conformation is induced for protein interaction. 
When intracellular domains of dimers are close to each other, tyrosine kinase are 
activated for transphosphorylation. During this process, phosphate group are 
transferred from ATP to tyrosine residues. Multiple sites of tyrosine residues have 
been identified as kinase activity domains ( Tyr-547, 553,  568, 570, 703, 721, 730, 
823, 900, 936)216. In fact, c-kit activation has been shown involved in regulating cells 
function in several systems including hematopoietic system, genital system, cardiac 
system and respiratory system. Our previous data have demonstrated that c-kit+ SPCs 
were involved in vascular remodelling under regulation of SCF after allo-
transplantation. However, how does SCF regulate c-kit+ SPCs was still unknown.   
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Since phosphorylation is activation form of c-kit, we firstly tested if c-kit is 
phosphorylated after SCF treatment. Phosphate group transfer via protein kinases is 
one common method for cells to regulate target proteins activity. Several methods 
were traditional used to detect target protein phosphorylation including kinases activity 
assay, phosphor-antibodies incubation, and western blot. Recently, cell-based ELISA, 
intracellular flow cytometry, mass spectrometry and multi-analytic profiling were 
developed based on signal cell or multiple target points. In our study, classic 
electrophoretic based western blot assay was employed to detect protein 
phosphorylation. Several points were needed to be take consideration when detecting 
phosphorylation proteins. First, since the posttranslational modification was easy to be 
disrupted, gentle protein harvest was performed to prevent pre-damage of 
phosphorylated proteins. Second, incubation buffer was replaced to TBST instead of 
PBST because previous data indicates phosphate group react with substrate in PBST. 
Our results showed that after SCF treatment, c-kit transformed into phosphorylated 
form rapidly (Figure 3.9B). This indicated that, binding with SCF stimulated c-kit 
transformation, to receive the phosphate group from energy providing substrate ATP. 
As one kind of kinase, multiple intracellular tyrosine sites could receive phosphate 
group to induce more than one response. In fact, SCF were reported to induce several 
response in c-kit+ cells216. However, the role of SCF in regulating vascular SPCs 
migration is still unknown. Therefore, further downstream signalling factors were 
tested. As indicated before, small GTPases including Rac1, CDC42 and RhoA are 
upstream factors that are involved in cell migration instantly after cytokines activation. 
Small GTPases or known as G-proteins serve as a switch in cytosol. When the bind 
with GDP, they are inactive whereas when they bind with GTP they are activated. After 
activated, they transfer phosphate group to downstream targets. Traditional method 
to detect GTPase activity is co-immunoprecipitation (Co-IP) assay. To test binding 
between GTP and small GTPases, cell lysate against GTPase would be isolated using 
microbeads. After electrophoresis, target proteins binding with GTP could be detected 
using specific antibodies. Recently, another technique called G-LISA is developed to 
detect small GTPases activity. Similar to ELISA assay, small GTPases effect proteins 
would be coated in the plate, and only GTP but not GDP bounded G protein could bind 
on the plate. After luminescence reaction, amount of specific GTP bounded G protein 
could be detected from absorbance number. Compared with Co-IP assay, G-LISA 
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assay required less time and can be quantified (Table 4.11). Therefore, our study used 
G-LISA assay to detect small GTPases activity. For our studies, data showed that after 
SCF stimulation, mount of active Cdc42, RhoA, and Rac1 within c-kit+ SPCs 
significantly increased at 0.5min, 1min and 2min, respectively (Figure 3.9C). This 
indicated that these small GTPases were rapidly activated after stimulation. Then the 
activated Cdc42 quickly promote F-actin assembly forming filopodia as a signal sensor. 
Meanwhile, Rac1 regulated lamellipodia formation and matured cell protrusion. 
Downstream of RhoA is MLC and MLC phosphorylation increase myosin II contractility, 
providing cells contacting force during migration. Mitogen-activated protein kinases 
(MAPKs) belongs to protein kinase that functions in several cellular activities. Because 
our initial results firstly related MAPKs with CDKs for cell proliferation, they were 
termed as mitogen activated proteins. However, our results showed that they were 
also related to cell migration. For example, previous studies pointed out that that ERK 
mutation impaired cell migration238. Downstream target of ERK to stimulate cell motility 
includes MLCK, deadhesion related proteins and calpain. Therefore, we investigated 
whether MAPK signalling respond after SCF treatment. In western blot result, data 
showed that MEK/ERK signalling is activated rapidly which facilitates and promotes 
MLC phosphorylation for cell migration (Figure 3.9B). Our result showed that JNK/c-
jun pathway could also be activated by phosphorylation (Figure 3.9B). C-jun is a 
protein which could bind with c-fos to forms AP-1, one early response transcription 
factor. Previous data showed that AP-1 could activate cell migration through MMPs 
release. Our ELISA data showed that after long term SCF regulation, MMP2 but not 
MMP9 was upregulated which assist ECMs digestion for cell motility (Figure 3.9E). In 
summary, after SCF treatment on c-kit+ SPCs, SCF/c-kit axis is activated, which 
promote multiple pathways to regulate cell migration. 
Table 4.11 Small GTPases activity assay 
 Co-IP GLISA 
Lysate amount Large Small 
Time consuming High Low 






4.12 VEGF Induced c-kit+ SPCs Migration 
As indicated before, VEGF family is a group of important molecules in vascular biology 
to induce ECs migration. Our data indicated that VEGF were also involved in c-kit+ 
SPCs regulation. We assessed VEGF expression after allo-transplantation in vivo. 
Data showed that after transplantation, VEGF distributed in all the neointima (Figure 
3.10A). This was possibly due to ECs death caused VEGF release. Although VEGF 
has been shown to induce angiogenesis, the effect of VEGF on SPCs was unknown. 
Therefore, transwell assay was used to detect the role of VEGF on c-kit+ SPCs 
migration. From our result, it was shown that VEGF significantly increased c-kit+ SPCs 
migration (Figure 3.10B). In single cell level, VEGF could induce c-kit+ SPCs 
cytoskeleton rearrangement (Figure 3.10C). Protein Kinase B (Akt) is an important 
kinase downstream of VEGF kinase receptor. Akt could promote various cell function 
including survival, metabolism, proliferation and migration. By western blot, our study 
showed that Akt could be rapidly phosphorylated after VEGF commitment on c-kit+ 
SPCs (Figure 3.10D). Meanwhile, phosphorylated Akt transfer phosphor group to 
downstream FAK leading to adhesion kinase activation for cell motility (Figure 3.10D). 
Our data also showed that Akt inhibitor could significantly reduce VEGF induced cell 
migration (Figure 3.10E). These data indicated that similar to SCF, VEGF acted as a 
chemoattractant for c-kit+ SPCs. Signalling pathway in SCF and VEGF on c-kit+ SPCs 
are drawn in Figure 4.11-12. 
175 
 
Figure 4.11-12 Schematic diagram illustrating possible mechanisms regulating 
c-Kit+ SPC migration. SCF stimulates c-Kit phosphorylation and induces activation of 
downstream small GTPases, MEK/ERK and JNK/c-Jun pathways. Activation of Rac1 
and Cdc42 facilitates F-actin rearrangement to form cell protrusion. MLC can be 
phosphorylated through MEK/ERK signaling and increases myosin contractibility. 
Activation of MEK/ERK and JNK/c-Jun pathways may further promote MMP-2 
expression. VEGF stimulates AKT1/2/3 phosphorylation and activates downstream 
FAK. These signaling pathways activated by SCF/c-Kit axis or VEGF concomitantly 










4.13 Future Work and Perspectives  
In summary, we demonstrate here that a recipient non-bone marrow source of c-kit+ 
SPCs give rise to both SMCs and ECs, contributing to neointima formation in an 
allograft transplantation model. Cytokines such as SCF and VEGF promote cell 
migration. These findings may provide novel insights into pathogenesis of neointima 
formation and further potential therapeutic implications for vascular diseases. 
However, several issues are left unanswered and will need to be addressed in future 
studies. 
Firstly, although our study indicates that a non-bone marrow source of c-kit+ SPCs 
play a key role in both neointima formation and EC regeneration after allo-
transplantation the precise source of these c-kit+ SPCs is still unclear. Tissues 
including the vessel wall, spleen, liver, heart and lungs are all reported to harbour 
SPCs. Therefore, they are potential candidate sources of c-kit+ SPCs. In future studies, 
if tagged c-kit+ SPCs can be successfully cultured from these specific tissues and then 
transplanted back into vascular allograft animals, function of these cells could be 
tested in vivo. In our studies, the fate of c-kit+ SPCs were tracked by lineage tracing 
studies. However, the role of other populations of SPCs such as sca-1+ and CD34+ 
cells is still unknown. Meanwhile, the relationship between each SPCs population is 
also unclear. Our study indicates that these SPCs populations overlap to a certain 
degree. Therefore, in future studies, lineage tracing studies targeting sca-1+ and 
CD34+ cells are necessary to address their fate. In the future work, if combined lineage 
tracing technique such as double, or even triple system based for these populations 
can be developed, the relationship between these cells can be expected to be 
demonstrated. In addition, our study also demonstrated the role of c-kit+ SPCs in a 
vascular allo-graft mouse model. However, atherosclerosis/ arteriosclerosis is not 
limited to a vascular allo-transplantation mouse model. Other atherosclerosis types 
including spontaneous, vascular injury and vein graft induced atherosclerosis are also 
reported. In future, if c-kitkit/CreER; ROSA26-RFP mice can be applied in these mouse 
model the difference in c-kit+ SPCs function can be compared in different mouse 
models.  
Our study also showed that only recipient c-kit+ SPCs are involved in vascular graft 
induced neointima formation. c-kit+ SPCs from donor animals were possibly killed by 
177 
 
the recipient immune system. However, results from some other studies are not totally 
the same. Some human studies have concluded that donor SPCs were responsible 
for neointima formation. A possible reason for this variation is that, 
immunosuppression drugs were not used in our animal model. In the clinic, 
immunosuppression drugs are regularly used to prevent immunoreaction, which partly 
explains the preservation of donor SPCs after surgery. Therefore, in future works, 
immunosuppression drugs can be applied in our animal model, to clarify whether this 
difference is because of these drugs. Furthermore, these kinds of studies are also 
helpful in observing the effect of immunosuppression drugs on both donor and 
recipient SPCs, which can help improve clinic treatment. Another issue need to be 
addressed, is our vascular mouse model. Although vascular allograft mouse model 
perfectly mimic vascular pathology after allo-transplantation, it was not entirely the 
same with solid organ transplantation. In fact, apart from transplanted vessel itself, 
graft is also affected by nearby graft parenchymal cells such as liver cells, 
cardiomyocytes and pulmonary cells. Therefore, further solid organ allo-
transplantation mouse models are advice to perform, though high level of difficulties. 
In this way, heart, liver and kidney transplantation, can be better mimicked in lineage 
tracing mouse model. This will give us more comprehensive information concerning 
solid organ allo-transplantation instead of sorely focusing on certain aspects. Further, 
as state before, immunoreaction is one of the main causes of allo-transplantation 
induced vasculopathy or arteriosclerosis. However, role of immunoreaction on SPCs 
are still unknown. We speculate that immunoreaction could do harm to SPCs, but this 
still need further studies to demonstrate. Meanwhile, if harmed SPCs can be acquired, 
comparison in disease model can be achieved between these cells and healthy SPCs. 
With this, new role of   immunoreaction in allo-transplantation induced vasculopathy 
can be addressed. Similarly, effect other risk factors can be addressed by this strategy.  
Thirdly, our results proposed that SCF and VEGF promote c-kit+ SPCs migration, 
which potentially contribute to neointima formation. This was verified by result that 
SCF significantly decreased vascular allograft induced lesion. However, in circulation, 
distribution of cytokines network is far more complex. Therefore, role of other 
chemoattractant and the relationship between each other could be examined in future 
studies. Moreover, although we provided the evidence that these cells can be attracted 
to the lesion, the underlying cell differentiation mechanism is still unknown. Data from 
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my colleague showed that TGFβ as a cytokine could stimulate c-kit+ SPCs for SMCs 
differentiation via glucose metabolism regulation (Figure 4.13). However, further 
studies on other molecules are still needed, which could give us better understanding 




Figure 4.13 Schematic diagram illustrating possible mechanisms regulating c-
Kit+ SPC differentiation. TGFβ1 increases glucose uptake and activates glucose 
metabolism in c-Kit+ SPCs. HK1-dependent glucose metablism leads to activation of 
the downstream glycolytic pathway and hexosamine biosynthetic pathway. The 
glycolytic pathway may provide biosynthetic substrates and energy for cell growth and 
differentiation. The hexosamine biosynthetic pathway provides UDP-N-
acetylglucosamine (UDP-GlcNAc), a substrate for protein O-GlcNAcylation, to 
increase O-GlcNAcylation of SRF and myocardin, which may further regulate smooth 
muscle gene expression.  
Figure 4.13  
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Chaper 5: Conclusion  
 
5.1. SPCs are one group of important cells distributing in aorta; 
5.2. c-kit+ SPCs involved in endothelial cells homeostasis; 
5.3. After vascular allograft surgery, donor c-kit+ SPCs were induced to death; 
5.4. Recipient but not donor source of c-kit+ SPCs contributed to vascular allograft              
induced arteriosclerosis formation; 
5.5. Non-bone marrow derivation of c-kit+ SPCs were responsible for ECs and 
SMCs repopulation after vascular allo-transplantation; 
5.6. From vascular allograft, c-kit+ SPCs could be harvested and these cells 
showed high heterogeneous character; 
5.7. As chemoattractant, both SCF and VEGF induced c-kit+ SPCs migration after 
vascular allograft surgery; 
5.8. c-kit blocking antibody ACK2 could partially inhibit SCF induced c-kit+ SPCs 
migration and decrease vascular allo-transplantation induced lesion area; 
5.9. SCF/c-kit axis is crucial in c-kit+ SPCs migration via regulating cell 
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